data_1nb1_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1nb1 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.593 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 18.6 m . . . . . 0 CA--C 1.516 -0.334 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.46 30.85 78.52 Favored Glycine 0 CA--C 1.507 -0.455 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -178.052 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -131.06 150.91 51.93 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 114.214 -0.993 . . . . 0.0 110.676 -178.07 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.615 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.7 p -113.54 143.82 43.9 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.374 178.612 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.6 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.5 p -117.34 47.75 1.46 Allowed 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.838 0.828 . . . . 0.0 109.337 178.564 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.449 HG22 ' HB ' ' A' ' 4' ' ' THR . 11.6 t -57.26 -32.31 40.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 114.458 -1.246 . . . . 0.0 109.51 179.407 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.13 20.67 49.9 Favored Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.873 178.358 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.55 39.86 97.93 Favored Glycine 0 C--N 1.335 0.525 0 C-N-CA 121.458 -0.401 . . . . 0.0 112.728 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.78 144.73 27.2 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.623 0.249 . . . . 0.0 111.455 -179.357 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.499 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.8 m -134.6 132.44 39.04 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.806 179.532 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -86.65 -36.17 18.93 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.585 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.616 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.6 m -62.34 118.36 39.54 Favored Pre-proline 0 C--O 1.235 0.324 0 CA-C-O 120.789 0.328 . . . . 0.0 110.625 -179.722 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -64.76 114.72 2.87 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 122.326 2.017 . . . . 0.0 112.382 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.44 -9.67 30.71 Favored Glycine 0 N--CA 1.446 -0.696 0 CA-C-N 115.445 -0.798 . . . . 0.0 111.594 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.616 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 100.0 m -89.89 121.69 32.23 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.364 0.602 . . . . 0.0 111.586 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.3 p -89.82 143.89 26.41 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.342 179.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.7 t -74.06 134.02 42.94 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.699 0.761 . . . . 0.0 110.905 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 m -147.27 69.08 1.15 Allowed 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.5 t90 -28.72 129.64 0.22 Allowed Pre-proline 0 C--O 1.232 0.157 0 CA-C-N 114.033 -1.44 . . . . 0.0 113.422 -176.086 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -98.59 24.98 19.93 Favored 'Cis proline' 0 N--CA 1.461 -0.432 0 C-N-CA 123.695 -1.377 . . . . 0.0 113.297 0.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.615 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.54 147.83 33.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -177.315 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.6 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 81.2 m -83.47 122.74 28.92 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.442 179.363 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.9 p -97.76 152.63 18.94 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.952 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.593 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 39.1 ttm180 -126.41 125.53 42.33 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 179.138 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 41.9 38.18 0.96 Allowed 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 113.587 0.958 . . . . 0.0 113.587 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.645 0 N-CA-C 115.472 0.949 . . . . 0.0 115.472 177.392 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.549 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 5.9 m . . . . . 0 CA--C 1.518 -0.285 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.78 32.21 83.4 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -178.29 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.573 ' OE2' ' HA ' ' A' ' 10' ' ' CYS . 27.3 tt0 -126.78 152.8 46.41 Favored 'General case' 0 N--CA 1.442 -0.843 0 CA-C-N 114.079 -1.06 . . . . 0.0 110.388 -177.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 29.1 p -111.83 141.33 45.6 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.778 178.824 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.652 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 23.3 p -115.61 46.73 1.45 Allowed 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.818 0.818 . . . . 0.0 109.341 178.163 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.9 t -57.78 -33.04 44.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 114.593 -1.185 . . . . 0.0 109.723 179.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.97 18.06 58.08 Favored Glycine 0 N--CA 1.447 -0.575 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.945 178.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 64.49 36.22 92.9 Favored Glycine 0 C--N 1.333 0.367 0 C-N-CA 121.274 -0.489 . . . . 0.0 112.768 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.6 154.77 43.9 Favored 'General case' 0 C--N 1.324 -0.515 0 O-C-N 122.749 -0.265 . . . . 0.0 110.31 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.573 ' HA ' ' OE2' ' A' ' 3' ' ' GLU . 86.2 m -139.57 133.98 31.51 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.664 179.037 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -89.19 -40.19 13.05 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.423 -179.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.684 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.5 m -60.95 119.67 47.02 Favored Pre-proline 0 C--O 1.237 0.402 0 CA-C-O 120.864 0.364 . . . . 0.0 110.668 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -64.72 114.16 2.63 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 122.478 2.118 . . . . 0.0 112.633 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 111.21 -6.91 28.78 Favored Glycine 0 N--CA 1.445 -0.717 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.659 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.684 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 75.3 m -91.54 122.76 34.41 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.48 0.657 . . . . 0.0 111.929 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.6 p -91.51 144.22 25.78 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.024 -0.989 . . . . 0.0 109.922 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.1 t -73.05 134.35 44.56 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.784 0.802 . . . . 0.0 111.116 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.9 m -146.79 67.37 1.16 Allowed 'General case' 0 C--N 1.31 -1.125 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 178.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.6 t90 -28.07 129.37 0.21 Allowed Pre-proline 0 N--CA 1.463 0.18 0 CA-C-N 113.86 -1.518 . . . . 0.0 113.386 -176.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -98.42 26.77 17.85 Favored 'Cis proline' 0 N--CA 1.461 -0.421 0 C-N-CA 123.719 -1.367 . . . . 0.0 113.3 0.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.608 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.1 m -132.21 147.71 32.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 113.782 1.03 . . . . 0.0 113.782 -177.367 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.652 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 95.3 m -83.97 124.95 31.57 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.673 179.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.9 p -103.75 155.64 18.44 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.651 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.549 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 36.1 ttp85 -135.85 124.24 23.39 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.126 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 62.41 29.15 17.15 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.732 -178.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.517 0 CA-C-N 115.81 -0.632 . . . . 0.0 114.108 179.063 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.639 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 21.8 m . . . . . 0 CA--C 1.518 -0.252 0 CA-C-O 120.701 0.286 . . . . 0.0 110.252 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 67.09 31.3 77.38 Favored Glycine 0 C--N 1.333 0.406 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 -177.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -131.76 150.8 52.04 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 114.241 -0.98 . . . . 0.0 110.431 -178.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.595 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.8 p -112.73 141.44 46.52 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.441 178.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.602 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 23.7 p -114.88 45.86 1.52 Allowed 'General case' 0 C--N 1.317 -0.829 0 CA-C-O 121.788 0.804 . . . . 0.0 109.494 178.335 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.45 HG23 ' HB ' ' A' ' 4' ' ' THR . 11.5 t -56.5 -32.49 36.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 114.646 -1.161 . . . . 0.0 109.778 179.487 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.57 21.68 44.07 Favored Glycine 0 N--CA 1.448 -0.567 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.969 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.82 40.19 98.92 Favored Glycine 0 C--N 1.334 0.44 0 C-N-CA 121.385 -0.436 . . . . 0.0 112.738 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.56 147.24 32.93 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.662 0.268 . . . . 0.0 111.448 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.529 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 84.6 m -143.46 127.67 17.64 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 178.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -91.9 -28.33 17.35 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.206 -179.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.684 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.4 m -62.71 122.83 76.68 Favored Pre-proline 0 C--O 1.234 0.268 0 CA-C-O 120.88 0.372 . . . . 0.0 110.348 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 24.4 Cg_exo -63.75 115.31 3.0 Favored 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 122.267 1.978 . . . . 0.0 113.065 -179.321 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.53 5.75 51.29 Favored Glycine 0 N--CA 1.444 -0.776 0 CA-C-N 115.175 -0.921 . . . . 0.0 111.932 179.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.684 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 99.6 m -101.45 122.45 43.8 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.54 0.686 . . . . 0.0 111.963 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.4 p -94.19 147.59 23.02 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-N 114.929 -1.032 . . . . 0.0 110.083 179.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.3 t -74.53 134.32 42.22 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.696 0.76 . . . . 0.0 111.129 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 26.0 m -147.46 67.46 1.13 Allowed 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 178.816 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.6 t90 -27.99 129.32 0.21 Allowed Pre-proline 0 N--CA 1.462 0.164 0 CA-C-N 113.963 -1.471 . . . . 0.0 113.449 -176.187 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -98.41 24.46 20.9 Favored 'Cis proline' 0 N--CA 1.46 -0.496 0 C-N-CA 123.71 -1.371 . . . . 0.0 113.342 0.315 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.595 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.24 148.2 33.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 N-CA-C 113.658 0.985 . . . . 0.0 113.658 -177.399 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.602 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.3 m -83.89 126.53 33.07 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.619 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.419 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 22.2 p -103.06 151.6 22.35 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.003 -179.822 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.639 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 38.5 ttp85 -133.68 132.07 40.25 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.089 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 18.9 p30 52.43 28.36 5.81 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 124.019 0.927 . . . . 0.0 112.627 -178.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.441 0 N-CA-C 114.782 0.673 . . . . 0.0 114.782 177.345 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.577 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 13.1 m . . . . . 0 CA--C 1.518 -0.25 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.3 28.85 73.98 Favored Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -177.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -127.5 151.38 48.94 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-N 114.231 -0.984 . . . . 0.0 110.572 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.61 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.0 p -113.05 143.45 44.3 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.253 178.651 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.615 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 24.9 p -116.85 47.26 1.5 Allowed 'General case' 0 C--N 1.318 -0.787 0 CA-C-O 121.874 0.845 . . . . 0.0 109.369 178.525 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.2 t -57.1 -32.22 39.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 114.482 -1.235 . . . . 0.0 109.524 179.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.92 21.13 47.69 Favored Glycine 0 N--CA 1.447 -0.588 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.85 178.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.37 40.11 98.19 Favored Glycine 0 C--N 1.335 0.484 0 C-N-CA 121.503 -0.379 . . . . 0.0 112.786 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.24 144.92 27.99 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.617 0.246 . . . . 0.0 111.461 -179.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.481 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 79.6 m -135.74 131.83 36.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.72 179.418 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.6 m-80 -88.2 -36.03 17.02 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.735 -179.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.71 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.1 m -61.64 119.62 48.95 Favored Pre-proline 0 C--O 1.235 0.305 0 CA-C-O 120.974 0.416 . . . . 0.0 110.7 -179.535 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -63.7 114.05 2.4 Favored 'Trans proline' 0 N--CA 1.459 -0.545 0 C-N-CA 122.462 2.108 . . . . 0.0 112.873 -179.233 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 108.36 -2.48 32.83 Favored Glycine 0 N--CA 1.444 -0.786 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.759 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.71 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 81.6 m -94.33 122.5 36.94 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.375 0.607 . . . . 0.0 111.82 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.1 p -91.8 144.01 25.93 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.088 179.151 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.5 t -73.57 134.07 43.67 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.698 0.761 . . . . 0.0 111.091 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.6 m -147.28 68.2 1.14 Allowed 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 106.377 -1.712 . . . . 0.0 106.377 178.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.4 t90 -28.54 129.54 0.22 Allowed Pre-proline 0 C--O 1.232 0.166 0 CA-C-N 113.964 -1.471 . . . . 0.0 113.419 -176.091 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 66.3 Cg_endo -98.49 24.64 20.54 Favored 'Cis proline' 0 N--CA 1.461 -0.428 0 C-N-CA 123.747 -1.355 . . . . 0.0 113.318 0.423 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.61 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.18 147.79 33.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 113.714 1.005 . . . . 0.0 113.714 -177.299 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.615 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.0 m -83.66 123.57 29.95 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.578 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.2 p -99.58 152.84 19.58 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.56 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.577 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 30.9 ttt180 -129.09 128.39 43.43 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.062 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 41.92 38.62 1.07 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 113.616 0.969 . . . . 0.0 113.616 -179.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.596 0 N-CA-C 115.611 1.004 . . . . 0.0 115.611 177.231 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.459 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 15.4 m . . . . . 0 CA--C 1.517 -0.303 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.76 31.09 79.77 Favored Glycine 0 C--N 1.333 0.41 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -177.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -134.38 148.81 50.74 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 113.983 -1.108 . . . . 0.0 110.349 -177.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 17.4 p -112.42 144.66 41.49 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.557 179.328 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.588 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.0 p -116.33 46.96 1.49 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.809 0.814 . . . . 0.0 109.402 178.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.451 HG21 ' HB ' ' A' ' 4' ' ' THR . 13.1 t -56.96 -32.81 40.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 114.638 -1.165 . . . . 0.0 109.505 179.344 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.35 21.94 43.44 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.947 178.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.39 40.31 98.47 Favored Glycine 0 C--N 1.334 0.472 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.684 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.77 144.63 27.15 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.735 0.302 . . . . 0.0 111.518 -179.218 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.544 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 78.1 m -136.95 133.12 35.3 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 179.319 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.3 m-80 -87.89 -32.27 19.04 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.18 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.609 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.7 m -63.56 117.06 30.93 Favored Pre-proline 0 C--O 1.236 0.352 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.706 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_exo -65.46 114.96 3.1 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 122.436 2.091 . . . . 0.0 112.372 -179.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.65 -7.55 31.86 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 115.472 -0.786 . . . . 0.0 111.533 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.609 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 86.3 m -91.21 121.78 33.28 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.461 0.648 . . . . 0.0 111.586 -179.84 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.7 p -89.99 141.78 28.33 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.201 179.324 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.0 t -72.02 133.87 45.55 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.607 0.717 . . . . 0.0 110.917 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.1 m -146.96 68.7 1.16 Allowed 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 179.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.1 t90 -28.65 129.98 0.21 Allowed Pre-proline 0 N--CA 1.462 0.14 0 CA-C-N 114.008 -1.451 . . . . 0.0 113.368 -176.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -97.88 22.71 24.17 Favored 'Cis proline' 0 N--CA 1.462 -0.378 0 C-N-CA 123.667 -1.389 . . . . 0.0 113.403 0.3 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.594 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -128.95 147.15 33.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -177.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.588 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.0 m -82.3 123.94 29.51 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.333 179.451 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 22.8 p -95.31 142.84 27.24 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.119 0.485 . . . . 0.0 110.495 179.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.459 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 49.9 ttp180 -103.49 111.87 24.51 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.699 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 20.6 p30 46.88 32.17 1.72 Allowed 'General case' 0 N--CA 1.471 0.619 0 O-C-N 124.334 1.021 . . . . 0.0 113.065 -178.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.468 0 C-N-CA 119.977 -1.106 . . . . 0.0 114.754 177.935 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.601 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 12.5 m . . . . . 0 CA--C 1.517 -0.297 0 CA-C-O 120.798 0.332 . . . . 0.0 110.128 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.99 30.7 77.53 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -177.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -130.29 150.99 51.28 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 114.211 -0.994 . . . . 0.0 110.608 -178.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.603 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.6 p -112.21 141.83 45.43 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.48 178.734 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.616 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 24.8 p -115.32 47.42 1.31 Allowed 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 121.87 0.843 . . . . 0.0 109.253 178.182 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.2 t -57.22 -32.04 39.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 114.599 -1.182 . . . . 0.0 109.453 179.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.68 21.13 47.71 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.855 178.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.17 39.9 97.8 Favored Glycine 0 C--N 1.335 0.492 0 C-N-CA 121.45 -0.405 . . . . 0.0 112.746 179.772 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.85 144.57 27.01 Favored 'General case' 0 C--N 1.324 -0.532 0 O-C-N 122.823 -0.222 . . . . 0.0 111.495 -179.361 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.506 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 81.7 m -135.04 133.44 39.37 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.826 179.543 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -89.81 -34.82 16.0 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.657 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.679 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.3 m -61.19 120.11 51.81 Favored Pre-proline 0 C--O 1.235 0.324 0 CA-C-O 120.95 0.405 . . . . 0.0 110.638 -179.589 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -63.92 113.49 2.2 Favored 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 122.425 2.083 . . . . 0.0 113.002 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 107.75 -1.53 34.06 Favored Glycine 0 N--CA 1.443 -0.854 0 CA-C-N 115.208 -0.905 . . . . 0.0 111.796 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.679 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 94.0 m -95.16 122.96 38.37 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.46 0.648 . . . . 0.0 111.844 -179.723 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.9 p -92.57 145.46 24.42 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 114.966 -1.016 . . . . 0.0 110.063 179.182 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.8 t -74.3 134.29 42.57 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.729 0.776 . . . . 0.0 111.175 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.7 m -147.49 68.12 1.13 Allowed 'General case' 0 C--N 1.311 -1.065 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.7 t90 -28.36 129.57 0.21 Allowed Pre-proline 0 N--CA 1.463 0.203 0 CA-C-N 113.936 -1.484 . . . . 0.0 113.41 -176.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -98.44 24.27 21.14 Favored 'Cis proline' 0 C--N 1.346 0.404 0 C-N-CA 123.678 -1.384 . . . . 0.0 113.24 0.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.603 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.1 m -129.93 148.45 33.2 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -177.316 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.616 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 82.6 m -84.1 124.56 31.24 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.655 179.657 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.7 p -100.26 150.48 22.51 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.514 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.601 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 36.9 ttt180 -126.78 128.67 46.95 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 179.161 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 41.74 38.51 0.97 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 113.75 1.019 . . . . 0.0 113.75 -179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.63 0 N-CA-C 115.598 0.999 . . . . 0.0 115.598 177.26 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.476 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 6.4 m . . . . . 0 CA--C 1.518 -0.285 0 CA-C-O 120.573 0.225 . . . . 0.0 110.572 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.81 30.74 78.76 Favored Glycine 0 C--N 1.334 0.43 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -178.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -126.71 152.42 46.83 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 114.24 -0.98 . . . . 0.0 110.363 -178.29 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.614 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.5 p -113.35 143.64 44.12 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.514 178.667 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.597 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.8 p -118.07 47.88 1.5 Allowed 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.85 0.833 . . . . 0.0 109.238 178.576 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.452 HG22 ' HB ' ' A' ' 4' ' ' THR . 11.3 t -57.26 -32.44 40.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 114.506 -1.225 . . . . 0.0 109.597 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.04 20.53 50.46 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.9 178.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.78 39.62 97.7 Favored Glycine 0 C--N 1.336 0.558 0 C-N-CA 121.42 -0.419 . . . . 0.0 112.77 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.69 144.79 27.35 Favored 'General case' 0 C--N 1.323 -0.551 0 O-C-N 122.793 -0.239 . . . . 0.0 111.363 -179.24 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.497 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.0 m -134.26 132.82 40.11 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.863 179.555 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -86.01 -36.53 19.7 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.559 -179.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.619 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.3 m -63.35 117.85 37.99 Favored Pre-proline 0 C--O 1.235 0.326 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.754 -179.565 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -64.92 115.0 3.02 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 122.336 2.024 . . . . 0.0 112.354 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 111.21 -9.6 28.97 Favored Glycine 0 N--CA 1.445 -0.742 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.511 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.619 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 79.5 m -90.75 121.64 32.81 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.338 0.59 . . . . 0.0 111.539 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 3.2 p -89.64 143.2 27.0 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.256 -0.883 . . . . 0.0 110.223 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.3 t -73.5 134.15 43.8 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.765 0.793 . . . . 0.0 110.922 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.8 m -146.98 68.8 1.16 Allowed 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 178.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.4 t90 -28.53 129.68 0.21 Allowed Pre-proline 0 C--O 1.232 0.17 0 CA-C-N 113.909 -1.496 . . . . 0.0 113.476 -176.077 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -98.41 25.62 19.34 Favored 'Cis proline' 0 N--CA 1.461 -0.434 0 C-N-CA 123.753 -1.353 . . . . 0.0 113.25 0.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.614 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.98 147.68 33.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 -177.287 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.597 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 79.2 m -83.46 122.13 28.11 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.426 179.291 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 35.4 p -100.17 148.85 24.15 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.176 0.512 . . . . 0.0 111.048 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.56 HH21 HG21 ' A' ' 12' ' ' THR . 39.9 ttm180 -114.45 112.23 22.66 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.33 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.4 m-20 60.31 33.42 20.86 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.41 -178.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.54 0 C-N-CA 120.686 -0.769 . . . . 0.0 114.158 179.238 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.594 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 30.5 m . . . . . 0 CA--C 1.516 -0.357 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.11 33.13 86.23 Favored Glycine 0 CA--C 1.507 -0.451 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 -177.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -138.03 147.4 44.11 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 113.963 -1.119 . . . . 0.0 110.453 -177.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 25.3 p -110.06 143.34 40.23 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.857 179.496 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.574 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 29.6 p -116.07 46.68 1.51 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.71 0.767 . . . . 0.0 109.277 177.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.48 HG22 ' HB ' ' A' ' 4' ' ' THR . 12.8 t -56.32 -32.65 35.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 114.712 -1.131 . . . . 0.0 109.691 179.385 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.44 23.05 37.79 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.854 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.98 40.5 98.55 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 121.477 -0.392 . . . . 0.0 112.638 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.23 144.0 27.38 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.75 0.31 . . . . 0.0 111.531 -179.268 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.562 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.3 m -136.91 132.96 35.19 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.367 179.31 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.6 m-80 -87.42 -31.72 19.91 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.097 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.594 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 2.0 m -63.84 117.17 32.83 Favored Pre-proline 0 C--O 1.236 0.345 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.852 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_exo -65.13 116.04 3.64 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 122.344 2.03 . . . . 0.0 112.261 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 107.78 -8.03 36.51 Favored Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.784 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.594 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 90.2 m -90.51 122.43 33.33 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.303 0.573 . . . . 0.0 111.639 -179.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.2 p -89.81 143.35 26.87 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.184 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.1 t -73.24 134.28 44.24 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.683 0.754 . . . . 0.0 111.02 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 m -147.06 68.66 1.16 Allowed 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 179.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.8 t90 -28.29 129.57 0.21 Allowed Pre-proline 0 C--O 1.232 0.17 0 CA-C-N 113.952 -1.476 . . . . 0.0 113.521 -176.272 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -98.14 23.12 23.21 Favored 'Cis proline' 0 N--CA 1.461 -0.422 0 C-N-CA 123.56 -1.433 . . . . 0.0 113.414 0.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.594 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.68 147.36 33.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 N-CA-C 113.66 0.985 . . . . 0.0 113.66 -177.503 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.574 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 76.0 m -82.29 125.61 31.17 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.482 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 30.2 p -101.03 145.89 28.14 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.104 0.478 . . . . 0.0 110.889 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.594 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 37.6 ttm180 -117.09 116.66 27.75 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 178.528 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.9 m-20 60.24 32.58 20.85 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 123.567 0.542 . . . . 0.0 110.681 -178.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.623 0 C-N-CA 120.84 -0.695 . . . . 0.0 114.373 179.012 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.2 m . . . . . 0 N--CA 1.455 -0.225 0 CA-C-O 120.82 0.343 . . . . 0.0 110.532 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.59 23.96 70.78 Favored Glycine 0 N--CA 1.45 -0.391 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 -178.572 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -117.51 152.15 35.66 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 114.015 -1.092 . . . . 0.0 109.702 -178.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.593 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.8 p -112.92 143.44 44.2 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 120.799 0.333 . . . . 0.0 110.884 179.471 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.573 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.8 p -117.07 46.93 1.58 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.756 0.789 . . . . 0.0 109.274 178.344 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.6 t -56.83 -32.69 39.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 114.55 -1.204 . . . . 0.0 109.631 179.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.65 21.51 45.74 Favored Glycine 0 N--CA 1.447 -0.615 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.836 178.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.66 39.32 97.24 Favored Glycine 0 C--N 1.335 0.527 0 C-N-CA 121.484 -0.389 . . . . 0.0 112.807 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.16 144.08 25.45 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.65 0.262 . . . . 0.0 111.585 -179.269 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.559 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.6 m -134.33 135.89 43.07 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.495 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -91.02 -31.49 16.28 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.694 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -63.23 117.71 36.23 Favored Pre-proline 0 C--O 1.237 0.418 0 CA-C-O 120.992 0.425 . . . . 0.0 110.69 -179.762 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -63.87 117.61 4.6 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 122.295 1.997 . . . . 0.0 112.554 -179.588 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.24 0.93 47.72 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.429 -0.805 . . . . 0.0 112.051 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.694 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 99.9 m -97.06 122.24 39.84 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.288 0.566 . . . . 0.0 111.262 -179.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.5 p -89.84 141.28 28.79 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.358 179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.3 t -72.39 134.1 45.26 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.68 0.752 . . . . 0.0 110.754 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.3 m -147.02 67.47 1.15 Allowed 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.8 t90 -27.94 129.64 0.2 Allowed Pre-proline 0 C--N 1.34 0.169 0 CA-C-N 113.917 -1.492 . . . . 0.0 113.526 -176.099 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -97.67 23.41 23.52 Favored 'Cis proline' 0 N--CA 1.461 -0.404 0 C-N-CA 123.574 -1.428 . . . . 0.0 113.364 0.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.593 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.62 146.3 34.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 N-CA-C 113.671 0.989 . . . . 0.0 113.671 -177.301 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.573 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.7 m -82.64 123.86 29.65 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.505 -0.771 . . . . 0.0 110.43 179.5 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 21.1 p -95.71 144.64 25.94 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.213 0.53 . . . . 0.0 111.076 179.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.9 103.88 15.84 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 178.237 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 20.1 p30 48.03 29.92 1.89 Allowed 'General case' 0 N--CA 1.472 0.661 0 O-C-N 124.249 0.968 . . . . 0.0 112.811 -178.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.473 0 C-N-CA 119.974 -1.108 . . . . 0.0 114.411 178.282 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 9.5 m . . . . . 0 N--CA 1.452 -0.329 0 CA-C-O 120.671 0.272 . . . . 0.0 110.368 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.41 28.17 73.29 Favored Glycine 0 C--N 1.334 0.459 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 -178.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -125.18 150.0 47.38 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 114.148 -1.026 . . . . 0.0 110.016 -178.378 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.588 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.3 p -111.48 143.72 41.86 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.557 179.097 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.583 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.0 p -116.14 47.49 1.39 Allowed 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.835 0.826 . . . . 0.0 109.281 178.475 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.476 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.4 t -57.2 -32.28 40.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 114.503 -1.226 . . . . 0.0 109.487 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.07 20.65 49.97 Favored Glycine 0 N--CA 1.448 -0.529 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.766 178.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.93 39.03 96.99 Favored Glycine 0 C--N 1.336 0.547 0 C-N-CA 121.602 -0.332 . . . . 0.0 112.775 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.13 144.28 25.6 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.698 0.285 . . . . 0.0 111.562 -179.345 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.535 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 72.6 m -133.7 135.35 43.98 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.32 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -93.98 -29.7 15.11 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.441 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.752 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -63.38 121.67 71.23 Favored Pre-proline 0 C--O 1.237 0.404 0 CA-C-O 121.15 0.5 . . . . 0.0 111.014 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.2 Cg_exo -64.45 118.54 5.5 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.396 2.064 . . . . 0.0 112.641 -179.752 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.61 8.93 51.38 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.076 -0.965 . . . . 0.0 111.864 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.752 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 71.1 m -105.18 123.42 47.8 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.485 0.66 . . . . 0.0 111.958 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.3 p -94.07 142.51 27.31 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.144 179.274 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.1 t -72.8 134.23 44.83 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.624 0.726 . . . . 0.0 111.217 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.9 m -147.5 67.88 1.13 Allowed 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 106.502 -1.666 . . . . 0.0 106.502 178.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.1 t90 -28.02 129.6 0.21 Allowed Pre-proline 0 N--CA 1.462 0.174 0 CA-C-N 113.936 -1.484 . . . . 0.0 113.517 -176.205 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -97.98 23.47 22.95 Favored 'Cis proline' 0 N--CA 1.462 -0.34 0 C-N-CA 123.625 -1.406 . . . . 0.0 113.312 0.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.588 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.9 146.98 33.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 -177.378 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.0 m -83.02 121.98 27.73 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.621 179.615 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 35.5 p -98.3 146.43 25.67 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.37 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 13.5 ttt180 -109.21 114.65 28.53 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 20.1 p30 47.58 31.29 1.99 Allowed 'General case' 0 N--CA 1.472 0.662 0 O-C-N 124.269 0.981 . . . . 0.0 113.041 -178.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.475 0 C-N-CA 120.035 -1.079 . . . . 0.0 114.602 177.852 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 19.0 m . . . . . 0 CA--C 1.518 -0.262 0 CA-C-O 120.562 0.22 . . . . 0.0 110.583 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.89 32.92 85.78 Favored Glycine 0 C--N 1.334 0.469 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -178.359 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -132.56 148.81 52.38 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 114.245 -0.978 . . . . 0.0 110.286 -178.178 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.592 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 25.7 p -108.83 143.05 38.52 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.076 179.511 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.588 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.8 p -116.27 46.94 1.49 Allowed 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.791 0.805 . . . . 0.0 109.295 177.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.473 HG22 ' HB ' ' A' ' 4' ' ' THR . 12.9 t -56.44 -32.62 36.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 114.639 -1.164 . . . . 0.0 109.803 179.579 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.11 22.66 39.82 Favored Glycine 0 N--CA 1.447 -0.606 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.944 178.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.21 40.25 98.31 Favored Glycine 0 C--N 1.336 0.572 0 C-N-CA 121.414 -0.422 . . . . 0.0 112.598 179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.28 144.07 27.37 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.683 0.278 . . . . 0.0 111.566 -179.195 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.534 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 84.5 m -136.02 133.05 37.06 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.355 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -88.3 -32.51 18.42 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.126 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.795 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.0 OUTLIER -64.97 118.32 47.93 Favored Pre-proline 0 C--O 1.237 0.426 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.05 -179.56 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -64.96 118.38 5.38 Favored 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 122.354 2.036 . . . . 0.0 112.485 -179.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 104.38 2.56 44.27 Favored Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.704 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.795 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 70.8 m -99.44 121.93 41.83 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.305 0.574 . . . . 0.0 111.77 -179.818 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.1 p -89.87 140.39 29.65 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.96 179.068 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.4 t -72.16 133.91 45.41 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.678 0.752 . . . . 0.0 110.891 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.7 m -147.06 68.83 1.16 Allowed 'General case' 0 C--N 1.311 -1.076 0 N-CA-C 106.519 -1.66 . . . . 0.0 106.519 179.161 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.1 t90 -28.45 129.48 0.21 Allowed Pre-proline 0 C--O 1.232 0.154 0 CA-C-N 113.987 -1.461 . . . . 0.0 113.445 -176.119 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -98.29 24.26 21.35 Favored 'Cis proline' 0 N--CA 1.46 -0.457 0 C-N-CA 123.672 -1.387 . . . . 0.0 113.328 0.419 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.592 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.52 147.26 33.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 113.767 1.025 . . . . 0.0 113.767 -177.297 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.588 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 72.7 m -82.33 124.45 30.0 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.322 -0.853 . . . . 0.0 110.269 179.341 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.3 p -101.63 149.95 23.6 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.313 0.578 . . . . 0.0 111.574 -179.536 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.594 HH21 HG23 ' A' ' 12' ' ' THR . 15.9 tpp85 -105.89 103.52 13.03 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 70.9 m-20 58.45 34.67 24.15 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 123.379 0.425 . . . . 0.0 110.547 -178.592 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.524 0 C-N-CA 120.49 -0.862 . . . . 0.0 114.13 179.368 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.422 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 12.7 m . . . . . 0 N--CA 1.452 -0.356 0 CA-C-O 120.793 0.33 . . . . 0.0 110.4 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.22 29.67 75.9 Favored Glycine 0 C--N 1.333 0.405 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 -178.228 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -129.76 149.62 51.42 Favored 'General case' 0 N--CA 1.445 -0.698 0 CA-C-N 114.043 -1.079 . . . . 0.0 110.045 -178.362 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.0 p -110.28 144.34 39.12 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.705 179.313 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.572 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.9 p -116.82 46.93 1.55 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.811 0.815 . . . . 0.0 109.316 178.45 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.4 t -56.83 -32.57 39.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 114.683 -1.144 . . . . 0.0 109.671 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.63 21.23 47.2 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.84 178.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.73 39.86 98.01 Favored Glycine 0 C--N 1.335 0.486 0 C-N-CA 121.455 -0.403 . . . . 0.0 112.669 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.8 144.57 27.08 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.645 0.26 . . . . 0.0 111.553 -179.256 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.521 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 80.1 m -135.52 134.1 39.13 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.969 -0.559 . . . . 0.0 109.523 179.505 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 62.8 m-80 -91.77 -31.43 15.77 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.216 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.71 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -63.2 121.17 67.74 Favored Pre-proline 0 C--O 1.236 0.365 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.122 -179.317 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.5 Cg_exo -64.17 118.51 5.46 Favored 'Trans proline' 0 N--CA 1.457 -0.67 0 C-N-CA 122.365 2.044 . . . . 0.0 112.688 -179.771 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.9 5.48 54.98 Favored Glycine 0 N--CA 1.446 -0.642 0 CA-C-N 115.2 -0.909 . . . . 0.0 112.013 179.657 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.71 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 86.1 m -102.14 120.87 41.16 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.607 0.718 . . . . 0.0 112.12 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 3.0 p -90.97 144.99 25.1 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.794 178.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.5 t -73.75 134.41 43.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.738 0.78 . . . . 0.0 111.066 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.8 m -146.78 67.71 1.16 Allowed 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 178.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.2 t90 -28.21 129.45 0.21 Allowed Pre-proline 0 C--O 1.232 0.172 0 CA-C-N 113.958 -1.474 . . . . 0.0 113.392 -176.118 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -98.3 24.65 20.78 Favored 'Cis proline' 0 N--CA 1.462 -0.376 0 C-N-CA 123.676 -1.385 . . . . 0.0 113.324 0.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.591 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -130.81 148.2 33.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -177.314 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.572 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.5 m -83.53 128.54 34.59 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.586 179.518 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.4 p -108.29 149.9 28.03 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.042 -179.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.422 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 20.7 ttp180 -131.64 126.07 33.75 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.5 m-20 62.17 28.57 17.15 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.708 -178.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.533 0 CA-C-N 115.715 -0.675 . . . . 0.0 114.101 179.087 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.677 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 23.7 m . . . . . 0 CA--C 1.518 -0.287 0 CA-C-O 120.867 0.365 . . . . 0.0 110.083 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.74 31.4 79.72 Favored Glycine 0 C--N 1.334 0.469 0 N-CA-C 109.199 -1.561 . . . . 0.0 109.199 -177.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -134.6 148.21 50.38 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 113.957 -1.122 . . . . 0.0 110.32 -177.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.588 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.3 p -110.29 142.77 41.45 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.811 179.422 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.583 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.8 p -115.24 46.65 1.42 Allowed 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.722 0.772 . . . . 0.0 109.261 177.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.493 HG21 ' HB ' ' A' ' 4' ' ' THR . 12.6 t -56.56 -32.42 36.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 114.666 -1.152 . . . . 0.0 109.652 179.385 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.71 22.41 41.1 Favored Glycine 0 N--CA 1.447 -0.596 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.858 178.327 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.03 40.06 97.97 Favored Glycine 0 C--N 1.335 0.475 0 C-N-CA 121.499 -0.382 . . . . 0.0 112.734 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.56 143.94 25.92 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.694 0.283 . . . . 0.0 111.581 -179.202 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.568 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 68.4 m -136.14 134.84 38.7 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.471 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -91.2 -30.23 16.77 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.358 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.69 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.7 m -62.55 118.66 43.23 Favored Pre-proline 0 C--O 1.235 0.293 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.718 -179.78 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.9 Cg_exo -64.13 115.02 2.89 Favored 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.394 2.063 . . . . 0.0 112.851 -179.385 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.33 0.9 40.91 Favored Glycine 0 N--CA 1.445 -0.707 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.786 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.69 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 86.2 m -96.9 123.65 40.66 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.398 0.618 . . . . 0.0 111.82 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.9 p -92.66 144.05 25.7 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.074 179.15 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.3 t -73.44 134.26 43.92 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.607 0.718 . . . . 0.0 111.017 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.3 m -147.3 67.68 1.14 Allowed 'General case' 0 C--N 1.312 -1.061 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 179.025 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.7 t90 -28.11 129.45 0.21 Allowed Pre-proline 0 C--O 1.232 0.17 0 CA-C-N 114.067 -1.424 . . . . 0.0 113.448 -176.228 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -98.08 22.94 23.55 Favored 'Cis proline' 0 N--CA 1.461 -0.419 0 C-N-CA 123.671 -1.387 . . . . 0.0 113.391 0.321 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.588 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.37 148.24 33.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 113.627 0.973 . . . . 0.0 113.627 -177.433 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.3 m -83.61 127.65 33.91 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.761 179.743 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 21.2 p -101.55 150.75 22.75 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.774 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.677 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 33.8 ttt180 -132.63 124.13 27.72 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.534 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 59.84 30.6 20.15 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.058 0.456 . . . . 0.0 111.203 -179.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.579 0 C-N-CA 121.095 -0.574 . . . . 0.0 114.29 178.968 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.534 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 7.9 m . . . . . 0 CA--C 1.517 -0.307 0 CA-C-O 120.56 0.219 . . . . 0.0 110.568 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.07 31.52 81.11 Favored Glycine 0 C--N 1.334 0.441 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -178.264 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -129.42 151.81 49.65 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 114.152 -1.024 . . . . 0.0 110.519 -178.118 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.3 p -112.41 141.85 45.65 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.678 178.821 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.612 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.0 p -116.11 47.85 1.33 Allowed 'General case' 0 C--N 1.318 -0.797 0 CA-C-O 121.873 0.844 . . . . 0.0 109.264 177.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.477 HG21 ' HB ' ' A' ' 4' ' ' THR . 12.2 t -57.24 -32.2 40.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 114.573 -1.194 . . . . 0.0 109.703 179.559 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -96.88 20.68 49.76 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.856 178.307 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.54 39.29 97.14 Favored Glycine 0 C--N 1.335 0.512 0 C-N-CA 121.468 -0.396 . . . . 0.0 112.662 179.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.22 144.2 26.39 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.62 0.248 . . . . 0.0 111.266 -179.248 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.52 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 76.7 m -133.32 133.93 43.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.022 -0.536 . . . . 0.0 109.952 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -87.45 -35.02 18.49 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.441 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.588 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.6 m -63.17 118.12 40.0 Favored Pre-proline 0 C--O 1.236 0.365 0 CA-C-O 120.748 0.309 . . . . 0.0 110.747 -179.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -65.17 114.88 3.02 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.338 2.025 . . . . 0.0 112.297 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.24 -8.52 30.96 Favored Glycine 0 N--CA 1.445 -0.701 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.601 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.588 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 96.5 m -91.43 121.98 33.62 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.366 0.603 . . . . 0.0 111.619 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.7 p -89.76 144.38 26.02 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.251 179.348 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.0 t -74.28 134.16 42.61 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.615 0.721 . . . . 0.0 111.016 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.9 m -147.29 68.77 1.14 Allowed 'General case' 0 C--N 1.311 -1.072 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.019 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.1 t90 -28.32 129.65 0.21 Allowed Pre-proline 0 C--O 1.232 0.178 0 CA-C-N 113.978 -1.465 . . . . 0.0 113.399 -176.207 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 65.4 Cg_endo -98.42 24.91 20.26 Favored 'Cis proline' 0 N--CA 1.461 -0.441 0 C-N-CA 123.694 -1.377 . . . . 0.0 113.263 0.31 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.608 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.64 147.98 33.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 N-CA-C 113.688 0.996 . . . . 0.0 113.688 -177.386 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.612 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.9 m -83.4 123.04 29.28 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.453 179.44 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 28.1 p -99.0 147.14 25.31 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.193 0.52 . . . . 0.0 111.108 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.534 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 40.5 ttm180 -114.14 112.86 23.88 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.386 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 60.43 33.06 20.71 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.438 -178.262 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.532 0 C-N-CA 120.75 -0.738 . . . . 0.0 114.207 179.175 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 35.3 m . . . . . 0 CA--C 1.519 -0.239 0 CA-C-O 120.729 0.299 . . . . 0.0 110.698 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.64 32.65 83.81 Favored Glycine 0 C--N 1.335 0.475 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -178.222 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -137.75 148.41 45.57 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 114.205 -0.997 . . . . 0.0 110.405 -178.101 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.593 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 27.1 p -108.85 142.91 38.74 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.897 179.355 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.592 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.3 p -116.28 46.86 1.5 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.777 0.798 . . . . 0.0 109.277 177.846 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.476 HG22 ' HB ' ' A' ' 4' ' ' THR . 11.8 t -56.62 -32.75 38.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 114.607 -1.179 . . . . 0.0 109.795 179.566 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.84 22.7 39.64 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.919 178.443 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.87 40.48 98.36 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 121.446 -0.407 . . . . 0.0 112.615 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -147.85 144.07 27.88 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.654 0.264 . . . . 0.0 111.355 -179.195 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.544 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 79.3 m -136.58 133.76 36.72 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.993 -0.549 . . . . 0.0 109.718 179.555 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 62.6 m-80 -91.12 -31.35 16.26 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.947 179.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.646 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -62.55 118.96 46.08 Favored Pre-proline 0 C--O 1.237 0.398 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.846 -179.547 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_exo -64.08 118.92 5.84 Favored 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 122.231 1.954 . . . . 0.0 112.739 -179.619 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.42 10.77 53.32 Favored Glycine 0 N--CA 1.446 -0.688 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.977 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.646 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 95.5 m -105.48 121.52 44.1 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.456 0.646 . . . . 0.0 111.723 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 8.0 p -89.76 143.25 26.95 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 115.102 -0.953 . . . . 0.0 109.898 179.07 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.0 t -72.61 134.19 45.04 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.668 0.747 . . . . 0.0 110.954 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.9 m -146.09 67.58 1.19 Allowed 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.6 t90 -27.94 129.39 0.21 Allowed Pre-proline 0 C--O 1.233 0.201 0 CA-C-N 113.919 -1.491 . . . . 0.0 113.528 -176.202 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -98.04 24.82 20.89 Favored 'Cis proline' 0 N--CA 1.462 -0.346 0 C-N-CA 123.658 -1.392 . . . . 0.0 113.307 0.468 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.593 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -131.61 146.9 32.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -177.413 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.592 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 78.3 m -81.66 132.11 35.29 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.224 179.343 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 63.0 p -117.16 147.39 42.5 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.017 0.437 . . . . 0.0 111.608 -178.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 54.0 ttm-85 -108.56 114.27 27.96 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 177.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 54.8 m-20 61.33 35.25 18.1 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.143 0.497 . . . . 0.0 109.683 -178.252 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 CA-C-N 115.69 -0.686 . . . . 0.0 112.244 -179.276 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 11.6 m . . . . . 0 CA--C 1.519 -0.241 0 CA-C-O 120.816 0.341 . . . . 0.0 110.47 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.44 31.96 82.6 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 109.476 -1.449 . . . . 0.0 109.476 -178.071 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -132.71 148.95 52.34 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 114.127 -1.036 . . . . 0.0 110.359 -177.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.595 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 25.7 p -110.12 142.72 41.23 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.891 179.34 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.581 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 29.9 p -115.72 46.97 1.42 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.655 0.74 . . . . 0.0 109.283 177.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.484 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.9 t -56.54 -32.64 37.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.685 179.492 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.05 22.0 43.13 Favored Glycine 0 N--CA 1.447 -0.617 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.836 178.443 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.27 39.58 97.41 Favored Glycine 0 C--N 1.335 0.518 0 C-N-CA 121.511 -0.376 . . . . 0.0 112.683 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -149.68 143.77 25.7 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.664 0.268 . . . . 0.0 111.557 -179.308 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.566 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 78.9 m -134.7 135.24 41.85 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 179.491 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -90.31 -30.84 17.22 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.633 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.5 m -62.95 117.97 37.84 Favored Pre-proline 0 C--O 1.236 0.35 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.655 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -64.37 116.48 3.78 Favored 'Trans proline' 0 N--CA 1.457 -0.658 0 C-N-CA 122.386 2.058 . . . . 0.0 112.662 -179.414 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.3 2.31 47.8 Favored Glycine 0 N--CA 1.445 -0.75 0 CA-C-N 115.373 -0.831 . . . . 0.0 112.107 179.635 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.633 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 88.9 m -97.78 123.13 41.6 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.334 0.588 . . . . 0.0 111.497 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.8 p -90.07 141.58 28.53 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.293 179.467 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.8 t -73.06 134.28 44.52 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.663 0.744 . . . . 0.0 110.95 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.2 m -147.19 68.61 1.15 Allowed 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.056 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.7 t90 -28.14 129.6 0.21 Allowed Pre-proline 0 N--CA 1.463 0.187 0 CA-C-N 113.962 -1.472 . . . . 0.0 113.421 -176.252 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -98.03 23.31 23.11 Favored 'Cis proline' 0 N--CA 1.461 -0.439 0 C-N-CA 123.62 -1.408 . . . . 0.0 113.275 0.307 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.595 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -129.99 147.02 33.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -177.4 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.581 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 77.3 m -82.05 125.34 30.71 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.494 179.464 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.4 p -101.06 146.47 27.41 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.156 0.503 . . . . 0.0 111.195 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.423 ' HG2' ' SG ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -101.79 107.86 19.19 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 177.879 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 17.7 p30 49.36 28.83 2.49 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 124.319 1.012 . . . . 0.0 112.776 -178.421 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.451 0 C-N-CA 120.035 -1.079 . . . . 0.0 114.518 178.141 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.659 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 8.9 m . . . . . 0 CA--C 1.518 -0.268 0 CA-C-O 120.763 0.316 . . . . 0.0 110.25 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.27 31.72 81.47 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -177.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -133.51 148.31 51.67 Favored 'General case' 0 N--CA 1.444 -0.766 0 CA-C-N 113.928 -1.136 . . . . 0.0 110.509 -177.72 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.588 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.4 p -110.45 142.86 41.6 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.808 179.325 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.565 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.6 p -115.36 46.95 1.38 Allowed 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.739 0.78 . . . . 0.0 109.278 178.071 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.478 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.8 t -56.55 -32.42 36.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 114.624 -1.171 . . . . 0.0 109.658 179.474 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.23 21.88 43.73 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 115.617 -0.72 . . . . 0.0 111.811 178.384 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.36 39.52 97.37 Favored Glycine 0 C--N 1.335 0.524 0 C-N-CA 121.527 -0.368 . . . . 0.0 112.668 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.03 143.86 25.43 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.684 0.278 . . . . 0.0 111.597 -179.294 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.565 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 70.4 m -134.78 135.01 41.51 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.421 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -88.58 -31.1 18.79 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.617 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.7 m -63.59 117.72 37.49 Favored Pre-proline 0 C--O 1.236 0.381 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.752 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_exo -65.05 115.66 3.41 Favored 'Trans proline' 0 N--CA 1.459 -0.536 0 C-N-CA 122.316 2.011 . . . . 0.0 112.438 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 108.87 -8.73 34.01 Favored Glycine 0 N--CA 1.446 -0.681 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.738 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.617 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 88.2 m -89.98 122.69 33.23 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.42 0.629 . . . . 0.0 111.762 -179.677 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.0 p -90.67 144.35 25.83 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.078 -0.964 . . . . 0.0 110.113 179.212 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.4 t -74.06 134.27 42.96 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.592 0.71 . . . . 0.0 111.092 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 m -147.45 68.27 1.13 Allowed 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 106.517 -1.661 . . . . 0.0 106.517 179.053 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.8 t90 -28.16 129.44 0.21 Allowed Pre-proline 0 N--CA 1.463 0.191 0 CA-C-N 114.007 -1.451 . . . . 0.0 113.437 -176.256 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -98.36 23.18 22.77 Favored 'Cis proline' 0 C--N 1.345 0.388 0 C-N-CA 123.617 -1.41 . . . . 0.0 113.257 0.334 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.588 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -129.48 148.64 33.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -177.447 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.56 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 73.5 m -83.55 126.19 32.55 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.723 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 20.1 p -99.68 148.2 24.6 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.771 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.659 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 57.9 ttp180 -130.4 131.94 45.52 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.024 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.6 p-10 44.59 36.4 1.72 Allowed 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 113.324 0.861 . . . . 0.0 113.324 -179.413 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.633 0 N-CA-C 115.621 1.008 . . . . 0.0 115.621 177.272 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.681 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 16.6 m . . . . . 0 CA--C 1.516 -0.33 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.5 30.28 76.24 Favored Glycine 0 N--CA 1.45 -0.422 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -177.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -130.24 152.69 49.38 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 114.126 -1.037 . . . . 0.0 110.544 -178.199 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.609 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.3 p -115.24 143.34 45.4 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.241 178.44 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.626 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.8 p -115.73 47.46 1.35 Allowed 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.915 0.865 . . . . 0.0 109.362 178.666 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -57.52 -32.23 41.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 114.552 -1.204 . . . . 0.0 109.481 179.387 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -96.51 19.9 52.69 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.828 178.281 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.9 39.73 97.91 Favored Glycine 0 C--N 1.335 0.48 0 C-N-CA 121.524 -0.37 . . . . 0.0 112.746 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.04 144.96 26.12 Favored 'General case' 0 C--N 1.324 -0.528 0 O-C-N 122.734 -0.274 . . . . 0.0 111.472 -179.275 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.513 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 85.6 m -134.62 133.57 40.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.088 -0.505 . . . . 0.0 109.81 179.539 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -90.14 -34.04 16.02 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.676 -179.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.679 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.1 m -61.98 121.19 63.82 Favored Pre-proline 0 C--O 1.236 0.366 0 CA-C-O 120.943 0.401 . . . . 0.0 110.654 -179.673 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -64.58 114.79 2.87 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.44 2.093 . . . . 0.0 112.691 -179.535 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 106.08 0.94 38.74 Favored Glycine 0 N--CA 1.445 -0.705 0 CA-C-N 115.465 -0.789 . . . . 0.0 111.68 179.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.679 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 84.2 m -98.91 119.74 38.19 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 121.46 0.648 . . . . 0.0 111.658 -179.8 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.8 p -90.59 144.82 25.39 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.023 179.095 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.7 t -72.84 134.4 44.85 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.697 0.761 . . . . 0.0 111.109 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.1 m -147.13 66.96 1.14 Allowed 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 106.217 -1.771 . . . . 0.0 106.217 178.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.9 t90 -28.24 129.53 0.21 Allowed Pre-proline 0 C--O 1.233 0.195 0 CA-C-N 113.89 -1.504 . . . . 0.0 113.436 -176.142 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -98.32 24.19 21.41 Favored 'Cis proline' 0 N--CA 1.461 -0.384 0 C-N-CA 123.645 -1.398 . . . . 0.0 113.284 0.43 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.609 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -129.15 147.76 33.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 -177.409 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.626 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 91.8 m -84.37 123.76 30.55 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.737 179.663 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 34.6 p -100.08 146.46 26.75 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.338 179.531 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.681 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 25.5 ttp85 -117.4 122.05 42.75 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 21.6 p30 46.82 32.3 1.74 Allowed 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.342 1.057 . . . . 0.0 113.595 -179.031 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.489 0 C-N-CA 119.92 -1.133 . . . . 0.0 115.325 177.133 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.535 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 11.6 m . . . . . 0 CA--C 1.517 -0.323 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.71 31.17 80.02 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 109.241 -1.543 . . . . 0.0 109.241 -178.099 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -132.76 149.08 52.32 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 114.0 -1.1 . . . . 0.0 110.147 -177.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.59 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.1 p -110.9 144.41 39.99 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.629 179.308 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.571 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.7 p -116.64 46.86 1.54 Allowed 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.789 0.804 . . . . 0.0 109.282 178.56 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.459 HG23 ' HB ' ' A' ' 4' ' ' THR . 11.9 t -56.85 -32.59 39.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 114.587 -1.188 . . . . 0.0 109.531 179.45 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.39 21.78 44.24 Favored Glycine 0 N--CA 1.446 -0.64 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.906 178.368 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.41 40.08 98.17 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 121.431 -0.414 . . . . 0.0 112.832 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.73 144.7 27.24 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.69 0.281 . . . . 0.0 111.514 -179.23 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.527 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.4 m -136.41 133.42 36.67 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.3 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -88.34 -32.21 18.52 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.189 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.661 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.6 m -63.25 118.85 47.37 Favored Pre-proline 0 C--O 1.236 0.382 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.816 -179.618 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -64.76 115.8 3.44 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.438 2.092 . . . . 0.0 112.553 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 106.4 -3.62 37.33 Favored Glycine 0 N--CA 1.445 -0.707 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.89 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.661 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 93.1 m -93.91 121.14 35.07 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.377 0.608 . . . . 0.0 111.822 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.4 p -89.88 143.87 26.43 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.053 178.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.6 t -73.26 134.36 44.23 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.7 0.762 . . . . 0.0 111.009 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.5 m -147.01 68.08 1.16 Allowed 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 106.378 -1.712 . . . . 0.0 106.378 178.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.3 t90 -28.3 129.52 0.21 Allowed Pre-proline 0 C--O 1.232 0.147 0 CA-C-N 113.874 -1.512 . . . . 0.0 113.413 -176.205 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -98.37 24.34 21.14 Favored 'Cis proline' 0 N--CA 1.46 -0.466 0 C-N-CA 123.696 -1.377 . . . . 0.0 113.324 0.34 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.59 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -130.32 148.27 33.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -177.325 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.571 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.5 m -83.59 127.23 33.58 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.602 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.1 p -105.46 149.04 26.52 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.762 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.535 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 41.3 ttp85 -130.86 123.94 30.14 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.253 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 79.4 m-20 62.11 29.31 17.55 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.779 -178.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.549 0 CA-C-N 115.704 -0.68 . . . . 0.0 114.055 179.112 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.531 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 4.0 m . . . . . 0 CA--C 1.518 -0.276 0 CA-C-O 120.793 0.33 . . . . 0.0 110.501 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.3 31.09 79.71 Favored Glycine 0 C--N 1.334 0.435 0 N-CA-C 109.439 -1.465 . . . . 0.0 109.439 -178.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -128.79 149.33 50.77 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 113.883 -1.159 . . . . 0.0 109.793 -177.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.57 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 27.2 p -109.74 142.6 40.73 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.136 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.571 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 29.8 p -116.54 45.31 1.83 Allowed 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.64 0.734 . . . . 0.0 109.296 177.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.4 t -55.75 -33.33 33.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 114.735 -1.121 . . . . 0.0 109.906 179.477 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.74 22.59 39.71 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.708 -0.678 . . . . 0.0 112.011 178.57 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.99 40.24 99.06 Favored Glycine 0 C--N 1.334 0.461 0 C-N-CA 121.3 -0.476 . . . . 0.0 112.63 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -146.2 146.17 30.7 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.822 0.344 . . . . 0.0 111.565 -179.357 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.568 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 80.1 m -141.33 130.53 23.48 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 178.763 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -89.31 -27.19 20.69 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.48 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.595 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.8 m -65.56 117.48 41.43 Favored Pre-proline 0 C--O 1.237 0.423 0 CA-C-O 120.949 0.404 . . . . 0.0 110.259 179.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -64.14 114.04 2.48 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 122.315 2.01 . . . . 0.0 113.149 -179.064 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 107.28 -5.41 35.8 Favored Glycine 0 N--CA 1.442 -0.936 0 CA-C-N 115.282 -0.872 . . . . 0.0 112.014 179.609 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.595 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 99.5 m -89.9 123.11 33.55 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.403 0.62 . . . . 0.0 111.49 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.6 p -90.01 141.54 28.57 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.305 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 50.7 t -71.94 134.52 46.03 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.706 0.765 . . . . 0.0 110.911 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.3 m -147.08 68.1 1.15 Allowed 'General case' 0 C--N 1.312 -1.043 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 179.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.7 t90 -27.73 129.26 0.2 Allowed Pre-proline 0 C--O 1.232 0.154 0 CA-C-N 113.976 -1.465 . . . . 0.0 113.516 -176.121 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 62.6 Cg_endo -97.91 23.14 23.54 Favored 'Cis proline' 0 N--CA 1.462 -0.376 0 C-N-CA 123.675 -1.386 . . . . 0.0 113.282 0.368 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.57 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.4 m -130.05 146.44 34.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 113.803 1.038 . . . . 0.0 113.803 -177.316 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.571 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 82.2 m -81.6 126.9 32.3 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.355 179.417 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.7 p -101.68 145.76 28.65 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.294 0.569 . . . . 0.0 111.426 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.531 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 27.1 tpt180 -117.48 117.28 29.03 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.212 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 63.5 m-20 60.48 32.23 20.47 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.465 -178.583 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.618 0 C-N-CA 120.808 -0.711 . . . . 0.0 114.214 179.14 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.593 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 18.6 m . . . . . 0 CA--C 1.516 -0.334 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.46 30.85 78.52 Favored Glycine 0 CA--C 1.507 -0.455 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -178.052 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -131.06 150.91 51.93 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 114.214 -0.993 . . . . 0.0 110.676 -178.07 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.615 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.7 p -113.54 143.82 43.9 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.374 178.612 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.6 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.5 p -117.34 47.75 1.46 Allowed 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.838 0.828 . . . . 0.0 109.337 178.564 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.449 HG22 ' HB ' ' A' ' 4' ' ' THR . 11.6 t -57.26 -32.31 40.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 114.458 -1.246 . . . . 0.0 109.51 179.407 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.13 20.67 49.9 Favored Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.873 178.358 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.55 39.86 97.93 Favored Glycine 0 C--N 1.335 0.525 0 C-N-CA 121.458 -0.401 . . . . 0.0 112.728 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.78 144.73 27.2 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.623 0.249 . . . . 0.0 111.455 -179.357 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.499 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.8 m -134.6 132.44 39.04 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.806 179.532 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -86.65 -36.17 18.93 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.585 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.616 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.6 m -62.34 118.36 39.54 Favored Pre-proline 0 C--O 1.235 0.324 0 CA-C-O 120.789 0.328 . . . . 0.0 110.625 -179.722 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -64.76 114.72 2.87 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 122.326 2.017 . . . . 0.0 112.382 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.44 -9.67 30.71 Favored Glycine 0 N--CA 1.446 -0.696 0 CA-C-N 115.445 -0.798 . . . . 0.0 111.594 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.616 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 100.0 m -89.89 121.69 32.23 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.364 0.602 . . . . 0.0 111.586 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.3 p -89.82 143.89 26.41 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.342 179.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.7 t -74.06 134.02 42.94 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.699 0.761 . . . . 0.0 110.905 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 m -147.27 69.08 1.15 Allowed 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.5 t90 -28.72 129.64 0.22 Allowed Pre-proline 0 C--O 1.232 0.157 0 CA-C-N 114.033 -1.44 . . . . 0.0 113.422 -176.086 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -98.59 24.98 19.93 Favored 'Cis proline' 0 N--CA 1.461 -0.432 0 C-N-CA 123.695 -1.377 . . . . 0.0 113.297 0.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.615 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.54 147.83 33.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -177.315 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.6 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 81.2 m -83.47 122.74 28.92 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.442 179.363 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.606 HG22 ' HG3' ' A' ' 28' ' ' PRO . 25.9 p -97.76 152.63 18.94 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.952 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.593 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 39.1 ttm180 -126.41 125.53 42.33 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 179.138 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 41.9 38.18 0.96 Allowed 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 113.587 0.958 . . . . 0.0 113.587 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 102.24 -0.93 50.54 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 115.472 0.949 . . . . 0.0 115.472 177.392 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.421 ' N ' HD21 ' A' ' 27' ' ' LEU . 1.7 pt? -153.89 138.33 11.18 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 118.473 1.137 . . . . 0.0 111.263 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.606 ' HG3' HG22 ' A' ' 23' ' ' THR . 13.6 Cg_exo -68.36 104.24 1.05 Allowed 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 122.469 2.113 . . . . 0.0 112.747 -179.516 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.9 m . . . . . 0 C--N 1.323 -0.581 0 CA-C-O 121.627 0.727 . . . . 0.0 109.801 179.292 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.549 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 5.9 m . . . . . 0 CA--C 1.518 -0.285 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.78 32.21 83.4 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -178.29 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.573 ' OE2' ' HA ' ' A' ' 10' ' ' CYS . 27.3 tt0 -126.78 152.8 46.41 Favored 'General case' 0 N--CA 1.442 -0.843 0 CA-C-N 114.079 -1.06 . . . . 0.0 110.388 -177.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 29.1 p -111.83 141.33 45.6 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.778 178.824 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.652 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 23.3 p -115.61 46.73 1.45 Allowed 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.818 0.818 . . . . 0.0 109.341 178.163 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.9 t -57.78 -33.04 44.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 114.593 -1.185 . . . . 0.0 109.723 179.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.97 18.06 58.08 Favored Glycine 0 N--CA 1.447 -0.575 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.945 178.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 64.49 36.22 92.9 Favored Glycine 0 C--N 1.333 0.367 0 C-N-CA 121.274 -0.489 . . . . 0.0 112.768 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.6 154.77 43.9 Favored 'General case' 0 C--N 1.324 -0.515 0 O-C-N 122.749 -0.265 . . . . 0.0 110.31 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.573 ' HA ' ' OE2' ' A' ' 3' ' ' GLU . 86.2 m -139.57 133.98 31.51 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.664 179.037 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -89.19 -40.19 13.05 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.423 -179.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.684 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.5 m -60.95 119.67 47.02 Favored Pre-proline 0 C--O 1.237 0.402 0 CA-C-O 120.864 0.364 . . . . 0.0 110.668 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -64.72 114.16 2.63 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 122.478 2.118 . . . . 0.0 112.633 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 111.21 -6.91 28.78 Favored Glycine 0 N--CA 1.445 -0.717 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.659 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.684 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 75.3 m -91.54 122.76 34.41 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.48 0.657 . . . . 0.0 111.929 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.6 p -91.51 144.22 25.78 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.024 -0.989 . . . . 0.0 109.922 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.1 t -73.05 134.35 44.56 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.784 0.802 . . . . 0.0 111.116 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.9 m -146.79 67.37 1.16 Allowed 'General case' 0 C--N 1.31 -1.125 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 178.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.6 t90 -28.07 129.37 0.21 Allowed Pre-proline 0 N--CA 1.463 0.18 0 CA-C-N 113.86 -1.518 . . . . 0.0 113.386 -176.019 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -98.42 26.77 17.85 Favored 'Cis proline' 0 N--CA 1.461 -0.421 0 C-N-CA 123.719 -1.367 . . . . 0.0 113.3 0.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.608 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.1 m -132.21 147.71 32.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 113.782 1.03 . . . . 0.0 113.782 -177.367 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.652 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 95.3 m -83.97 124.95 31.57 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.673 179.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.459 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 32.9 p -103.75 155.64 18.44 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.651 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.549 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 36.1 ttp85 -135.85 124.24 23.39 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.126 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 62.41 29.15 17.15 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.732 -178.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.92 3.2 77.02 Favored Glycine 0 CA--C 1.522 0.517 0 CA-C-N 115.81 -0.632 . . . . 0.0 114.108 179.063 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.408 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.8 pt? -145.86 140.59 15.81 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 117.775 0.788 . . . . 0.0 110.611 179.456 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.459 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 24.2 Cg_exo -63.54 104.02 0.42 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.509 2.139 . . . . 0.0 113.021 -178.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.3 t . . . . . 0 C--N 1.326 -0.443 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.043 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.639 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 21.8 m . . . . . 0 CA--C 1.518 -0.252 0 CA-C-O 120.701 0.286 . . . . 0.0 110.252 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 67.09 31.3 77.38 Favored Glycine 0 C--N 1.333 0.406 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 -177.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -131.76 150.8 52.04 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 114.241 -0.98 . . . . 0.0 110.431 -178.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.595 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.8 p -112.73 141.44 46.52 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.441 178.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.602 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 23.7 p -114.88 45.86 1.52 Allowed 'General case' 0 C--N 1.317 -0.829 0 CA-C-O 121.788 0.804 . . . . 0.0 109.494 178.335 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.45 HG23 ' HB ' ' A' ' 4' ' ' THR . 11.5 t -56.5 -32.49 36.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 114.646 -1.161 . . . . 0.0 109.778 179.487 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.57 21.68 44.07 Favored Glycine 0 N--CA 1.448 -0.567 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.969 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.82 40.19 98.92 Favored Glycine 0 C--N 1.334 0.44 0 C-N-CA 121.385 -0.436 . . . . 0.0 112.738 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.56 147.24 32.93 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.662 0.268 . . . . 0.0 111.448 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.529 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 84.6 m -143.46 127.67 17.64 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 178.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -91.9 -28.33 17.35 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.206 -179.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.684 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.4 m -62.71 122.83 76.68 Favored Pre-proline 0 C--O 1.234 0.268 0 CA-C-O 120.88 0.372 . . . . 0.0 110.348 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 24.4 Cg_exo -63.75 115.31 3.0 Favored 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 122.267 1.978 . . . . 0.0 113.065 -179.321 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.53 5.75 51.29 Favored Glycine 0 N--CA 1.444 -0.776 0 CA-C-N 115.175 -0.921 . . . . 0.0 111.932 179.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.684 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 99.6 m -101.45 122.45 43.8 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.54 0.686 . . . . 0.0 111.963 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.4 p -94.19 147.59 23.02 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-N 114.929 -1.032 . . . . 0.0 110.083 179.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.3 t -74.53 134.32 42.22 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.696 0.76 . . . . 0.0 111.129 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 26.0 m -147.46 67.46 1.13 Allowed 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 178.816 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.6 t90 -27.99 129.32 0.21 Allowed Pre-proline 0 N--CA 1.462 0.164 0 CA-C-N 113.963 -1.471 . . . . 0.0 113.449 -176.187 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -98.41 24.46 20.9 Favored 'Cis proline' 0 N--CA 1.46 -0.496 0 C-N-CA 123.71 -1.371 . . . . 0.0 113.342 0.315 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.595 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.24 148.2 33.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 N-CA-C 113.658 0.985 . . . . 0.0 113.658 -177.399 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.602 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.3 m -83.89 126.53 33.07 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.619 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.419 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 22.2 p -103.06 151.6 22.35 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.003 -179.822 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.639 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 38.5 ttp85 -133.68 132.07 40.25 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.089 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 18.9 p30 52.43 28.36 5.81 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 124.019 0.927 . . . . 0.0 112.627 -178.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 97.48 5.58 57.82 Favored Glycine 0 CA--C 1.521 0.441 0 N-CA-C 114.782 0.673 . . . . 0.0 114.782 177.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.9 pp -154.18 146.85 17.64 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 118.103 0.952 . . . . 0.0 111.111 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -66.33 107.21 1.15 Allowed 'Trans proline' 0 N--CA 1.462 -0.359 0 C-N-CA 122.611 2.207 . . . . 0.0 111.95 -179.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.5 p . . . . . 0 C--N 1.32 -0.681 0 CA-C-O 122.63 1.205 . . . . 0.0 109.182 -179.964 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.577 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 13.1 m . . . . . 0 CA--C 1.518 -0.25 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.3 28.85 73.98 Favored Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -177.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -127.5 151.38 48.94 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-N 114.231 -0.984 . . . . 0.0 110.572 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.61 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.0 p -113.05 143.45 44.3 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.253 178.651 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.615 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 24.9 p -116.85 47.26 1.5 Allowed 'General case' 0 C--N 1.318 -0.787 0 CA-C-O 121.874 0.845 . . . . 0.0 109.369 178.525 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.2 t -57.1 -32.22 39.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 114.482 -1.235 . . . . 0.0 109.524 179.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.92 21.13 47.69 Favored Glycine 0 N--CA 1.447 -0.588 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.85 178.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.37 40.11 98.19 Favored Glycine 0 C--N 1.335 0.484 0 C-N-CA 121.503 -0.379 . . . . 0.0 112.786 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.24 144.92 27.99 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.617 0.246 . . . . 0.0 111.461 -179.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.481 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 79.6 m -135.74 131.83 36.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.72 179.418 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.6 m-80 -88.2 -36.03 17.02 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.735 -179.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.71 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.1 m -61.64 119.62 48.95 Favored Pre-proline 0 C--O 1.235 0.305 0 CA-C-O 120.974 0.416 . . . . 0.0 110.7 -179.535 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -63.7 114.05 2.4 Favored 'Trans proline' 0 N--CA 1.459 -0.545 0 C-N-CA 122.462 2.108 . . . . 0.0 112.873 -179.233 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 108.36 -2.48 32.83 Favored Glycine 0 N--CA 1.444 -0.786 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.759 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.71 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 81.6 m -94.33 122.5 36.94 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.375 0.607 . . . . 0.0 111.82 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.1 p -91.8 144.01 25.93 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.088 179.151 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.5 t -73.57 134.07 43.67 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.698 0.761 . . . . 0.0 111.091 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.6 m -147.28 68.2 1.14 Allowed 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 106.377 -1.712 . . . . 0.0 106.377 178.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.4 t90 -28.54 129.54 0.22 Allowed Pre-proline 0 C--O 1.232 0.166 0 CA-C-N 113.964 -1.471 . . . . 0.0 113.419 -176.091 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 66.3 Cg_endo -98.49 24.64 20.54 Favored 'Cis proline' 0 N--CA 1.461 -0.428 0 C-N-CA 123.747 -1.355 . . . . 0.0 113.318 0.423 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.61 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.18 147.79 33.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 113.714 1.005 . . . . 0.0 113.714 -177.299 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.615 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.0 m -83.66 123.57 29.95 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.578 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.564 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 27.2 p -99.58 152.84 19.58 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.56 179.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.577 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 30.9 ttt180 -129.09 128.39 43.43 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.062 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 41.92 38.62 1.07 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 113.616 0.969 . . . . 0.0 113.616 -179.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.28 2.19 55.73 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 115.611 1.004 . . . . 0.0 115.611 177.231 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.431 ' N ' HD21 ' A' ' 27' ' ' LEU . 1.9 pt? -157.76 139.19 9.77 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 118.532 1.166 . . . . 0.0 111.222 179.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.564 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 13.2 Cg_exo -68.61 103.92 1.05 Allowed 'Trans proline' 0 N--CA 1.462 -0.379 0 C-N-CA 122.418 2.079 . . . . 0.0 112.585 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.0 m . . . . . 0 C--N 1.322 -0.609 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.0 179.506 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.459 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 15.4 m . . . . . 0 CA--C 1.517 -0.303 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.76 31.09 79.77 Favored Glycine 0 C--N 1.333 0.41 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -177.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -134.38 148.81 50.74 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 113.983 -1.108 . . . . 0.0 110.349 -177.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 17.4 p -112.42 144.66 41.49 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.557 179.328 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.588 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.0 p -116.33 46.96 1.49 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.809 0.814 . . . . 0.0 109.402 178.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.451 HG21 ' HB ' ' A' ' 4' ' ' THR . 13.1 t -56.96 -32.81 40.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 114.638 -1.165 . . . . 0.0 109.505 179.344 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.35 21.94 43.44 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.947 178.318 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.39 40.31 98.47 Favored Glycine 0 C--N 1.334 0.472 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.684 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.77 144.63 27.15 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.735 0.302 . . . . 0.0 111.518 -179.218 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.544 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 78.1 m -136.95 133.12 35.3 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 179.319 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.3 m-80 -87.89 -32.27 19.04 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.18 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.609 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.7 m -63.56 117.06 30.93 Favored Pre-proline 0 C--O 1.236 0.352 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.706 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_exo -65.46 114.96 3.1 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 122.436 2.091 . . . . 0.0 112.372 -179.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.65 -7.55 31.86 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 115.472 -0.786 . . . . 0.0 111.533 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.609 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 86.3 m -91.21 121.78 33.28 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.461 0.648 . . . . 0.0 111.586 -179.84 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.7 p -89.99 141.78 28.33 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.201 179.324 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.0 t -72.02 133.87 45.55 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.607 0.717 . . . . 0.0 110.917 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.1 m -146.96 68.7 1.16 Allowed 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 179.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.1 t90 -28.65 129.98 0.21 Allowed Pre-proline 0 N--CA 1.462 0.14 0 CA-C-N 114.008 -1.451 . . . . 0.0 113.368 -176.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -97.88 22.71 24.17 Favored 'Cis proline' 0 N--CA 1.462 -0.378 0 C-N-CA 123.667 -1.389 . . . . 0.0 113.403 0.3 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.594 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -128.95 147.15 33.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -177.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.588 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.0 m -82.3 123.94 29.51 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.333 179.451 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.549 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 22.8 p -95.31 142.84 27.24 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.119 0.485 . . . . 0.0 110.495 179.416 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.459 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 49.9 ttp180 -103.49 111.87 24.51 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.699 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 20.6 p30 46.88 32.17 1.72 Allowed 'General case' 0 N--CA 1.471 0.619 0 O-C-N 124.334 1.021 . . . . 0.0 113.065 -178.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 122.86 -27.44 5.93 Favored Glycine 0 CA--C 1.521 0.468 0 C-N-CA 119.977 -1.106 . . . . 0.0 114.754 177.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -134.91 138.67 30.12 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 117.899 0.849 . . . . 0.0 111.306 -178.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.549 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 33.4 Cg_exo -60.64 103.75 0.24 Allowed 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.872 2.382 . . . . 0.0 113.269 -178.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.436 HG11 ' NH2' ' A' ' 24' ' ' ARG . 3.5 t . . . . . 0 C--N 1.325 -0.475 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 178.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.601 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 12.5 m . . . . . 0 CA--C 1.517 -0.297 0 CA-C-O 120.798 0.332 . . . . 0.0 110.128 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.99 30.7 77.53 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -177.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -130.29 150.99 51.28 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 114.211 -0.994 . . . . 0.0 110.608 -178.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.603 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.6 p -112.21 141.83 45.43 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.48 178.734 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.616 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 24.8 p -115.32 47.42 1.31 Allowed 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 121.87 0.843 . . . . 0.0 109.253 178.182 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.2 t -57.22 -32.04 39.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 114.599 -1.182 . . . . 0.0 109.453 179.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.68 21.13 47.71 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.855 178.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.17 39.9 97.8 Favored Glycine 0 C--N 1.335 0.492 0 C-N-CA 121.45 -0.405 . . . . 0.0 112.746 179.772 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.85 144.57 27.01 Favored 'General case' 0 C--N 1.324 -0.532 0 O-C-N 122.823 -0.222 . . . . 0.0 111.495 -179.361 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.506 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 81.7 m -135.04 133.44 39.37 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.826 179.543 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -89.81 -34.82 16.0 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.657 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.679 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.3 m -61.19 120.11 51.81 Favored Pre-proline 0 C--O 1.235 0.324 0 CA-C-O 120.95 0.405 . . . . 0.0 110.638 -179.589 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -63.92 113.49 2.2 Favored 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 122.425 2.083 . . . . 0.0 113.002 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 107.75 -1.53 34.06 Favored Glycine 0 N--CA 1.443 -0.854 0 CA-C-N 115.208 -0.905 . . . . 0.0 111.796 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.679 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 94.0 m -95.16 122.96 38.37 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.46 0.648 . . . . 0.0 111.844 -179.723 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.9 p -92.57 145.46 24.42 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 114.966 -1.016 . . . . 0.0 110.063 179.182 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.8 t -74.3 134.29 42.57 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.729 0.776 . . . . 0.0 111.175 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.7 m -147.49 68.12 1.13 Allowed 'General case' 0 C--N 1.311 -1.065 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.7 t90 -28.36 129.57 0.21 Allowed Pre-proline 0 N--CA 1.463 0.203 0 CA-C-N 113.936 -1.484 . . . . 0.0 113.41 -176.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -98.44 24.27 21.14 Favored 'Cis proline' 0 C--N 1.346 0.404 0 C-N-CA 123.678 -1.384 . . . . 0.0 113.24 0.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.603 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.1 m -129.93 148.45 33.2 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -177.316 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.616 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 82.6 m -84.1 124.56 31.24 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.655 179.657 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.621 HG22 ' HG3' ' A' ' 28' ' ' PRO . 25.7 p -100.26 150.48 22.51 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.514 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.601 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 36.9 ttt180 -126.78 128.67 46.95 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 179.161 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 41.74 38.51 0.97 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 113.75 1.019 . . . . 0.0 113.75 -179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.91 3.39 55.94 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 115.598 0.999 . . . . 0.0 115.598 177.26 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.8 pt? -158.17 138.73 9.16 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 118.465 1.132 . . . . 0.0 111.255 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.621 ' HG3' HG22 ' A' ' 23' ' ' THR . 13.2 Cg_exo -68.51 103.56 0.98 Allowed 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.511 2.141 . . . . 0.0 112.485 -179.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.6 m . . . . . 0 C--N 1.321 -0.638 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.929 179.554 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.476 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 6.4 m . . . . . 0 CA--C 1.518 -0.285 0 CA-C-O 120.573 0.225 . . . . 0.0 110.572 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.81 30.74 78.76 Favored Glycine 0 C--N 1.334 0.43 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -178.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -126.71 152.42 46.83 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 114.24 -0.98 . . . . 0.0 110.363 -178.29 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.614 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.5 p -113.35 143.64 44.12 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.514 178.667 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.597 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.8 p -118.07 47.88 1.5 Allowed 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.85 0.833 . . . . 0.0 109.238 178.576 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.452 HG22 ' HB ' ' A' ' 4' ' ' THR . 11.3 t -57.26 -32.44 40.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 114.506 -1.225 . . . . 0.0 109.597 179.518 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.04 20.53 50.46 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.9 178.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.78 39.62 97.7 Favored Glycine 0 C--N 1.336 0.558 0 C-N-CA 121.42 -0.419 . . . . 0.0 112.77 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.69 144.79 27.35 Favored 'General case' 0 C--N 1.323 -0.551 0 O-C-N 122.793 -0.239 . . . . 0.0 111.363 -179.24 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.497 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.0 m -134.26 132.82 40.11 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.863 179.555 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -86.01 -36.53 19.7 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.559 -179.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.619 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.3 m -63.35 117.85 37.99 Favored Pre-proline 0 C--O 1.235 0.326 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.754 -179.565 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -64.92 115.0 3.02 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 122.336 2.024 . . . . 0.0 112.354 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 111.21 -9.6 28.97 Favored Glycine 0 N--CA 1.445 -0.742 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.511 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.619 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 79.5 m -90.75 121.64 32.81 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.338 0.59 . . . . 0.0 111.539 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 3.2 p -89.64 143.2 27.0 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.256 -0.883 . . . . 0.0 110.223 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.3 t -73.5 134.15 43.8 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.765 0.793 . . . . 0.0 110.922 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.8 m -146.98 68.8 1.16 Allowed 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 178.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.4 t90 -28.53 129.68 0.21 Allowed Pre-proline 0 C--O 1.232 0.17 0 CA-C-N 113.909 -1.496 . . . . 0.0 113.476 -176.077 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -98.41 25.62 19.34 Favored 'Cis proline' 0 N--CA 1.461 -0.434 0 C-N-CA 123.753 -1.353 . . . . 0.0 113.25 0.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.614 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.98 147.68 33.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 -177.287 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.597 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 79.2 m -83.46 122.13 28.11 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.426 179.291 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.494 HG23 ' HG3' ' A' ' 28' ' ' PRO . 35.4 p -100.17 148.85 24.15 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.176 0.512 . . . . 0.0 111.048 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.56 HH21 HG21 ' A' ' 12' ' ' THR . 39.9 ttm180 -114.45 112.23 22.66 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.33 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.4 m-20 60.31 33.42 20.86 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.41 -178.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.59 -17.67 58.86 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 120.686 -0.769 . . . . 0.0 114.158 179.238 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.438 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.4 pt? -123.06 133.47 24.52 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 117.943 0.872 . . . . 0.0 110.76 -179.648 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.494 ' HG3' HG23 ' A' ' 23' ' ' THR . 24.6 Cg_exo -62.96 104.82 0.41 Allowed 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 122.854 2.369 . . . . 0.0 113.475 -178.761 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 4.4 t . . . . . 0 C--N 1.327 -0.404 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 178.905 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.594 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 30.5 m . . . . . 0 CA--C 1.516 -0.357 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.11 33.13 86.23 Favored Glycine 0 CA--C 1.507 -0.451 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 -177.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -138.03 147.4 44.11 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 113.963 -1.119 . . . . 0.0 110.453 -177.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 25.3 p -110.06 143.34 40.23 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.857 179.496 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.574 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 29.6 p -116.07 46.68 1.51 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.71 0.767 . . . . 0.0 109.277 177.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.48 HG22 ' HB ' ' A' ' 4' ' ' THR . 12.8 t -56.32 -32.65 35.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 114.712 -1.131 . . . . 0.0 109.691 179.385 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.44 23.05 37.79 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.854 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.98 40.5 98.55 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 121.477 -0.392 . . . . 0.0 112.638 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.23 144.0 27.38 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.75 0.31 . . . . 0.0 111.531 -179.268 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.562 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.3 m -136.91 132.96 35.19 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.367 179.31 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.6 m-80 -87.42 -31.72 19.91 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.097 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.594 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 2.0 m -63.84 117.17 32.83 Favored Pre-proline 0 C--O 1.236 0.345 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.852 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_exo -65.13 116.04 3.64 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 122.344 2.03 . . . . 0.0 112.261 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 107.78 -8.03 36.51 Favored Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.784 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.594 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 90.2 m -90.51 122.43 33.33 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.303 0.573 . . . . 0.0 111.639 -179.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.2 p -89.81 143.35 26.87 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.184 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.1 t -73.24 134.28 44.24 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.683 0.754 . . . . 0.0 111.02 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 m -147.06 68.66 1.16 Allowed 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 179.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.8 t90 -28.29 129.57 0.21 Allowed Pre-proline 0 C--O 1.232 0.17 0 CA-C-N 113.952 -1.476 . . . . 0.0 113.521 -176.272 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -98.14 23.12 23.21 Favored 'Cis proline' 0 N--CA 1.461 -0.422 0 C-N-CA 123.56 -1.433 . . . . 0.0 113.414 0.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.594 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.68 147.36 33.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 N-CA-C 113.66 0.985 . . . . 0.0 113.66 -177.503 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.574 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 76.0 m -82.29 125.61 31.17 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.482 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.47 HG21 ' HG3' ' A' ' 28' ' ' PRO . 30.2 p -101.03 145.89 28.14 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.104 0.478 . . . . 0.0 110.889 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.594 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 37.6 ttm180 -117.09 116.66 27.75 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 178.528 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.9 m-20 60.24 32.58 20.85 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 123.567 0.542 . . . . 0.0 110.681 -178.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 92.65 -12.22 70.31 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 120.84 -0.695 . . . . 0.0 114.373 179.012 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -124.94 134.8 26.02 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 118.113 0.957 . . . . 0.0 111.052 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.47 ' HG3' HG21 ' A' ' 23' ' ' THR . 15.9 Cg_exo -67.24 103.17 0.74 Allowed 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.671 2.248 . . . . 0.0 113.046 -179.318 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.415 HG22 ' HB3' ' A' ' 24' ' ' ARG . 10.3 m . . . . . 0 C--N 1.322 -0.614 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.625 179.113 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.2 m . . . . . 0 N--CA 1.455 -0.225 0 CA-C-O 120.82 0.343 . . . . 0.0 110.532 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.59 23.96 70.78 Favored Glycine 0 N--CA 1.45 -0.391 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 -178.572 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -117.51 152.15 35.66 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 114.015 -1.092 . . . . 0.0 109.702 -178.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.593 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.8 p -112.92 143.44 44.2 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 120.799 0.333 . . . . 0.0 110.884 179.471 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.573 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.8 p -117.07 46.93 1.58 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.756 0.789 . . . . 0.0 109.274 178.344 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.6 t -56.83 -32.69 39.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 114.55 -1.204 . . . . 0.0 109.631 179.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.65 21.51 45.74 Favored Glycine 0 N--CA 1.447 -0.615 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.836 178.303 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.66 39.32 97.24 Favored Glycine 0 C--N 1.335 0.527 0 C-N-CA 121.484 -0.389 . . . . 0.0 112.807 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.16 144.08 25.45 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.65 0.262 . . . . 0.0 111.585 -179.269 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.559 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.6 m -134.33 135.89 43.07 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.495 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -91.02 -31.49 16.28 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.694 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -63.23 117.71 36.23 Favored Pre-proline 0 C--O 1.237 0.418 0 CA-C-O 120.992 0.425 . . . . 0.0 110.69 -179.762 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -63.87 117.61 4.6 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 122.295 1.997 . . . . 0.0 112.554 -179.588 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.24 0.93 47.72 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.429 -0.805 . . . . 0.0 112.051 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.694 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 99.9 m -97.06 122.24 39.84 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.288 0.566 . . . . 0.0 111.262 -179.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.5 p -89.84 141.28 28.79 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.358 179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.3 t -72.39 134.1 45.26 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.68 0.752 . . . . 0.0 110.754 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.3 m -147.02 67.47 1.15 Allowed 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.8 t90 -27.94 129.64 0.2 Allowed Pre-proline 0 C--N 1.34 0.169 0 CA-C-N 113.917 -1.492 . . . . 0.0 113.526 -176.099 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -97.67 23.41 23.52 Favored 'Cis proline' 0 N--CA 1.461 -0.404 0 C-N-CA 123.574 -1.428 . . . . 0.0 113.364 0.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.593 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.62 146.3 34.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 N-CA-C 113.671 0.989 . . . . 0.0 113.671 -177.301 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.573 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.7 m -82.64 123.86 29.65 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.505 -0.771 . . . . 0.0 110.43 179.5 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.428 HG21 ' HG3' ' A' ' 28' ' ' PRO . 21.1 p -95.71 144.64 25.94 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.213 0.53 . . . . 0.0 111.076 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.9 103.88 15.84 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 178.237 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 20.1 p30 48.03 29.92 1.89 Allowed 'General case' 0 N--CA 1.472 0.661 0 O-C-N 124.249 0.968 . . . . 0.0 112.811 -178.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.57 -31.6 3.73 Favored Glycine 0 CA--C 1.522 0.473 0 C-N-CA 119.974 -1.108 . . . . 0.0 114.411 178.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.8 pt? -126.91 135.87 27.99 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 117.756 0.778 . . . . 0.0 111.393 -178.794 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.428 ' HG3' HG21 ' A' ' 23' ' ' THR . 39.2 Cg_exo -60.63 104.41 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.848 2.365 . . . . 0.0 113.293 -179.072 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.501 ' O ' HG13 ' A' ' 29' ' ' VAL . 25.8 t . . . . . 0 C--N 1.325 -0.497 0 CA-C-O 121.942 0.877 . . . . 0.0 108.882 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 9.5 m . . . . . 0 N--CA 1.452 -0.329 0 CA-C-O 120.671 0.272 . . . . 0.0 110.368 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.41 28.17 73.29 Favored Glycine 0 C--N 1.334 0.459 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 -178.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -125.18 150.0 47.38 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 114.148 -1.026 . . . . 0.0 110.016 -178.378 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.588 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.3 p -111.48 143.72 41.86 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.557 179.097 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.583 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.0 p -116.14 47.49 1.39 Allowed 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.835 0.826 . . . . 0.0 109.281 178.475 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.476 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.4 t -57.2 -32.28 40.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 114.503 -1.226 . . . . 0.0 109.487 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.07 20.65 49.97 Favored Glycine 0 N--CA 1.448 -0.529 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.766 178.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.93 39.03 96.99 Favored Glycine 0 C--N 1.336 0.547 0 C-N-CA 121.602 -0.332 . . . . 0.0 112.775 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.13 144.28 25.6 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.698 0.285 . . . . 0.0 111.562 -179.345 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.535 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 72.6 m -133.7 135.35 43.98 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.32 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -93.98 -29.7 15.11 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.441 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.752 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -63.38 121.67 71.23 Favored Pre-proline 0 C--O 1.237 0.404 0 CA-C-O 121.15 0.5 . . . . 0.0 111.014 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.2 Cg_exo -64.45 118.54 5.5 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.396 2.064 . . . . 0.0 112.641 -179.752 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.61 8.93 51.38 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.076 -0.965 . . . . 0.0 111.864 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.752 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 71.1 m -105.18 123.42 47.8 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.485 0.66 . . . . 0.0 111.958 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.3 p -94.07 142.51 27.31 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.144 179.274 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.1 t -72.8 134.23 44.83 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.624 0.726 . . . . 0.0 111.217 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.9 m -147.5 67.88 1.13 Allowed 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 106.502 -1.666 . . . . 0.0 106.502 178.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.1 t90 -28.02 129.6 0.21 Allowed Pre-proline 0 N--CA 1.462 0.174 0 CA-C-N 113.936 -1.484 . . . . 0.0 113.517 -176.205 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -97.98 23.47 22.95 Favored 'Cis proline' 0 N--CA 1.462 -0.34 0 C-N-CA 123.625 -1.406 . . . . 0.0 113.312 0.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.588 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.9 146.98 33.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 -177.378 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.0 m -83.02 121.98 27.73 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.621 179.615 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.47 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 35.5 p -98.3 146.43 25.67 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.37 179.56 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 13.5 ttt180 -109.21 114.65 28.53 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 20.1 p30 47.58 31.29 1.99 Allowed 'General case' 0 N--CA 1.472 0.662 0 O-C-N 124.269 0.981 . . . . 0.0 113.041 -178.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.9 -27.39 6.21 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 120.035 -1.079 . . . . 0.0 114.602 177.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.415 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 2.2 pt? -137.1 141.92 36.27 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 117.782 0.791 . . . . 0.0 111.17 -178.813 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.47 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 33.5 Cg_exo -58.07 105.88 0.23 Allowed 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 122.874 2.382 . . . . 0.0 113.539 -178.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.7 t . . . . . 0 C--N 1.325 -0.498 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 178.453 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 19.0 m . . . . . 0 CA--C 1.518 -0.262 0 CA-C-O 120.562 0.22 . . . . 0.0 110.583 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.89 32.92 85.78 Favored Glycine 0 C--N 1.334 0.469 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -178.359 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -132.56 148.81 52.38 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 114.245 -0.978 . . . . 0.0 110.286 -178.178 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.592 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 25.7 p -108.83 143.05 38.52 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.076 179.511 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.588 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.8 p -116.27 46.94 1.49 Allowed 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.791 0.805 . . . . 0.0 109.295 177.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.473 HG22 ' HB ' ' A' ' 4' ' ' THR . 12.9 t -56.44 -32.62 36.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 114.639 -1.164 . . . . 0.0 109.803 179.579 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.11 22.66 39.82 Favored Glycine 0 N--CA 1.447 -0.606 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.944 178.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.21 40.25 98.31 Favored Glycine 0 C--N 1.336 0.572 0 C-N-CA 121.414 -0.422 . . . . 0.0 112.598 179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.28 144.07 27.37 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.683 0.278 . . . . 0.0 111.566 -179.195 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.534 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 84.5 m -136.02 133.05 37.06 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.355 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -88.3 -32.51 18.42 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.126 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.795 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.0 OUTLIER -64.97 118.32 47.93 Favored Pre-proline 0 C--O 1.237 0.426 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.05 -179.56 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -64.96 118.38 5.38 Favored 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 122.354 2.036 . . . . 0.0 112.485 -179.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 104.38 2.56 44.27 Favored Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.704 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.795 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 70.8 m -99.44 121.93 41.83 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.305 0.574 . . . . 0.0 111.77 -179.818 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.1 p -89.87 140.39 29.65 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.96 179.068 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.4 t -72.16 133.91 45.41 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.678 0.752 . . . . 0.0 110.891 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.7 m -147.06 68.83 1.16 Allowed 'General case' 0 C--N 1.311 -1.076 0 N-CA-C 106.519 -1.66 . . . . 0.0 106.519 179.161 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.1 t90 -28.45 129.48 0.21 Allowed Pre-proline 0 C--O 1.232 0.154 0 CA-C-N 113.987 -1.461 . . . . 0.0 113.445 -176.119 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -98.29 24.26 21.35 Favored 'Cis proline' 0 N--CA 1.46 -0.457 0 C-N-CA 123.672 -1.387 . . . . 0.0 113.328 0.419 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.592 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.52 147.26 33.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 113.767 1.025 . . . . 0.0 113.767 -177.297 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.588 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 72.7 m -82.33 124.45 30.0 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.322 -0.853 . . . . 0.0 110.269 179.341 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.426 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 32.3 p -101.63 149.95 23.6 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.313 0.578 . . . . 0.0 111.574 -179.536 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.594 HH21 HG23 ' A' ' 12' ' ' THR . 15.9 tpp85 -105.89 103.52 13.03 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 70.9 m-20 58.45 34.67 24.15 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 123.379 0.425 . . . . 0.0 110.547 -178.592 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 102.01 -24.05 32.54 Favored Glycine 0 CA--C 1.522 0.524 0 C-N-CA 120.49 -0.862 . . . . 0.0 114.13 179.368 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.427 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.2 pt? -118.12 130.59 24.64 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 117.964 0.882 . . . . 0.0 110.709 -179.602 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 31.1 Cg_exo -59.22 105.91 0.27 Allowed 'Trans proline' 0 CA--C 1.526 0.109 0 C-N-CA 123.153 2.569 . . . . 0.0 113.722 -178.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 5.9 t . . . . . 0 C--N 1.327 -0.408 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 178.604 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.422 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 12.7 m . . . . . 0 N--CA 1.452 -0.356 0 CA-C-O 120.793 0.33 . . . . 0.0 110.4 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.22 29.67 75.9 Favored Glycine 0 C--N 1.333 0.405 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 -178.228 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -129.76 149.62 51.42 Favored 'General case' 0 N--CA 1.445 -0.698 0 CA-C-N 114.043 -1.079 . . . . 0.0 110.045 -178.362 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.591 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.0 p -110.28 144.34 39.12 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.705 179.313 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.572 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.9 p -116.82 46.93 1.55 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.811 0.815 . . . . 0.0 109.316 178.45 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.4 t -56.83 -32.57 39.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 114.683 -1.144 . . . . 0.0 109.671 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.63 21.23 47.2 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.84 178.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.73 39.86 98.01 Favored Glycine 0 C--N 1.335 0.486 0 C-N-CA 121.455 -0.403 . . . . 0.0 112.669 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.8 144.57 27.08 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.645 0.26 . . . . 0.0 111.553 -179.256 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.521 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 80.1 m -135.52 134.1 39.13 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.969 -0.559 . . . . 0.0 109.523 179.505 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 62.8 m-80 -91.77 -31.43 15.77 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.216 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.71 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -63.2 121.17 67.74 Favored Pre-proline 0 C--O 1.236 0.365 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.122 -179.317 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.5 Cg_exo -64.17 118.51 5.46 Favored 'Trans proline' 0 N--CA 1.457 -0.67 0 C-N-CA 122.365 2.044 . . . . 0.0 112.688 -179.771 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.9 5.48 54.98 Favored Glycine 0 N--CA 1.446 -0.642 0 CA-C-N 115.2 -0.909 . . . . 0.0 112.013 179.657 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.71 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 86.1 m -102.14 120.87 41.16 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.607 0.718 . . . . 0.0 112.12 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 3.0 p -90.97 144.99 25.1 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.794 178.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.5 t -73.75 134.41 43.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.738 0.78 . . . . 0.0 111.066 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.8 m -146.78 67.71 1.16 Allowed 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 178.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.2 t90 -28.21 129.45 0.21 Allowed Pre-proline 0 C--O 1.232 0.172 0 CA-C-N 113.958 -1.474 . . . . 0.0 113.392 -176.118 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -98.3 24.65 20.78 Favored 'Cis proline' 0 N--CA 1.462 -0.376 0 C-N-CA 123.676 -1.385 . . . . 0.0 113.324 0.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.591 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -130.81 148.2 33.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -177.314 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.572 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.5 m -83.53 128.54 34.59 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.586 179.518 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.4 p -108.29 149.9 28.03 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.042 -179.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.422 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 20.7 ttp180 -131.64 126.07 33.75 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.5 m-20 62.17 28.57 17.15 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.708 -178.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.99 5.32 77.29 Favored Glycine 0 CA--C 1.523 0.533 0 CA-C-N 115.715 -0.675 . . . . 0.0 114.101 179.087 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.463 ' HG ' HG23 ' A' ' 29' ' ' VAL . 1.8 pt? -148.21 142.65 16.65 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 117.851 0.825 . . . . 0.0 110.748 179.527 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 27.4 Cg_exo -62.6 104.58 0.37 Allowed 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.601 2.201 . . . . 0.0 112.926 -179.083 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.463 HG23 ' HG ' ' A' ' 27' ' ' LEU . 5.2 t . . . . . 0 C--N 1.324 -0.512 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 178.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.677 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 23.7 m . . . . . 0 CA--C 1.518 -0.287 0 CA-C-O 120.867 0.365 . . . . 0.0 110.083 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.74 31.4 79.72 Favored Glycine 0 C--N 1.334 0.469 0 N-CA-C 109.199 -1.561 . . . . 0.0 109.199 -177.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -134.6 148.21 50.38 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 113.957 -1.122 . . . . 0.0 110.32 -177.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.588 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.3 p -110.29 142.77 41.45 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.811 179.422 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.583 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.8 p -115.24 46.65 1.42 Allowed 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.722 0.772 . . . . 0.0 109.261 177.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.493 HG21 ' HB ' ' A' ' 4' ' ' THR . 12.6 t -56.56 -32.42 36.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 114.666 -1.152 . . . . 0.0 109.652 179.385 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.71 22.41 41.1 Favored Glycine 0 N--CA 1.447 -0.596 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.858 178.327 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.03 40.06 97.97 Favored Glycine 0 C--N 1.335 0.475 0 C-N-CA 121.499 -0.382 . . . . 0.0 112.734 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.56 143.94 25.92 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.694 0.283 . . . . 0.0 111.581 -179.202 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.568 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 68.4 m -136.14 134.84 38.7 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.471 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -91.2 -30.23 16.77 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.358 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.69 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.7 m -62.55 118.66 43.23 Favored Pre-proline 0 C--O 1.235 0.293 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.718 -179.78 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.9 Cg_exo -64.13 115.02 2.89 Favored 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.394 2.063 . . . . 0.0 112.851 -179.385 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.33 0.9 40.91 Favored Glycine 0 N--CA 1.445 -0.707 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.786 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.69 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 86.2 m -96.9 123.65 40.66 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.398 0.618 . . . . 0.0 111.82 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.9 p -92.66 144.05 25.7 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.074 179.15 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.3 t -73.44 134.26 43.92 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.607 0.718 . . . . 0.0 111.017 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.3 m -147.3 67.68 1.14 Allowed 'General case' 0 C--N 1.312 -1.061 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 179.025 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.7 t90 -28.11 129.45 0.21 Allowed Pre-proline 0 C--O 1.232 0.17 0 CA-C-N 114.067 -1.424 . . . . 0.0 113.448 -176.228 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -98.08 22.94 23.55 Favored 'Cis proline' 0 N--CA 1.461 -0.419 0 C-N-CA 123.671 -1.387 . . . . 0.0 113.391 0.321 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.588 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.37 148.24 33.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 113.627 0.973 . . . . 0.0 113.627 -177.433 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.3 m -83.61 127.65 33.91 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.761 179.743 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.472 HG21 ' HG3' ' A' ' 28' ' ' PRO . 21.2 p -101.55 150.75 22.75 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.774 179.786 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.677 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 33.8 ttt180 -132.63 124.13 27.72 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.534 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 59.84 30.6 20.15 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.058 0.456 . . . . 0.0 111.203 -179.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.81 7.58 74.43 Favored Glycine 0 CA--C 1.523 0.579 0 C-N-CA 121.095 -0.574 . . . . 0.0 114.29 178.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.505 HD12 HG13 ' A' ' 29' ' ' VAL . 1.5 pt? -148.32 137.6 12.15 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 117.875 0.838 . . . . 0.0 110.674 179.182 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.472 ' HG3' HG21 ' A' ' 23' ' ' THR . 16.9 Cg_exo -66.77 103.45 0.71 Allowed 'Trans proline' 0 N--CA 1.465 -0.185 0 C-N-CA 122.541 2.161 . . . . 0.0 112.656 -179.26 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.505 HG13 HD12 ' A' ' 27' ' ' LEU . 11.3 m . . . . . 0 C--N 1.323 -0.559 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.986 179.414 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.534 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 7.9 m . . . . . 0 CA--C 1.517 -0.307 0 CA-C-O 120.56 0.219 . . . . 0.0 110.568 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.07 31.52 81.11 Favored Glycine 0 C--N 1.334 0.441 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -178.264 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -129.42 151.81 49.65 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 114.152 -1.024 . . . . 0.0 110.519 -178.118 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.3 p -112.41 141.85 45.65 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.678 178.821 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.612 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.0 p -116.11 47.85 1.33 Allowed 'General case' 0 C--N 1.318 -0.797 0 CA-C-O 121.873 0.844 . . . . 0.0 109.264 177.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.477 HG21 ' HB ' ' A' ' 4' ' ' THR . 12.2 t -57.24 -32.2 40.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 114.573 -1.194 . . . . 0.0 109.703 179.559 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -96.88 20.68 49.76 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.856 178.307 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.54 39.29 97.14 Favored Glycine 0 C--N 1.335 0.512 0 C-N-CA 121.468 -0.396 . . . . 0.0 112.662 179.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.22 144.2 26.39 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.62 0.248 . . . . 0.0 111.266 -179.248 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.52 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 76.7 m -133.32 133.93 43.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.022 -0.536 . . . . 0.0 109.952 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -87.45 -35.02 18.49 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.441 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.588 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.6 m -63.17 118.12 40.0 Favored Pre-proline 0 C--O 1.236 0.365 0 CA-C-O 120.748 0.309 . . . . 0.0 110.747 -179.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -65.17 114.88 3.02 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.338 2.025 . . . . 0.0 112.297 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.24 -8.52 30.96 Favored Glycine 0 N--CA 1.445 -0.701 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.601 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.588 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 96.5 m -91.43 121.98 33.62 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.366 0.603 . . . . 0.0 111.619 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.7 p -89.76 144.38 26.02 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.251 179.348 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.0 t -74.28 134.16 42.61 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.615 0.721 . . . . 0.0 111.016 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.9 m -147.29 68.77 1.14 Allowed 'General case' 0 C--N 1.311 -1.072 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.019 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.1 t90 -28.32 129.65 0.21 Allowed Pre-proline 0 C--O 1.232 0.178 0 CA-C-N 113.978 -1.465 . . . . 0.0 113.399 -176.207 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 65.4 Cg_endo -98.42 24.91 20.26 Favored 'Cis proline' 0 N--CA 1.461 -0.441 0 C-N-CA 123.694 -1.377 . . . . 0.0 113.263 0.31 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.608 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.64 147.98 33.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 N-CA-C 113.688 0.996 . . . . 0.0 113.688 -177.386 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.612 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.9 m -83.4 123.04 29.28 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.453 179.44 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.484 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 28.1 p -99.0 147.14 25.31 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.193 0.52 . . . . 0.0 111.108 -179.732 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.534 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 40.5 ttm180 -114.14 112.86 23.88 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.386 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 60.43 33.06 20.71 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.438 -178.262 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.51 -16.97 60.19 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.75 -0.738 . . . . 0.0 114.207 179.175 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.423 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.4 pt? -123.91 133.99 25.04 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 117.935 0.868 . . . . 0.0 110.743 -179.651 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.484 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 24.5 Cg_exo -62.82 104.14 0.37 Allowed 'Trans proline' 0 N--CA 1.466 -0.115 0 C-N-CA 122.838 2.359 . . . . 0.0 113.523 -178.858 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 4.3 t . . . . . 0 C--N 1.327 -0.402 0 CA-C-O 122.108 0.956 . . . . 0.0 108.592 178.916 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 35.3 m . . . . . 0 CA--C 1.519 -0.239 0 CA-C-O 120.729 0.299 . . . . 0.0 110.698 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.64 32.65 83.81 Favored Glycine 0 C--N 1.335 0.475 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -178.222 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -137.75 148.41 45.57 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 114.205 -0.997 . . . . 0.0 110.405 -178.101 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.593 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 27.1 p -108.85 142.91 38.74 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.897 179.355 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.592 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.3 p -116.28 46.86 1.5 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.777 0.798 . . . . 0.0 109.277 177.846 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.476 HG22 ' HB ' ' A' ' 4' ' ' THR . 11.8 t -56.62 -32.75 38.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 114.607 -1.179 . . . . 0.0 109.795 179.566 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.84 22.7 39.64 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.919 178.443 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.87 40.48 98.36 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 121.446 -0.407 . . . . 0.0 112.615 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -147.85 144.07 27.88 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.654 0.264 . . . . 0.0 111.355 -179.195 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.544 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 79.3 m -136.58 133.76 36.72 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.993 -0.549 . . . . 0.0 109.718 179.555 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 62.6 m-80 -91.12 -31.35 16.26 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.947 179.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.646 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -62.55 118.96 46.08 Favored Pre-proline 0 C--O 1.237 0.398 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.846 -179.547 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_exo -64.08 118.92 5.84 Favored 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 122.231 1.954 . . . . 0.0 112.739 -179.619 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.42 10.77 53.32 Favored Glycine 0 N--CA 1.446 -0.688 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.977 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.646 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 95.5 m -105.48 121.52 44.1 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.456 0.646 . . . . 0.0 111.723 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 8.0 p -89.76 143.25 26.95 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 115.102 -0.953 . . . . 0.0 109.898 179.07 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.0 t -72.61 134.19 45.04 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.668 0.747 . . . . 0.0 110.954 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.9 m -146.09 67.58 1.19 Allowed 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.6 t90 -27.94 129.39 0.21 Allowed Pre-proline 0 C--O 1.233 0.201 0 CA-C-N 113.919 -1.491 . . . . 0.0 113.528 -176.202 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -98.04 24.82 20.89 Favored 'Cis proline' 0 N--CA 1.462 -0.346 0 C-N-CA 123.658 -1.392 . . . . 0.0 113.307 0.468 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.593 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -131.61 146.9 32.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -177.413 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.592 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 78.3 m -81.66 132.11 35.29 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.224 179.343 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 63.0 p -117.16 147.39 42.5 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.017 0.437 . . . . 0.0 111.608 -178.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 54.0 ttm-85 -108.56 114.27 27.96 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 177.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 54.8 m-20 61.33 35.25 18.1 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.143 0.497 . . . . 0.0 109.683 -178.252 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 72.83 27.82 68.22 Favored Glycine 0 N--CA 1.452 -0.269 0 CA-C-N 115.69 -0.686 . . . . 0.0 112.244 -179.276 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 10.1 tt -140.95 120.03 8.31 Favored Pre-proline 0 C--N 1.328 -0.355 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_exo -64.98 102.85 0.45 Allowed 'Trans proline' 0 N--CA 1.465 -0.148 0 C-N-CA 122.524 2.149 . . . . 0.0 112.841 -179.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.1 p . . . . . 0 C--N 1.322 -0.622 0 CA-C-O 122.055 0.931 . . . . 0.0 109.736 179.701 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 11.6 m . . . . . 0 CA--C 1.519 -0.241 0 CA-C-O 120.816 0.341 . . . . 0.0 110.47 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.44 31.96 82.6 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 109.476 -1.449 . . . . 0.0 109.476 -178.071 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -132.71 148.95 52.34 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 114.127 -1.036 . . . . 0.0 110.359 -177.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.595 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 25.7 p -110.12 142.72 41.23 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.891 179.34 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.581 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 29.9 p -115.72 46.97 1.42 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.655 0.74 . . . . 0.0 109.283 177.979 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.484 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.9 t -56.54 -32.64 37.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.685 179.492 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.05 22.0 43.13 Favored Glycine 0 N--CA 1.447 -0.617 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.836 178.443 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.27 39.58 97.41 Favored Glycine 0 C--N 1.335 0.518 0 C-N-CA 121.511 -0.376 . . . . 0.0 112.683 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -149.68 143.77 25.7 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.664 0.268 . . . . 0.0 111.557 -179.308 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.566 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 78.9 m -134.7 135.24 41.85 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 179.491 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -90.31 -30.84 17.22 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.633 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.5 m -62.95 117.97 37.84 Favored Pre-proline 0 C--O 1.236 0.35 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.655 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -64.37 116.48 3.78 Favored 'Trans proline' 0 N--CA 1.457 -0.658 0 C-N-CA 122.386 2.058 . . . . 0.0 112.662 -179.414 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.3 2.31 47.8 Favored Glycine 0 N--CA 1.445 -0.75 0 CA-C-N 115.373 -0.831 . . . . 0.0 112.107 179.635 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.633 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 88.9 m -97.78 123.13 41.6 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.334 0.588 . . . . 0.0 111.497 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.8 p -90.07 141.58 28.53 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.293 179.467 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.8 t -73.06 134.28 44.52 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.663 0.744 . . . . 0.0 110.95 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.2 m -147.19 68.61 1.15 Allowed 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.056 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.7 t90 -28.14 129.6 0.21 Allowed Pre-proline 0 N--CA 1.463 0.187 0 CA-C-N 113.962 -1.472 . . . . 0.0 113.421 -176.252 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -98.03 23.31 23.11 Favored 'Cis proline' 0 N--CA 1.461 -0.439 0 C-N-CA 123.62 -1.408 . . . . 0.0 113.275 0.307 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.595 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -129.99 147.02 33.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -177.4 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.581 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 77.3 m -82.05 125.34 30.71 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.494 179.464 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.538 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 32.4 p -101.06 146.47 27.41 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.156 0.503 . . . . 0.0 111.195 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.423 ' HG2' ' SG ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -101.79 107.86 19.19 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 177.879 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 17.7 p30 49.36 28.83 2.49 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 124.319 1.012 . . . . 0.0 112.776 -178.421 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 124.33 -29.62 4.99 Favored Glycine 0 CA--C 1.521 0.451 0 C-N-CA 120.035 -1.079 . . . . 0.0 114.518 178.141 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.412 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.7 pt? -125.81 135.46 27.05 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 117.776 0.788 . . . . 0.0 111.109 -179.007 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.538 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 35.0 Cg_exo -60.85 104.75 0.28 Allowed 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.861 2.374 . . . . 0.0 113.404 -178.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 6.1 t . . . . . 0 C--N 1.325 -0.475 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 178.874 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.659 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 8.9 m . . . . . 0 CA--C 1.518 -0.268 0 CA-C-O 120.763 0.316 . . . . 0.0 110.25 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.27 31.72 81.47 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -177.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -133.51 148.31 51.67 Favored 'General case' 0 N--CA 1.444 -0.766 0 CA-C-N 113.928 -1.136 . . . . 0.0 110.509 -177.72 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.588 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.4 p -110.45 142.86 41.6 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.808 179.325 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.565 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.6 p -115.36 46.95 1.38 Allowed 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.739 0.78 . . . . 0.0 109.278 178.071 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.478 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.8 t -56.55 -32.42 36.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 114.624 -1.171 . . . . 0.0 109.658 179.474 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.23 21.88 43.73 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 115.617 -0.72 . . . . 0.0 111.811 178.384 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.36 39.52 97.37 Favored Glycine 0 C--N 1.335 0.524 0 C-N-CA 121.527 -0.368 . . . . 0.0 112.668 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.03 143.86 25.43 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.684 0.278 . . . . 0.0 111.597 -179.294 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.565 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 70.4 m -134.78 135.01 41.51 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.421 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -88.58 -31.1 18.79 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.617 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.7 m -63.59 117.72 37.49 Favored Pre-proline 0 C--O 1.236 0.381 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.752 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_exo -65.05 115.66 3.41 Favored 'Trans proline' 0 N--CA 1.459 -0.536 0 C-N-CA 122.316 2.011 . . . . 0.0 112.438 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 108.87 -8.73 34.01 Favored Glycine 0 N--CA 1.446 -0.681 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.738 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.617 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 88.2 m -89.98 122.69 33.23 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.42 0.629 . . . . 0.0 111.762 -179.677 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.0 p -90.67 144.35 25.83 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.078 -0.964 . . . . 0.0 110.113 179.212 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.4 t -74.06 134.27 42.96 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.592 0.71 . . . . 0.0 111.092 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 m -147.45 68.27 1.13 Allowed 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 106.517 -1.661 . . . . 0.0 106.517 179.053 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.8 t90 -28.16 129.44 0.21 Allowed Pre-proline 0 N--CA 1.463 0.191 0 CA-C-N 114.007 -1.451 . . . . 0.0 113.437 -176.256 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -98.36 23.18 22.77 Favored 'Cis proline' 0 C--N 1.345 0.388 0 C-N-CA 123.617 -1.41 . . . . 0.0 113.257 0.334 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.588 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -129.48 148.64 33.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -177.447 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.56 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 73.5 m -83.55 126.19 32.55 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.723 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.536 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 20.1 p -99.68 148.2 24.6 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.771 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.659 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 57.9 ttp180 -130.4 131.94 45.52 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.024 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.6 p-10 44.59 36.4 1.72 Allowed 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 113.324 0.861 . . . . 0.0 113.324 -179.413 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.17 0.84 55.89 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 115.621 1.008 . . . . 0.0 115.621 177.272 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.448 HD22 ' N ' ' A' ' 27' ' ' LEU . 1.9 pt? -161.61 144.97 9.41 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 118.473 1.137 . . . . 0.0 111.046 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.536 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 20.8 Cg_exo -65.14 104.32 0.59 Allowed 'Trans proline' 0 N--CA 1.464 -0.255 0 C-N-CA 122.444 2.096 . . . . 0.0 112.904 -179.109 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.9 t . . . . . 0 C--N 1.325 -0.498 0 CA-C-O 122.063 0.935 . . . . 0.0 108.551 179.112 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.681 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 16.6 m . . . . . 0 CA--C 1.516 -0.33 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.5 30.28 76.24 Favored Glycine 0 N--CA 1.45 -0.422 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -177.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -130.24 152.69 49.38 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 114.126 -1.037 . . . . 0.0 110.544 -178.199 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.609 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.3 p -115.24 143.34 45.4 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.241 178.44 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.626 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.8 p -115.73 47.46 1.35 Allowed 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.915 0.865 . . . . 0.0 109.362 178.666 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -57.52 -32.23 41.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 114.552 -1.204 . . . . 0.0 109.481 179.387 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -96.51 19.9 52.69 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.828 178.281 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.9 39.73 97.91 Favored Glycine 0 C--N 1.335 0.48 0 C-N-CA 121.524 -0.37 . . . . 0.0 112.746 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.04 144.96 26.12 Favored 'General case' 0 C--N 1.324 -0.528 0 O-C-N 122.734 -0.274 . . . . 0.0 111.472 -179.275 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.513 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 85.6 m -134.62 133.57 40.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.088 -0.505 . . . . 0.0 109.81 179.539 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -90.14 -34.04 16.02 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.676 -179.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.679 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.1 m -61.98 121.19 63.82 Favored Pre-proline 0 C--O 1.236 0.366 0 CA-C-O 120.943 0.401 . . . . 0.0 110.654 -179.673 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -64.58 114.79 2.87 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.44 2.093 . . . . 0.0 112.691 -179.535 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 106.08 0.94 38.74 Favored Glycine 0 N--CA 1.445 -0.705 0 CA-C-N 115.465 -0.789 . . . . 0.0 111.68 179.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.679 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 84.2 m -98.91 119.74 38.19 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 121.46 0.648 . . . . 0.0 111.658 -179.8 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.8 p -90.59 144.82 25.39 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.023 179.095 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.7 t -72.84 134.4 44.85 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.697 0.761 . . . . 0.0 111.109 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.1 m -147.13 66.96 1.14 Allowed 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 106.217 -1.771 . . . . 0.0 106.217 178.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.9 t90 -28.24 129.53 0.21 Allowed Pre-proline 0 C--O 1.233 0.195 0 CA-C-N 113.89 -1.504 . . . . 0.0 113.436 -176.142 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 64.6 Cg_endo -98.32 24.19 21.41 Favored 'Cis proline' 0 N--CA 1.461 -0.384 0 C-N-CA 123.645 -1.398 . . . . 0.0 113.284 0.43 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.609 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -129.15 147.76 33.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 -177.409 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.626 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 91.8 m -84.37 123.76 30.55 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.737 179.663 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.54 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 34.6 p -100.08 146.46 26.75 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.338 179.531 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.681 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 25.5 ttp85 -117.4 122.05 42.75 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.879 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 21.6 p30 46.82 32.3 1.74 Allowed 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.342 1.057 . . . . 0.0 113.595 -179.031 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.48 -17.44 14.02 Favored Glycine 0 CA--C 1.522 0.489 0 C-N-CA 119.92 -1.133 . . . . 0.0 115.325 177.133 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.419 HD22 ' N ' ' A' ' 27' ' ' LEU . 2.2 pt? -144.13 144.36 25.83 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-N 118.367 1.083 . . . . 0.0 111.669 -178.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.54 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 16.9 Cg_exo -65.93 103.61 0.62 Allowed 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 122.623 2.215 . . . . 0.0 112.479 -179.738 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.435 ' CG2' ' HB3' ' A' ' 24' ' ' ARG . 3.6 m . . . . . 0 C--N 1.321 -0.651 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.231 179.22 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.535 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 11.6 m . . . . . 0 CA--C 1.517 -0.323 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.71 31.17 80.02 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 109.241 -1.543 . . . . 0.0 109.241 -178.099 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -132.76 149.08 52.32 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 114.0 -1.1 . . . . 0.0 110.147 -177.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.59 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.1 p -110.9 144.41 39.99 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.629 179.308 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.571 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.7 p -116.64 46.86 1.54 Allowed 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.789 0.804 . . . . 0.0 109.282 178.56 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.459 HG23 ' HB ' ' A' ' 4' ' ' THR . 11.9 t -56.85 -32.59 39.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 114.587 -1.188 . . . . 0.0 109.531 179.45 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.39 21.78 44.24 Favored Glycine 0 N--CA 1.446 -0.64 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.906 178.368 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.41 40.08 98.17 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 121.431 -0.414 . . . . 0.0 112.832 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.73 144.7 27.24 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.69 0.281 . . . . 0.0 111.514 -179.23 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.527 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.4 m -136.41 133.42 36.67 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.3 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -88.34 -32.21 18.52 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.189 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.661 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.6 m -63.25 118.85 47.37 Favored Pre-proline 0 C--O 1.236 0.382 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.816 -179.618 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -64.76 115.8 3.44 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.438 2.092 . . . . 0.0 112.553 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 106.4 -3.62 37.33 Favored Glycine 0 N--CA 1.445 -0.707 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.89 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.661 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 93.1 m -93.91 121.14 35.07 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.377 0.608 . . . . 0.0 111.822 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.4 p -89.88 143.87 26.43 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.053 178.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.6 t -73.26 134.36 44.23 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.7 0.762 . . . . 0.0 111.009 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.5 m -147.01 68.08 1.16 Allowed 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 106.378 -1.712 . . . . 0.0 106.378 178.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 8.3 t90 -28.3 129.52 0.21 Allowed Pre-proline 0 C--O 1.232 0.147 0 CA-C-N 113.874 -1.512 . . . . 0.0 113.413 -176.205 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -98.37 24.34 21.14 Favored 'Cis proline' 0 N--CA 1.46 -0.466 0 C-N-CA 123.696 -1.377 . . . . 0.0 113.324 0.34 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.59 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -130.32 148.27 33.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -177.325 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.571 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.5 m -83.59 127.23 33.58 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.602 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.436 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 32.1 p -105.46 149.04 26.52 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.762 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.535 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 41.3 ttp85 -130.86 123.94 30.14 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.253 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 79.4 m-20 62.11 29.31 17.55 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.779 -178.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.42 5.18 75.95 Favored Glycine 0 CA--C 1.523 0.549 0 CA-C-N 115.704 -0.68 . . . . 0.0 114.055 179.112 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.409 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.7 pt? -147.23 139.13 13.73 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 117.845 0.822 . . . . 0.0 110.765 179.415 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.436 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 23.4 Cg_exo -64.3 104.81 0.54 Allowed 'Trans proline' 0 N--CA 1.466 -0.142 0 C-N-CA 122.63 2.22 . . . . 0.0 112.878 -178.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.2 t . . . . . 0 C--N 1.326 -0.435 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.062 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.531 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 4.0 m . . . . . 0 CA--C 1.518 -0.276 0 CA-C-O 120.793 0.33 . . . . 0.0 110.501 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.3 31.09 79.71 Favored Glycine 0 C--N 1.334 0.435 0 N-CA-C 109.439 -1.465 . . . . 0.0 109.439 -178.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -128.79 149.33 50.77 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 113.883 -1.159 . . . . 0.0 109.793 -177.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.57 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 27.2 p -109.74 142.6 40.73 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.136 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.571 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 29.8 p -116.54 45.31 1.83 Allowed 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.64 0.734 . . . . 0.0 109.296 177.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.4 t -55.75 -33.33 33.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 114.735 -1.121 . . . . 0.0 109.906 179.477 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.74 22.59 39.71 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.708 -0.678 . . . . 0.0 112.011 178.57 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.99 40.24 99.06 Favored Glycine 0 C--N 1.334 0.461 0 C-N-CA 121.3 -0.476 . . . . 0.0 112.63 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -146.2 146.17 30.7 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.822 0.344 . . . . 0.0 111.565 -179.357 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.568 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 80.1 m -141.33 130.53 23.48 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 178.763 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -89.31 -27.19 20.69 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.48 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.595 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.8 m -65.56 117.48 41.43 Favored Pre-proline 0 C--O 1.237 0.423 0 CA-C-O 120.949 0.404 . . . . 0.0 110.259 179.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -64.14 114.04 2.48 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 122.315 2.01 . . . . 0.0 113.149 -179.064 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 107.28 -5.41 35.8 Favored Glycine 0 N--CA 1.442 -0.936 0 CA-C-N 115.282 -0.872 . . . . 0.0 112.014 179.609 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.595 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 99.5 m -89.9 123.11 33.55 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.403 0.62 . . . . 0.0 111.49 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.6 p -90.01 141.54 28.57 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.305 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 50.7 t -71.94 134.52 46.03 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.706 0.765 . . . . 0.0 110.911 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.3 m -147.08 68.1 1.15 Allowed 'General case' 0 C--N 1.312 -1.043 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 179.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . . . . . . . . . 7.7 t90 -27.73 129.26 0.2 Allowed Pre-proline 0 C--O 1.232 0.154 0 CA-C-N 113.976 -1.465 . . . . 0.0 113.516 -176.121 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 62.6 Cg_endo -97.91 23.14 23.54 Favored 'Cis proline' 0 N--CA 1.462 -0.376 0 C-N-CA 123.675 -1.386 . . . . 0.0 113.282 0.368 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.57 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.4 m -130.05 146.44 34.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 113.803 1.038 . . . . 0.0 113.803 -177.316 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.571 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 82.2 m -81.6 126.9 32.3 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.355 179.417 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.447 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 24.7 p -101.68 145.76 28.65 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.294 0.569 . . . . 0.0 111.426 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.531 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 27.1 tpt180 -117.48 117.28 29.03 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.212 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 63.5 m-20 60.48 32.23 20.47 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.465 -178.583 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.45 -12.73 69.08 Favored Glycine 0 CA--C 1.524 0.618 0 C-N-CA 120.808 -0.711 . . . . 0.0 114.214 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.405 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.5 pt? -129.21 137.14 30.34 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 118.113 0.956 . . . . 0.0 110.95 -179.814 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.447 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 24.7 Cg_exo -63.03 103.8 0.37 Allowed 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.679 2.252 . . . . 0.0 113.252 -178.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.455 ' O ' HG11 ' A' ' 29' ' ' VAL . 13.5 t . . . . . 0 C--N 1.325 -0.458 0 CA-C-O 121.958 0.885 . . . . 0.0 108.931 179.424 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.603 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 18.6 m . . . . . 0 CA--C 1.516 -0.334 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.46 30.85 78.52 Favored Glycine 0 CA--C 1.507 -0.455 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -178.052 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -131.06 150.91 51.93 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 114.214 -0.993 . . . . 0.0 110.676 -178.07 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.629 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.7 p -113.54 143.82 43.9 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.374 178.612 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.613 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.5 p -117.34 47.75 1.46 Allowed 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.838 0.828 . . . . 0.0 109.337 178.564 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.6 t -57.26 -32.31 40.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 114.458 -1.246 . . . . 0.0 109.51 179.407 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.13 20.67 49.9 Favored Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.873 178.358 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.55 39.86 97.93 Favored Glycine 0 C--N 1.335 0.525 0 C-N-CA 121.458 -0.401 . . . . 0.0 112.728 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.78 144.73 27.2 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.623 0.249 . . . . 0.0 111.455 -179.357 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.516 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.8 m -134.6 132.44 39.04 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.806 179.532 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -86.65 -36.17 18.93 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.585 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.718 HG21 HH21 ' A' ' 24' ' ' ARG . 3.6 m -62.34 118.36 39.54 Favored Pre-proline 0 C--O 1.235 0.324 0 CA-C-O 120.789 0.328 . . . . 0.0 110.625 -179.722 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -64.76 114.72 2.87 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 122.326 2.017 . . . . 0.0 112.382 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.44 -9.67 30.71 Favored Glycine 0 N--CA 1.446 -0.696 0 CA-C-N 115.445 -0.798 . . . . 0.0 111.594 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.607 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 100.0 m -89.89 121.69 32.23 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.364 0.602 . . . . 0.0 111.586 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.3 p -89.82 143.89 26.41 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.342 179.372 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.7 t -74.06 134.02 42.94 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.699 0.761 . . . . 0.0 110.905 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 m -147.27 69.08 1.15 Allowed 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.5 t90 -28.72 129.64 0.22 Allowed Pre-proline 0 C--O 1.232 0.157 0 CA-C-N 114.033 -1.44 . . . . 0.0 113.422 -176.086 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.449 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.9 Cg_endo -98.59 24.98 19.93 Favored 'Cis proline' 0 N--CA 1.461 -0.432 0 C-N-CA 123.695 -1.377 . . . . 0.0 113.297 0.389 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.629 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.54 147.83 33.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -177.315 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.613 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 81.2 m -83.47 122.74 28.92 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.442 179.363 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.9 p -97.76 152.63 18.94 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.952 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.718 HH21 HG21 ' A' ' 12' ' ' THR . 39.1 ttm180 -126.41 125.53 42.33 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 179.138 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 41.9 38.18 0.96 Allowed 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 113.587 0.958 . . . . 0.0 113.587 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.645 0 N-CA-C 115.472 0.949 . . . . 0.0 115.472 177.392 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.567 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 5.9 m . . . . . 0 CA--C 1.518 -0.285 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.78 32.21 83.4 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -178.29 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.577 ' OE2' ' HA ' ' A' ' 10' ' ' CYS . 27.3 tt0 -126.78 152.8 46.41 Favored 'General case' 0 N--CA 1.442 -0.843 0 CA-C-N 114.079 -1.06 . . . . 0.0 110.388 -177.776 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.643 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 29.1 p -111.83 141.33 45.6 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.778 178.824 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.669 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 23.3 p -115.61 46.73 1.45 Allowed 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.818 0.818 . . . . 0.0 109.341 178.163 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.415 HG23 ' HB ' ' A' ' 4' ' ' THR . 9.9 t -57.78 -33.04 44.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 114.593 -1.185 . . . . 0.0 109.723 179.5 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.97 18.06 58.08 Favored Glycine 0 N--CA 1.447 -0.575 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.945 178.433 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 64.49 36.22 92.9 Favored Glycine 0 C--N 1.333 0.367 0 C-N-CA 121.274 -0.489 . . . . 0.0 112.768 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.6 154.77 43.9 Favored 'General case' 0 C--N 1.324 -0.515 0 O-C-N 122.749 -0.265 . . . . 0.0 110.31 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.577 ' HA ' ' OE2' ' A' ' 3' ' ' GLU . 86.2 m -139.57 133.98 31.51 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.664 179.037 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -89.19 -40.19 13.05 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.423 -179.351 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.678 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.5 m -60.95 119.67 47.02 Favored Pre-proline 0 C--O 1.237 0.402 0 CA-C-O 120.864 0.364 . . . . 0.0 110.668 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -64.72 114.16 2.63 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 122.478 2.118 . . . . 0.0 112.633 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 111.21 -6.91 28.78 Favored Glycine 0 N--CA 1.445 -0.717 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.659 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.678 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 75.3 m -91.54 122.76 34.41 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.48 0.657 . . . . 0.0 111.929 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.6 p -91.51 144.22 25.78 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.024 -0.989 . . . . 0.0 109.922 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.1 t -73.05 134.35 44.56 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.784 0.802 . . . . 0.0 111.116 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.9 m -146.79 67.37 1.16 Allowed 'General case' 0 C--N 1.31 -1.125 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 178.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.407 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.6 t90 -28.07 129.37 0.21 Allowed Pre-proline 0 N--CA 1.463 0.18 0 CA-C-N 113.86 -1.518 . . . . 0.0 113.386 -176.019 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.5 Cg_endo -98.42 26.77 17.85 Favored 'Cis proline' 0 N--CA 1.461 -0.421 0 C-N-CA 123.719 -1.367 . . . . 0.0 113.3 0.269 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.643 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.1 m -132.21 147.71 32.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 113.782 1.03 . . . . 0.0 113.782 -177.367 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.669 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 95.3 m -83.97 124.95 31.57 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.673 179.516 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.413 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 32.9 p -103.75 155.64 18.44 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.651 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.567 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 36.1 ttp85 -135.85 124.24 23.39 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.126 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 62.41 29.15 17.15 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.732 -178.523 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.517 0 CA-C-N 115.81 -0.632 . . . . 0.0 114.108 179.063 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.654 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 21.8 m . . . . . 0 CA--C 1.518 -0.252 0 CA-C-O 120.701 0.286 . . . . 0.0 110.252 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 67.09 31.3 77.38 Favored Glycine 0 C--N 1.333 0.406 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 -177.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -131.76 150.8 52.04 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 114.241 -0.98 . . . . 0.0 110.431 -178.105 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.614 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.8 p -112.73 141.44 46.52 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.441 178.732 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.616 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 23.7 p -114.88 45.86 1.52 Allowed 'General case' 0 C--N 1.317 -0.829 0 CA-C-O 121.788 0.804 . . . . 0.0 109.494 178.335 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.415 HG23 ' HB ' ' A' ' 4' ' ' THR . 11.5 t -56.5 -32.49 36.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 114.646 -1.161 . . . . 0.0 109.778 179.487 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.57 21.68 44.07 Favored Glycine 0 N--CA 1.448 -0.567 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.969 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.82 40.19 98.92 Favored Glycine 0 C--N 1.334 0.44 0 C-N-CA 121.385 -0.436 . . . . 0.0 112.738 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.56 147.24 32.93 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.662 0.268 . . . . 0.0 111.448 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.544 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 84.6 m -143.46 127.67 17.64 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 178.817 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -91.9 -28.33 17.35 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.206 -179.52 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.677 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.4 m -62.71 122.83 76.68 Favored Pre-proline 0 C--O 1.234 0.268 0 CA-C-O 120.88 0.372 . . . . 0.0 110.348 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 24.4 Cg_exo -63.75 115.31 3.0 Favored 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 122.267 1.978 . . . . 0.0 113.065 -179.321 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.53 5.75 51.29 Favored Glycine 0 N--CA 1.444 -0.776 0 CA-C-N 115.175 -0.921 . . . . 0.0 111.932 179.581 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.677 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 99.6 m -101.45 122.45 43.8 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.54 0.686 . . . . 0.0 111.963 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.4 p -94.19 147.59 23.02 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-N 114.929 -1.032 . . . . 0.0 110.083 179.158 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.3 t -74.53 134.32 42.22 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.696 0.76 . . . . 0.0 111.129 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 26.0 m -147.46 67.46 1.13 Allowed 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 178.816 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.463 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.6 t90 -27.99 129.32 0.21 Allowed Pre-proline 0 N--CA 1.462 0.164 0 CA-C-N 113.963 -1.471 . . . . 0.0 113.449 -176.187 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.5 Cg_endo -98.41 24.46 20.9 Favored 'Cis proline' 0 N--CA 1.46 -0.496 0 C-N-CA 123.71 -1.371 . . . . 0.0 113.342 0.315 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.614 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.24 148.2 33.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 N-CA-C 113.658 0.985 . . . . 0.0 113.658 -177.399 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.616 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.3 m -83.89 126.53 33.07 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.619 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.437 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 22.2 p -103.06 151.6 22.35 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.003 -179.822 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.654 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 38.5 ttp85 -133.68 132.07 40.25 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.089 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 18.9 p30 52.43 28.36 5.81 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 124.019 0.927 . . . . 0.0 112.627 -178.594 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.441 0 N-CA-C 114.782 0.673 . . . . 0.0 114.782 177.345 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.584 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 13.1 m . . . . . 0 CA--C 1.518 -0.25 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.3 28.85 73.98 Favored Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -177.871 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -127.5 151.38 48.94 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-N 114.231 -0.984 . . . . 0.0 110.572 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.625 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.0 p -113.05 143.45 44.3 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.253 178.651 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.629 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 24.9 p -116.85 47.26 1.5 Allowed 'General case' 0 C--N 1.318 -0.787 0 CA-C-O 121.874 0.845 . . . . 0.0 109.369 178.525 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.2 t -57.1 -32.22 39.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 114.482 -1.235 . . . . 0.0 109.524 179.323 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.92 21.13 47.69 Favored Glycine 0 N--CA 1.447 -0.588 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.85 178.346 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.37 40.11 98.19 Favored Glycine 0 C--N 1.335 0.484 0 C-N-CA 121.503 -0.379 . . . . 0.0 112.786 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.24 144.92 27.99 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.617 0.246 . . . . 0.0 111.461 -179.229 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.497 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 79.6 m -135.74 131.83 36.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.72 179.418 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.6 m-80 -88.2 -36.03 17.02 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.735 -179.411 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.708 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.1 m -61.64 119.62 48.95 Favored Pre-proline 0 C--O 1.235 0.305 0 CA-C-O 120.974 0.416 . . . . 0.0 110.7 -179.535 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -63.7 114.05 2.4 Favored 'Trans proline' 0 N--CA 1.459 -0.545 0 C-N-CA 122.462 2.108 . . . . 0.0 112.873 -179.233 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 108.36 -2.48 32.83 Favored Glycine 0 N--CA 1.444 -0.786 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.759 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.708 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 81.6 m -94.33 122.5 36.94 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.375 0.607 . . . . 0.0 111.82 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.1 p -91.8 144.01 25.93 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.088 179.151 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.5 t -73.57 134.07 43.67 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.698 0.761 . . . . 0.0 111.091 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.6 m -147.28 68.2 1.14 Allowed 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 106.377 -1.712 . . . . 0.0 106.377 178.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.458 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.4 t90 -28.54 129.54 0.22 Allowed Pre-proline 0 C--O 1.232 0.166 0 CA-C-N 113.964 -1.471 . . . . 0.0 113.419 -176.091 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.3 Cg_endo -98.49 24.64 20.54 Favored 'Cis proline' 0 N--CA 1.461 -0.428 0 C-N-CA 123.747 -1.355 . . . . 0.0 113.318 0.423 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.625 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.18 147.79 33.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 113.714 1.005 . . . . 0.0 113.714 -177.299 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.629 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.0 m -83.66 123.57 29.95 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.578 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.2 p -99.58 152.84 19.58 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.56 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.584 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 30.9 ttt180 -129.09 128.39 43.43 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.062 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 41.92 38.62 1.07 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 113.616 0.969 . . . . 0.0 113.616 -179.602 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.596 0 N-CA-C 115.611 1.004 . . . . 0.0 115.611 177.231 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.46 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 15.4 m . . . . . 0 CA--C 1.517 -0.303 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.76 31.09 79.77 Favored Glycine 0 C--N 1.333 0.41 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -177.821 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -134.38 148.81 50.74 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 113.983 -1.108 . . . . 0.0 110.349 -177.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 17.4 p -112.42 144.66 41.49 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.557 179.328 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.599 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.0 p -116.33 46.96 1.49 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.809 0.814 . . . . 0.0 109.402 178.515 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -56.96 -32.81 40.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 114.638 -1.165 . . . . 0.0 109.505 179.344 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.35 21.94 43.44 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.947 178.318 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.39 40.31 98.47 Favored Glycine 0 C--N 1.334 0.472 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.684 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.77 144.63 27.15 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.735 0.302 . . . . 0.0 111.518 -179.218 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.559 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 78.1 m -136.95 133.12 35.3 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 179.319 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.3 m-80 -87.89 -32.27 19.04 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.18 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.607 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.7 m -63.56 117.06 30.93 Favored Pre-proline 0 C--O 1.236 0.352 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.706 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_exo -65.46 114.96 3.1 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 122.436 2.091 . . . . 0.0 112.372 -179.608 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.65 -7.55 31.86 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 115.472 -0.786 . . . . 0.0 111.533 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.607 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 86.3 m -91.21 121.78 33.28 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.461 0.648 . . . . 0.0 111.586 -179.84 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.7 p -89.99 141.78 28.33 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.201 179.324 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.0 t -72.02 133.87 45.55 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.607 0.717 . . . . 0.0 110.917 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.1 m -146.96 68.7 1.16 Allowed 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 179.052 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.453 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.1 t90 -28.65 129.98 0.21 Allowed Pre-proline 0 N--CA 1.462 0.14 0 CA-C-N 114.008 -1.451 . . . . 0.0 113.368 -176.172 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 63.8 Cg_endo -97.88 22.71 24.17 Favored 'Cis proline' 0 N--CA 1.462 -0.378 0 C-N-CA 123.667 -1.389 . . . . 0.0 113.403 0.3 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.608 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -128.95 147.15 33.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -177.402 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.599 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.0 m -82.3 123.94 29.51 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.333 179.451 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 22.8 p -95.31 142.84 27.24 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.119 0.485 . . . . 0.0 110.495 179.416 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.46 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 49.9 ttp180 -103.49 111.87 24.51 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.699 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 20.6 p30 46.88 32.17 1.72 Allowed 'General case' 0 N--CA 1.471 0.619 0 O-C-N 124.334 1.021 . . . . 0.0 113.065 -178.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.468 0 C-N-CA 119.977 -1.106 . . . . 0.0 114.754 177.935 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.602 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 12.5 m . . . . . 0 CA--C 1.517 -0.297 0 CA-C-O 120.798 0.332 . . . . 0.0 110.128 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.99 30.7 77.53 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -177.887 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -130.29 150.99 51.28 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 114.211 -0.994 . . . . 0.0 110.608 -178.141 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.619 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.6 p -112.21 141.83 45.43 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.48 178.734 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.629 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 24.8 p -115.32 47.42 1.31 Allowed 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 121.87 0.843 . . . . 0.0 109.253 178.182 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.406 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.2 t -57.22 -32.04 39.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 114.599 -1.182 . . . . 0.0 109.453 179.486 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.68 21.13 47.71 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.855 178.326 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.17 39.9 97.8 Favored Glycine 0 C--N 1.335 0.492 0 C-N-CA 121.45 -0.405 . . . . 0.0 112.746 179.772 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.85 144.57 27.01 Favored 'General case' 0 C--N 1.324 -0.532 0 O-C-N 122.823 -0.222 . . . . 0.0 111.495 -179.361 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.522 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 81.7 m -135.04 133.44 39.37 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.826 179.543 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 33.1 m-20 -89.81 -34.82 16.0 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.657 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.678 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.3 m -61.19 120.11 51.81 Favored Pre-proline 0 C--O 1.235 0.324 0 CA-C-O 120.95 0.405 . . . . 0.0 110.638 -179.589 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -63.92 113.49 2.2 Favored 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 122.425 2.083 . . . . 0.0 113.002 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 107.75 -1.53 34.06 Favored Glycine 0 N--CA 1.443 -0.854 0 CA-C-N 115.208 -0.905 . . . . 0.0 111.796 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.678 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 94.0 m -95.16 122.96 38.37 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.46 0.648 . . . . 0.0 111.844 -179.723 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.9 p -92.57 145.46 24.42 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 114.966 -1.016 . . . . 0.0 110.063 179.182 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.8 t -74.3 134.29 42.57 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.729 0.776 . . . . 0.0 111.175 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.7 m -147.49 68.12 1.13 Allowed 'General case' 0 C--N 1.311 -1.065 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.7 t90 -28.36 129.57 0.21 Allowed Pre-proline 0 N--CA 1.463 0.203 0 CA-C-N 113.936 -1.484 . . . . 0.0 113.41 -176.129 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 65.1 Cg_endo -98.44 24.27 21.14 Favored 'Cis proline' 0 C--N 1.346 0.404 0 C-N-CA 123.678 -1.384 . . . . 0.0 113.24 0.315 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.619 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.1 m -129.93 148.45 33.2 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -177.316 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.629 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 82.6 m -84.1 124.56 31.24 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.655 179.657 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.7 p -100.26 150.48 22.51 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.514 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.602 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 36.9 ttt180 -126.78 128.67 46.95 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 179.161 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 41.74 38.51 0.97 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 113.75 1.019 . . . . 0.0 113.75 -179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.63 0 N-CA-C 115.598 0.999 . . . . 0.0 115.598 177.26 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.486 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 6.4 m . . . . . 0 CA--C 1.518 -0.285 0 CA-C-O 120.573 0.225 . . . . 0.0 110.572 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.81 30.74 78.76 Favored Glycine 0 C--N 1.334 0.43 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -178.213 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -126.71 152.42 46.83 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 114.24 -0.98 . . . . 0.0 110.363 -178.29 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.63 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.5 p -113.35 143.64 44.12 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.514 178.667 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.609 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.8 p -118.07 47.88 1.5 Allowed 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.85 0.833 . . . . 0.0 109.238 178.576 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.3 t -57.26 -32.44 40.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 114.506 -1.225 . . . . 0.0 109.597 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.04 20.53 50.46 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.9 178.389 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.78 39.62 97.7 Favored Glycine 0 C--N 1.336 0.558 0 C-N-CA 121.42 -0.419 . . . . 0.0 112.77 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.69 144.79 27.35 Favored 'General case' 0 C--N 1.323 -0.551 0 O-C-N 122.793 -0.239 . . . . 0.0 111.363 -179.24 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.514 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.0 m -134.26 132.82 40.11 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.863 179.555 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -86.01 -36.53 19.7 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.559 -179.71 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.699 HG21 HH21 ' A' ' 24' ' ' ARG . 3.3 m -63.35 117.85 37.99 Favored Pre-proline 0 C--O 1.235 0.326 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.754 -179.565 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -64.92 115.0 3.02 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 122.336 2.024 . . . . 0.0 112.354 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 111.21 -9.6 28.97 Favored Glycine 0 N--CA 1.445 -0.742 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.511 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.611 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 79.5 m -90.75 121.64 32.81 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.338 0.59 . . . . 0.0 111.539 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 3.2 p -89.64 143.2 27.0 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.256 -0.883 . . . . 0.0 110.223 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.3 t -73.5 134.15 43.8 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.765 0.793 . . . . 0.0 110.922 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.8 m -146.98 68.8 1.16 Allowed 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 178.926 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.4 t90 -28.53 129.68 0.21 Allowed Pre-proline 0 C--O 1.232 0.17 0 CA-C-N 113.909 -1.496 . . . . 0.0 113.476 -176.077 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.0 Cg_endo -98.41 25.62 19.34 Favored 'Cis proline' 0 N--CA 1.461 -0.434 0 C-N-CA 123.753 -1.353 . . . . 0.0 113.25 0.362 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.63 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.98 147.68 33.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 -177.287 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.609 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 79.2 m -83.46 122.13 28.11 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.426 179.291 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 35.4 p -100.17 148.85 24.15 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.176 0.512 . . . . 0.0 111.048 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.699 HH21 HG21 ' A' ' 12' ' ' THR . 39.9 ttm180 -114.45 112.23 22.66 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.33 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.4 m-20 60.31 33.42 20.86 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.41 -178.318 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.54 0 C-N-CA 120.686 -0.769 . . . . 0.0 114.158 179.238 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.606 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 30.5 m . . . . . 0 CA--C 1.516 -0.357 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.11 33.13 86.23 Favored Glycine 0 CA--C 1.507 -0.451 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 -177.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -138.03 147.4 44.11 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 113.963 -1.119 . . . . 0.0 110.453 -177.707 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.609 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 25.3 p -110.06 143.34 40.23 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.857 179.496 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.585 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 29.6 p -116.07 46.68 1.51 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.71 0.767 . . . . 0.0 109.277 177.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.403 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.8 t -56.32 -32.65 35.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 114.712 -1.131 . . . . 0.0 109.691 179.385 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.44 23.05 37.79 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.854 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.98 40.5 98.55 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 121.477 -0.392 . . . . 0.0 112.638 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.23 144.0 27.38 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.75 0.31 . . . . 0.0 111.531 -179.268 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.578 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.3 m -136.91 132.96 35.19 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.367 179.31 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.6 m-80 -87.42 -31.72 19.91 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.097 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.726 HG21 HH21 ' A' ' 24' ' ' ARG . 2.0 m -63.84 117.17 32.83 Favored Pre-proline 0 C--O 1.236 0.345 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.852 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_exo -65.13 116.04 3.64 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 122.344 2.03 . . . . 0.0 112.261 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 107.78 -8.03 36.51 Favored Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.784 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.586 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 90.2 m -90.51 122.43 33.33 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.303 0.573 . . . . 0.0 111.639 -179.842 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.2 p -89.81 143.35 26.87 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.184 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.1 t -73.24 134.28 44.24 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.683 0.754 . . . . 0.0 111.02 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 m -147.06 68.66 1.16 Allowed 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 179.064 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.8 t90 -28.29 129.57 0.21 Allowed Pre-proline 0 C--O 1.232 0.17 0 CA-C-N 113.952 -1.476 . . . . 0.0 113.521 -176.272 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.9 Cg_endo -98.14 23.12 23.21 Favored 'Cis proline' 0 N--CA 1.461 -0.422 0 C-N-CA 123.56 -1.433 . . . . 0.0 113.414 0.381 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.609 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.68 147.36 33.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 N-CA-C 113.66 0.985 . . . . 0.0 113.66 -177.503 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.585 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 76.0 m -82.29 125.61 31.17 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.482 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 30.2 p -101.03 145.89 28.14 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.104 0.478 . . . . 0.0 110.889 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.726 HH21 HG21 ' A' ' 12' ' ' THR . 37.6 ttm180 -117.09 116.66 27.75 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 178.528 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.9 m-20 60.24 32.58 20.85 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 123.567 0.542 . . . . 0.0 110.681 -178.463 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.623 0 C-N-CA 120.84 -0.695 . . . . 0.0 114.373 179.012 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.2 m . . . . . 0 N--CA 1.455 -0.225 0 CA-C-O 120.82 0.343 . . . . 0.0 110.532 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.59 23.96 70.78 Favored Glycine 0 N--CA 1.45 -0.391 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 -178.572 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -117.51 152.15 35.66 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 114.015 -1.092 . . . . 0.0 109.702 -178.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.614 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.8 p -112.92 143.44 44.2 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 120.799 0.333 . . . . 0.0 110.884 179.471 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.585 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.8 p -117.07 46.93 1.58 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.756 0.789 . . . . 0.0 109.274 178.344 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.402 HG23 ' HB ' ' A' ' 4' ' ' THR . 11.6 t -56.83 -32.69 39.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 114.55 -1.204 . . . . 0.0 109.631 179.307 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.65 21.51 45.74 Favored Glycine 0 N--CA 1.447 -0.615 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.836 178.303 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.66 39.32 97.24 Favored Glycine 0 C--N 1.335 0.527 0 C-N-CA 121.484 -0.389 . . . . 0.0 112.807 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.16 144.08 25.45 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.65 0.262 . . . . 0.0 111.585 -179.269 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.576 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.6 m -134.33 135.89 43.07 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.495 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 45.8 m-20 -91.02 -31.49 16.28 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.691 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -63.23 117.71 36.23 Favored Pre-proline 0 C--O 1.237 0.418 0 CA-C-O 120.992 0.425 . . . . 0.0 110.69 -179.762 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -63.87 117.61 4.6 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 122.295 1.997 . . . . 0.0 112.554 -179.588 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.24 0.93 47.72 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.429 -0.805 . . . . 0.0 112.051 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.691 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 99.9 m -97.06 122.24 39.84 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.288 0.566 . . . . 0.0 111.262 -179.889 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.5 p -89.84 141.28 28.79 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.358 179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.3 t -72.39 134.1 45.26 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.68 0.752 . . . . 0.0 110.754 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.3 m -147.02 67.47 1.15 Allowed 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.423 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.8 t90 -27.94 129.64 0.2 Allowed Pre-proline 0 C--N 1.34 0.169 0 CA-C-N 113.917 -1.492 . . . . 0.0 113.526 -176.099 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.423 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.5 Cg_endo -97.67 23.41 23.52 Favored 'Cis proline' 0 N--CA 1.461 -0.404 0 C-N-CA 123.574 -1.428 . . . . 0.0 113.364 0.317 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.614 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.62 146.3 34.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 N-CA-C 113.671 0.989 . . . . 0.0 113.671 -177.301 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.585 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.7 m -82.64 123.86 29.65 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.505 -0.771 . . . . 0.0 110.43 179.5 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 21.1 p -95.71 144.64 25.94 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.213 0.53 . . . . 0.0 111.076 179.767 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.9 103.88 15.84 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 178.237 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 48.03 29.92 1.89 Allowed 'General case' 0 N--CA 1.472 0.661 0 O-C-N 124.249 0.968 . . . . 0.0 112.811 -178.362 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.473 0 C-N-CA 119.974 -1.108 . . . . 0.0 114.411 178.282 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 9.5 m . . . . . 0 N--CA 1.452 -0.329 0 CA-C-O 120.671 0.272 . . . . 0.0 110.368 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.41 28.17 73.29 Favored Glycine 0 C--N 1.334 0.459 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 -178.354 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -125.18 150.0 47.38 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 114.148 -1.026 . . . . 0.0 110.016 -178.378 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.604 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.3 p -111.48 143.72 41.86 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.557 179.097 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.594 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.0 p -116.14 47.49 1.39 Allowed 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.835 0.826 . . . . 0.0 109.281 178.475 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.403 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.4 t -57.2 -32.28 40.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 114.503 -1.226 . . . . 0.0 109.487 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.07 20.65 49.97 Favored Glycine 0 N--CA 1.448 -0.529 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.766 178.285 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.93 39.03 96.99 Favored Glycine 0 C--N 1.336 0.547 0 C-N-CA 121.602 -0.332 . . . . 0.0 112.775 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.13 144.28 25.6 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.698 0.285 . . . . 0.0 111.562 -179.345 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.551 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 72.6 m -133.7 135.35 43.98 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.32 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 48.4 m-20 -93.98 -29.7 15.11 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.441 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.749 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -63.38 121.67 71.23 Favored Pre-proline 0 C--O 1.237 0.404 0 CA-C-O 121.15 0.5 . . . . 0.0 111.014 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.2 Cg_exo -64.45 118.54 5.5 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.396 2.064 . . . . 0.0 112.641 -179.752 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.61 8.93 51.38 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.076 -0.965 . . . . 0.0 111.864 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.749 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 71.1 m -105.18 123.42 47.8 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.485 0.66 . . . . 0.0 111.958 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.3 p -94.07 142.51 27.31 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.144 179.274 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.1 t -72.8 134.23 44.83 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.624 0.726 . . . . 0.0 111.217 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.9 m -147.5 67.88 1.13 Allowed 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 106.502 -1.666 . . . . 0.0 106.502 178.837 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.1 t90 -28.02 129.6 0.21 Allowed Pre-proline 0 N--CA 1.462 0.174 0 CA-C-N 113.936 -1.484 . . . . 0.0 113.517 -176.205 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 64.2 Cg_endo -97.98 23.47 22.95 Favored 'Cis proline' 0 N--CA 1.462 -0.34 0 C-N-CA 123.625 -1.406 . . . . 0.0 113.312 0.356 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.604 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.9 146.98 33.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 -177.378 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.0 m -83.02 121.98 27.73 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.621 179.615 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 35.5 p -98.3 146.43 25.67 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.37 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 13.5 ttt180 -109.21 114.65 28.53 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.483 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 20.1 p30 47.58 31.29 1.99 Allowed 'General case' 0 N--CA 1.472 0.662 0 O-C-N 124.269 0.981 . . . . 0.0 113.041 -178.686 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.475 0 C-N-CA 120.035 -1.079 . . . . 0.0 114.602 177.852 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 19.0 m . . . . . 0 CA--C 1.518 -0.262 0 CA-C-O 120.562 0.22 . . . . 0.0 110.583 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.89 32.92 85.78 Favored Glycine 0 C--N 1.334 0.469 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -178.359 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -132.56 148.81 52.38 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 114.245 -0.978 . . . . 0.0 110.286 -178.178 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.606 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 25.7 p -108.83 143.05 38.52 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.076 179.511 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.6 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.8 p -116.27 46.94 1.49 Allowed 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.791 0.805 . . . . 0.0 109.295 177.918 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.9 t -56.44 -32.62 36.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 114.639 -1.164 . . . . 0.0 109.803 179.579 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.11 22.66 39.82 Favored Glycine 0 N--CA 1.447 -0.606 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.944 178.369 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.21 40.25 98.31 Favored Glycine 0 C--N 1.336 0.572 0 C-N-CA 121.414 -0.422 . . . . 0.0 112.598 179.857 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.28 144.07 27.37 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.683 0.278 . . . . 0.0 111.566 -179.195 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.552 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 84.5 m -136.02 133.05 37.06 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.355 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -88.3 -32.51 18.42 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.126 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.792 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.0 OUTLIER -64.97 118.32 47.93 Favored Pre-proline 0 C--O 1.237 0.426 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.05 -179.56 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -64.96 118.38 5.38 Favored 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 122.354 2.036 . . . . 0.0 112.485 -179.838 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 104.38 2.56 44.27 Favored Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.704 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.792 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 70.8 m -99.44 121.93 41.83 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.305 0.574 . . . . 0.0 111.77 -179.818 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.1 p -89.87 140.39 29.65 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.96 179.068 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.4 t -72.16 133.91 45.41 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.678 0.752 . . . . 0.0 110.891 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.7 m -147.06 68.83 1.16 Allowed 'General case' 0 C--N 1.311 -1.076 0 N-CA-C 106.519 -1.66 . . . . 0.0 106.519 179.161 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.424 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.1 t90 -28.45 129.48 0.21 Allowed Pre-proline 0 C--O 1.232 0.154 0 CA-C-N 113.987 -1.461 . . . . 0.0 113.445 -176.119 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.0 Cg_endo -98.29 24.26 21.35 Favored 'Cis proline' 0 N--CA 1.46 -0.457 0 C-N-CA 123.672 -1.387 . . . . 0.0 113.328 0.419 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.606 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.52 147.26 33.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 113.767 1.025 . . . . 0.0 113.767 -177.297 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.6 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 72.7 m -82.33 124.45 30.0 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.322 -0.853 . . . . 0.0 110.269 179.341 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.3 p -101.63 149.95 23.6 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.313 0.578 . . . . 0.0 111.574 -179.536 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 15.9 tpp85 -105.89 103.52 13.03 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.985 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 70.9 m-20 58.45 34.67 24.15 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 123.379 0.425 . . . . 0.0 110.547 -178.592 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.524 0 C-N-CA 120.49 -0.862 . . . . 0.0 114.13 179.368 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.442 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 12.7 m . . . . . 0 N--CA 1.452 -0.356 0 CA-C-O 120.793 0.33 . . . . 0.0 110.4 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.22 29.67 75.9 Favored Glycine 0 C--N 1.333 0.405 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 -178.228 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.414 ' CD ' ' H ' ' A' ' 11' ' ' ASN . 38.6 tt0 -129.76 149.62 51.42 Favored 'General case' 0 N--CA 1.445 -0.698 0 CA-C-N 114.043 -1.079 . . . . 0.0 110.045 -178.362 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.606 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.0 p -110.28 144.34 39.12 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.705 179.313 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.585 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.9 p -116.82 46.93 1.55 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.811 0.815 . . . . 0.0 109.316 178.45 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.4 t -56.83 -32.57 39.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 114.683 -1.144 . . . . 0.0 109.671 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.63 21.23 47.2 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.84 178.319 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.73 39.86 98.01 Favored Glycine 0 C--N 1.335 0.486 0 C-N-CA 121.455 -0.403 . . . . 0.0 112.669 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.8 144.57 27.08 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.645 0.26 . . . . 0.0 111.553 -179.256 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.537 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 80.1 m -135.52 134.1 39.13 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.969 -0.559 . . . . 0.0 109.523 179.505 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ASN . . . . . 0.414 ' H ' ' CD ' ' A' ' 3' ' ' GLU . 62.8 m-80 -91.77 -31.43 15.77 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.216 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.707 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -63.2 121.17 67.74 Favored Pre-proline 0 C--O 1.236 0.365 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.122 -179.317 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.5 Cg_exo -64.17 118.51 5.46 Favored 'Trans proline' 0 N--CA 1.457 -0.67 0 C-N-CA 122.365 2.044 . . . . 0.0 112.688 -179.771 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.9 5.48 54.98 Favored Glycine 0 N--CA 1.446 -0.642 0 CA-C-N 115.2 -0.909 . . . . 0.0 112.013 179.657 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.707 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 86.1 m -102.14 120.87 41.16 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.607 0.718 . . . . 0.0 112.12 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 3.0 p -90.97 144.99 25.1 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.794 178.801 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.5 t -73.75 134.41 43.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.738 0.78 . . . . 0.0 111.066 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.8 m -146.78 67.71 1.16 Allowed 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 178.971 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.2 t90 -28.21 129.45 0.21 Allowed Pre-proline 0 C--O 1.232 0.172 0 CA-C-N 113.958 -1.474 . . . . 0.0 113.392 -176.118 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.6 Cg_endo -98.3 24.65 20.78 Favored 'Cis proline' 0 N--CA 1.462 -0.376 0 C-N-CA 123.676 -1.385 . . . . 0.0 113.324 0.357 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.606 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -130.81 148.2 33.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -177.314 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.585 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.5 m -83.53 128.54 34.59 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.586 179.518 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.4 p -108.29 149.9 28.03 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.042 -179.719 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.442 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 20.7 ttp180 -131.64 126.07 33.75 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.849 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.5 m-20 62.17 28.57 17.15 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.708 -178.693 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.533 0 CA-C-N 115.715 -0.675 . . . . 0.0 114.101 179.087 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.686 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 23.7 m . . . . . 0 CA--C 1.518 -0.287 0 CA-C-O 120.867 0.365 . . . . 0.0 110.083 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.74 31.4 79.72 Favored Glycine 0 C--N 1.334 0.469 0 N-CA-C 109.199 -1.561 . . . . 0.0 109.199 -177.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -134.6 148.21 50.38 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 113.957 -1.122 . . . . 0.0 110.32 -177.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.604 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.3 p -110.29 142.77 41.45 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.811 179.422 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.596 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.8 p -115.24 46.65 1.42 Allowed 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.722 0.772 . . . . 0.0 109.261 177.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.42 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.6 t -56.56 -32.42 36.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 114.666 -1.152 . . . . 0.0 109.652 179.385 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.71 22.41 41.1 Favored Glycine 0 N--CA 1.447 -0.596 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.858 178.327 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.03 40.06 97.97 Favored Glycine 0 C--N 1.335 0.475 0 C-N-CA 121.499 -0.382 . . . . 0.0 112.734 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.56 143.94 25.92 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.694 0.283 . . . . 0.0 111.581 -179.202 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.584 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 68.4 m -136.14 134.84 38.7 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.471 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 44.9 m-20 -91.2 -30.23 16.77 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.358 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.688 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.7 m -62.55 118.66 43.23 Favored Pre-proline 0 C--O 1.235 0.293 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.718 -179.78 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.9 Cg_exo -64.13 115.02 2.89 Favored 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.394 2.063 . . . . 0.0 112.851 -179.385 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.33 0.9 40.91 Favored Glycine 0 N--CA 1.445 -0.707 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.786 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.688 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 86.2 m -96.9 123.65 40.66 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.398 0.618 . . . . 0.0 111.82 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.9 p -92.66 144.05 25.7 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.074 179.15 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.3 t -73.44 134.26 43.92 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.607 0.718 . . . . 0.0 111.017 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.3 m -147.3 67.68 1.14 Allowed 'General case' 0 C--N 1.312 -1.061 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 179.025 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.7 t90 -28.11 129.45 0.21 Allowed Pre-proline 0 C--O 1.232 0.17 0 CA-C-N 114.067 -1.424 . . . . 0.0 113.448 -176.228 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 63.7 Cg_endo -98.08 22.94 23.55 Favored 'Cis proline' 0 N--CA 1.461 -0.419 0 C-N-CA 123.671 -1.387 . . . . 0.0 113.391 0.321 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.604 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.37 148.24 33.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 113.627 0.973 . . . . 0.0 113.627 -177.433 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.596 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.3 m -83.61 127.65 33.91 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.761 179.743 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 21.2 p -101.55 150.75 22.75 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.774 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.686 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 33.8 ttt180 -132.63 124.13 27.72 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.534 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 59.84 30.6 20.15 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.058 0.456 . . . . 0.0 111.203 -179.294 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.579 0 C-N-CA 121.095 -0.574 . . . . 0.0 114.29 178.968 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.541 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 7.9 m . . . . . 0 CA--C 1.517 -0.307 0 CA-C-O 120.56 0.219 . . . . 0.0 110.568 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.07 31.52 81.11 Favored Glycine 0 C--N 1.334 0.441 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -178.264 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -129.42 151.81 49.65 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 114.152 -1.024 . . . . 0.0 110.519 -178.118 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.632 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.3 p -112.41 141.85 45.65 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.678 178.821 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.626 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.0 p -116.11 47.85 1.33 Allowed 'General case' 0 C--N 1.318 -0.797 0 CA-C-O 121.873 0.844 . . . . 0.0 109.264 177.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.2 t -57.24 -32.2 40.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 114.573 -1.194 . . . . 0.0 109.703 179.559 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -96.88 20.68 49.76 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.856 178.307 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.54 39.29 97.14 Favored Glycine 0 C--N 1.335 0.512 0 C-N-CA 121.468 -0.396 . . . . 0.0 112.662 179.829 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.22 144.2 26.39 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.62 0.248 . . . . 0.0 111.266 -179.248 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.536 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 76.7 m -133.32 133.93 43.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.022 -0.536 . . . . 0.0 109.952 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 33.7 m-20 -87.45 -35.02 18.49 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.441 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.717 HG21 HH21 ' A' ' 24' ' ' ARG . 3.6 m -63.17 118.12 40.0 Favored Pre-proline 0 C--O 1.236 0.365 0 CA-C-O 120.748 0.309 . . . . 0.0 110.747 -179.751 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -65.17 114.88 3.02 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.338 2.025 . . . . 0.0 112.297 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.24 -8.52 30.96 Favored Glycine 0 N--CA 1.445 -0.701 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.601 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.581 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 96.5 m -91.43 121.98 33.62 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.366 0.603 . . . . 0.0 111.619 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.7 p -89.76 144.38 26.02 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.251 179.348 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.0 t -74.28 134.16 42.61 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.615 0.721 . . . . 0.0 111.016 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.9 m -147.29 68.77 1.14 Allowed 'General case' 0 C--N 1.311 -1.072 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.019 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.1 t90 -28.32 129.65 0.21 Allowed Pre-proline 0 C--O 1.232 0.178 0 CA-C-N 113.978 -1.465 . . . . 0.0 113.399 -176.207 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 65.4 Cg_endo -98.42 24.91 20.26 Favored 'Cis proline' 0 N--CA 1.461 -0.441 0 C-N-CA 123.694 -1.377 . . . . 0.0 113.263 0.31 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.632 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.64 147.98 33.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 N-CA-C 113.688 0.996 . . . . 0.0 113.688 -177.386 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.626 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.9 m -83.4 123.04 29.28 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.453 179.44 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 28.1 p -99.0 147.14 25.31 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.193 0.52 . . . . 0.0 111.108 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.717 HH21 HG21 ' A' ' 12' ' ' THR . 40.5 ttm180 -114.14 112.86 23.88 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.386 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 60.43 33.06 20.71 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.438 -178.262 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.532 0 C-N-CA 120.75 -0.738 . . . . 0.0 114.207 179.175 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 35.3 m . . . . . 0 CA--C 1.519 -0.239 0 CA-C-O 120.729 0.299 . . . . 0.0 110.698 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.64 32.65 83.81 Favored Glycine 0 C--N 1.335 0.475 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -178.222 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.418 ' CD ' ' H ' ' A' ' 11' ' ' ASN . 38.4 tt0 -137.75 148.41 45.57 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 114.205 -0.997 . . . . 0.0 110.405 -178.101 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.615 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 27.1 p -108.85 142.91 38.74 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.897 179.355 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.604 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.3 p -116.28 46.86 1.5 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.777 0.798 . . . . 0.0 109.277 177.846 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.8 t -56.62 -32.75 38.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 114.607 -1.179 . . . . 0.0 109.795 179.566 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.84 22.7 39.64 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.919 178.443 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.87 40.48 98.36 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 121.446 -0.407 . . . . 0.0 112.615 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -147.85 144.07 27.88 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.654 0.264 . . . . 0.0 111.355 -179.195 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.56 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 79.3 m -136.58 133.76 36.72 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.993 -0.549 . . . . 0.0 109.718 179.555 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ASN . . . . . 0.418 ' H ' ' CD ' ' A' ' 3' ' ' GLU . 62.6 m-80 -91.12 -31.35 16.26 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.947 179.757 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.637 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -62.55 118.96 46.08 Favored Pre-proline 0 C--O 1.237 0.398 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.846 -179.547 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.8 Cg_exo -64.08 118.92 5.84 Favored 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 122.231 1.954 . . . . 0.0 112.739 -179.619 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.42 10.77 53.32 Favored Glycine 0 N--CA 1.446 -0.688 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.977 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.637 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 95.5 m -105.48 121.52 44.1 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.456 0.646 . . . . 0.0 111.723 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 8.0 p -89.76 143.25 26.95 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 115.102 -0.953 . . . . 0.0 109.898 179.07 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.0 t -72.61 134.19 45.04 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.668 0.747 . . . . 0.0 110.954 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.9 m -146.09 67.58 1.19 Allowed 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.424 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.6 t90 -27.94 129.39 0.21 Allowed Pre-proline 0 C--O 1.233 0.201 0 CA-C-N 113.919 -1.491 . . . . 0.0 113.528 -176.202 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.9 Cg_endo -98.04 24.82 20.89 Favored 'Cis proline' 0 N--CA 1.462 -0.346 0 C-N-CA 123.658 -1.392 . . . . 0.0 113.307 0.468 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.615 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -131.61 146.9 32.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -177.413 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.604 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 78.3 m -81.66 132.11 35.29 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.224 179.343 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 63.0 p -117.16 147.39 42.5 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.017 0.437 . . . . 0.0 111.608 -178.939 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 54.0 ttm-85 -108.56 114.27 27.96 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 177.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 16.1 m120 61.33 35.25 18.1 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.143 0.497 . . . . 0.0 109.683 -178.252 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 CA-C-N 115.69 -0.686 . . . . 0.0 112.244 -179.276 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 11.6 m . . . . . 0 CA--C 1.519 -0.241 0 CA-C-O 120.816 0.341 . . . . 0.0 110.47 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.44 31.96 82.6 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 109.476 -1.449 . . . . 0.0 109.476 -178.071 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -132.71 148.95 52.34 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 114.127 -1.036 . . . . 0.0 110.359 -177.899 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.61 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 25.7 p -110.12 142.72 41.23 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.891 179.34 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.594 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 29.9 p -115.72 46.97 1.42 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.655 0.74 . . . . 0.0 109.283 177.979 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.406 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.9 t -56.54 -32.64 37.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.685 179.492 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.05 22.0 43.13 Favored Glycine 0 N--CA 1.447 -0.617 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.836 178.443 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.27 39.58 97.41 Favored Glycine 0 C--N 1.335 0.518 0 C-N-CA 121.511 -0.376 . . . . 0.0 112.683 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -149.68 143.77 25.7 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.664 0.268 . . . . 0.0 111.557 -179.308 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 78.9 m -134.7 135.24 41.85 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 179.491 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 44.1 m-20 -90.31 -30.84 17.22 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.63 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.5 m -62.95 117.97 37.84 Favored Pre-proline 0 C--O 1.236 0.35 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.655 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.6 Cg_exo -64.37 116.48 3.78 Favored 'Trans proline' 0 N--CA 1.457 -0.658 0 C-N-CA 122.386 2.058 . . . . 0.0 112.662 -179.414 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.3 2.31 47.8 Favored Glycine 0 N--CA 1.445 -0.75 0 CA-C-N 115.373 -0.831 . . . . 0.0 112.107 179.635 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.63 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 88.9 m -97.78 123.13 41.6 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.334 0.588 . . . . 0.0 111.497 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.8 p -90.07 141.58 28.53 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.293 179.467 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.8 t -73.06 134.28 44.52 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.663 0.744 . . . . 0.0 110.95 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.2 m -147.19 68.61 1.15 Allowed 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.056 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.426 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.7 t90 -28.14 129.6 0.21 Allowed Pre-proline 0 N--CA 1.463 0.187 0 CA-C-N 113.962 -1.472 . . . . 0.0 113.421 -176.252 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.426 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 68.8 Cg_endo -98.03 23.31 23.11 Favored 'Cis proline' 0 N--CA 1.461 -0.439 0 C-N-CA 123.62 -1.408 . . . . 0.0 113.275 0.307 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.61 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -129.99 147.02 33.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -177.4 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 77.3 m -82.05 125.34 30.71 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.494 179.464 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.4 p -101.06 146.47 27.41 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.156 0.503 . . . . 0.0 111.195 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.435 ' HG2' ' SG ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -101.79 107.86 19.19 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 177.879 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 17.7 p30 49.36 28.83 2.49 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 124.319 1.012 . . . . 0.0 112.776 -178.421 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.451 0 C-N-CA 120.035 -1.079 . . . . 0.0 114.518 178.141 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.671 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 8.9 m . . . . . 0 CA--C 1.518 -0.268 0 CA-C-O 120.763 0.316 . . . . 0.0 110.25 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.27 31.72 81.47 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -177.817 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -133.51 148.31 51.67 Favored 'General case' 0 N--CA 1.444 -0.766 0 CA-C-N 113.928 -1.136 . . . . 0.0 110.509 -177.72 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.6 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.4 p -110.45 142.86 41.6 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.808 179.325 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.582 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.6 p -115.36 46.95 1.38 Allowed 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.739 0.78 . . . . 0.0 109.278 178.071 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.408 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.8 t -56.55 -32.42 36.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 114.624 -1.171 . . . . 0.0 109.658 179.474 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.23 21.88 43.73 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 115.617 -0.72 . . . . 0.0 111.811 178.384 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.36 39.52 97.37 Favored Glycine 0 C--N 1.335 0.524 0 C-N-CA 121.527 -0.368 . . . . 0.0 112.668 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.03 143.86 25.43 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.684 0.278 . . . . 0.0 111.597 -179.294 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.582 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 70.4 m -134.78 135.01 41.51 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.421 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.1 m-20 -88.58 -31.1 18.79 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.615 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.7 m -63.59 117.72 37.49 Favored Pre-proline 0 C--O 1.236 0.381 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.752 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_exo -65.05 115.66 3.41 Favored 'Trans proline' 0 N--CA 1.459 -0.536 0 C-N-CA 122.316 2.011 . . . . 0.0 112.438 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 108.87 -8.73 34.01 Favored Glycine 0 N--CA 1.446 -0.681 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.738 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.615 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 88.2 m -89.98 122.69 33.23 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.42 0.629 . . . . 0.0 111.762 -179.677 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.0 p -90.67 144.35 25.83 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.078 -0.964 . . . . 0.0 110.113 179.212 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.4 t -74.06 134.27 42.96 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.592 0.71 . . . . 0.0 111.092 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 m -147.45 68.27 1.13 Allowed 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 106.517 -1.661 . . . . 0.0 106.517 179.053 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.451 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.8 t90 -28.16 129.44 0.21 Allowed Pre-proline 0 N--CA 1.463 0.191 0 CA-C-N 114.007 -1.451 . . . . 0.0 113.437 -176.256 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.451 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.9 Cg_endo -98.36 23.18 22.77 Favored 'Cis proline' 0 C--N 1.345 0.388 0 C-N-CA 123.617 -1.41 . . . . 0.0 113.257 0.334 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.6 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -129.48 148.64 33.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -177.447 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.572 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 73.5 m -83.55 126.19 32.55 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.723 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 20.1 p -99.68 148.2 24.6 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.771 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.671 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 57.9 ttp180 -130.4 131.94 45.52 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.024 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.6 p-10 44.59 36.4 1.72 Allowed 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 113.324 0.861 . . . . 0.0 113.324 -179.413 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.633 0 N-CA-C 115.621 1.008 . . . . 0.0 115.621 177.272 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.693 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 16.6 m . . . . . 0 CA--C 1.516 -0.33 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.5 30.28 76.24 Favored Glycine 0 N--CA 1.45 -0.422 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -177.89 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -130.24 152.69 49.38 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 114.126 -1.037 . . . . 0.0 110.544 -178.199 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.63 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.3 p -115.24 143.34 45.4 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.241 178.44 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.639 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.8 p -115.73 47.46 1.35 Allowed 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.915 0.865 . . . . 0.0 109.362 178.666 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -57.52 -32.23 41.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 114.552 -1.204 . . . . 0.0 109.481 179.387 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -96.51 19.9 52.69 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.828 178.281 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.9 39.73 97.91 Favored Glycine 0 C--N 1.335 0.48 0 C-N-CA 121.524 -0.37 . . . . 0.0 112.746 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.04 144.96 26.12 Favored 'General case' 0 C--N 1.324 -0.528 0 O-C-N 122.734 -0.274 . . . . 0.0 111.472 -179.275 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.529 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 85.6 m -134.62 133.57 40.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.088 -0.505 . . . . 0.0 109.81 179.539 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 34.2 m-20 -90.14 -34.04 16.02 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.676 -179.667 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.673 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.1 m -61.98 121.19 63.82 Favored Pre-proline 0 C--O 1.236 0.366 0 CA-C-O 120.943 0.401 . . . . 0.0 110.654 -179.673 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -64.58 114.79 2.87 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.44 2.093 . . . . 0.0 112.691 -179.535 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 106.08 0.94 38.74 Favored Glycine 0 N--CA 1.445 -0.705 0 CA-C-N 115.465 -0.789 . . . . 0.0 111.68 179.764 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.673 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 84.2 m -98.91 119.74 38.19 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 121.46 0.648 . . . . 0.0 111.658 -179.8 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.8 p -90.59 144.82 25.39 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.023 179.095 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.7 t -72.84 134.4 44.85 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.697 0.761 . . . . 0.0 111.109 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.1 m -147.13 66.96 1.14 Allowed 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 106.217 -1.771 . . . . 0.0 106.217 178.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.9 t90 -28.24 129.53 0.21 Allowed Pre-proline 0 C--O 1.233 0.195 0 CA-C-N 113.89 -1.504 . . . . 0.0 113.436 -176.142 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 64.6 Cg_endo -98.32 24.19 21.41 Favored 'Cis proline' 0 N--CA 1.461 -0.384 0 C-N-CA 123.645 -1.398 . . . . 0.0 113.284 0.43 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.63 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -129.15 147.76 33.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 -177.409 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.639 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 91.8 m -84.37 123.76 30.55 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.737 179.663 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 34.6 p -100.08 146.46 26.75 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.338 179.531 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.693 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 25.5 ttp85 -117.4 122.05 42.75 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.879 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 21.6 p30 46.82 32.3 1.74 Allowed 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.342 1.057 . . . . 0.0 113.595 -179.031 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.489 0 C-N-CA 119.92 -1.133 . . . . 0.0 115.325 177.133 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.549 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 11.6 m . . . . . 0 CA--C 1.517 -0.323 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.71 31.17 80.02 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 109.241 -1.543 . . . . 0.0 109.241 -178.099 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.407 ' CD ' ' H ' ' A' ' 11' ' ' ASN . 38.4 tt0 -132.76 149.08 52.32 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 114.0 -1.1 . . . . 0.0 110.147 -177.888 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.604 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.1 p -110.9 144.41 39.99 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.629 179.308 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.583 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.7 p -116.64 46.86 1.54 Allowed 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.789 0.804 . . . . 0.0 109.282 178.56 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -56.85 -32.59 39.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 114.587 -1.188 . . . . 0.0 109.531 179.45 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.39 21.78 44.24 Favored Glycine 0 N--CA 1.446 -0.64 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.906 178.368 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.41 40.08 98.17 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 121.431 -0.414 . . . . 0.0 112.832 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.73 144.7 27.24 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.69 0.281 . . . . 0.0 111.514 -179.23 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.544 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.4 m -136.41 133.42 36.67 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.3 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ASN . . . . . 0.407 ' H ' ' CD ' ' A' ' 3' ' ' GLU . 64.7 m-80 -88.34 -32.21 18.52 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.189 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.659 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.6 m -63.25 118.85 47.37 Favored Pre-proline 0 C--O 1.236 0.382 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.816 -179.618 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -64.76 115.8 3.44 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.438 2.092 . . . . 0.0 112.553 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 106.4 -3.62 37.33 Favored Glycine 0 N--CA 1.445 -0.707 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.89 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.659 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 93.1 m -93.91 121.14 35.07 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.377 0.608 . . . . 0.0 111.822 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.4 p -89.88 143.87 26.43 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.053 178.897 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.6 t -73.26 134.36 44.23 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.7 0.762 . . . . 0.0 111.009 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.5 m -147.01 68.08 1.16 Allowed 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 106.378 -1.712 . . . . 0.0 106.378 178.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.3 t90 -28.3 129.52 0.21 Allowed Pre-proline 0 C--O 1.232 0.147 0 CA-C-N 113.874 -1.512 . . . . 0.0 113.413 -176.205 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.462 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.0 Cg_endo -98.37 24.34 21.14 Favored 'Cis proline' 0 N--CA 1.46 -0.466 0 C-N-CA 123.696 -1.377 . . . . 0.0 113.324 0.34 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.604 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -130.32 148.27 33.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -177.325 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.5 m -83.59 127.23 33.58 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.602 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.1 p -105.46 149.04 26.52 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.762 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.549 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 41.3 ttp85 -130.86 123.94 30.14 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.253 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 79.4 m-20 62.11 29.31 17.55 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.779 -178.465 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.549 0 CA-C-N 115.704 -0.68 . . . . 0.0 114.055 179.112 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.544 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 4.0 m . . . . . 0 CA--C 1.518 -0.276 0 CA-C-O 120.793 0.33 . . . . 0.0 110.501 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.3 31.09 79.71 Favored Glycine 0 C--N 1.334 0.435 0 N-CA-C 109.439 -1.465 . . . . 0.0 109.439 -178.186 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -128.79 149.33 50.77 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 113.883 -1.159 . . . . 0.0 109.793 -177.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.587 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 27.2 p -109.74 142.6 40.73 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.136 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.583 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 29.8 p -116.54 45.31 1.83 Allowed 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.64 0.734 . . . . 0.0 109.296 177.771 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.44 HG23 ' HB ' ' A' ' 4' ' ' THR . 11.4 t -55.75 -33.33 33.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 114.735 -1.121 . . . . 0.0 109.906 179.477 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.74 22.59 39.71 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.708 -0.678 . . . . 0.0 112.011 178.57 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.99 40.24 99.06 Favored Glycine 0 C--N 1.334 0.461 0 C-N-CA 121.3 -0.476 . . . . 0.0 112.63 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -146.2 146.17 30.7 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.822 0.344 . . . . 0.0 111.565 -179.357 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 80.1 m -141.33 130.53 23.48 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 178.763 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -89.31 -27.19 20.69 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.48 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.594 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.8 m -65.56 117.48 41.43 Favored Pre-proline 0 C--O 1.237 0.423 0 CA-C-O 120.949 0.404 . . . . 0.0 110.259 179.771 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -64.14 114.04 2.48 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 122.315 2.01 . . . . 0.0 113.149 -179.064 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 107.28 -5.41 35.8 Favored Glycine 0 N--CA 1.442 -0.936 0 CA-C-N 115.282 -0.872 . . . . 0.0 112.014 179.609 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.594 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 99.5 m -89.9 123.11 33.55 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.403 0.62 . . . . 0.0 111.49 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.6 p -90.01 141.54 28.57 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.305 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 50.7 t -71.94 134.52 46.03 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.706 0.765 . . . . 0.0 110.911 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.3 m -147.08 68.1 1.15 Allowed 'General case' 0 C--N 1.312 -1.043 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 179.192 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.422 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.7 t90 -27.73 129.26 0.2 Allowed Pre-proline 0 C--O 1.232 0.154 0 CA-C-N 113.976 -1.465 . . . . 0.0 113.516 -176.121 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.422 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 62.6 Cg_endo -97.91 23.14 23.54 Favored 'Cis proline' 0 N--CA 1.462 -0.376 0 C-N-CA 123.675 -1.386 . . . . 0.0 113.282 0.368 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.587 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.4 m -130.05 146.44 34.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 113.803 1.038 . . . . 0.0 113.803 -177.316 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 82.2 m -81.6 126.9 32.3 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.355 179.417 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.7 p -101.68 145.76 28.65 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.294 0.569 . . . . 0.0 111.426 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.544 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 27.1 tpt180 -117.48 117.28 29.03 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.212 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 63.5 m-20 60.48 32.23 20.47 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.465 -178.583 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.618 0 C-N-CA 120.808 -0.711 . . . . 0.0 114.214 179.14 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.603 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 18.6 m . . . . . 0 CA--C 1.516 -0.334 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.46 30.85 78.52 Favored Glycine 0 CA--C 1.507 -0.455 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -178.052 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -131.06 150.91 51.93 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 114.214 -0.993 . . . . 0.0 110.676 -178.07 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.629 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.7 p -113.54 143.82 43.9 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.374 178.612 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.613 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.5 p -117.34 47.75 1.46 Allowed 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.838 0.828 . . . . 0.0 109.337 178.564 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.6 t -57.26 -32.31 40.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 114.458 -1.246 . . . . 0.0 109.51 179.407 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.13 20.67 49.9 Favored Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.873 178.358 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.55 39.86 97.93 Favored Glycine 0 C--N 1.335 0.525 0 C-N-CA 121.458 -0.401 . . . . 0.0 112.728 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.78 144.73 27.2 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.623 0.249 . . . . 0.0 111.455 -179.357 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.516 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.8 m -134.6 132.44 39.04 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.806 179.532 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -86.65 -36.17 18.93 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.585 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.718 HG21 HH21 ' A' ' 24' ' ' ARG . 3.6 m -62.34 118.36 39.54 Favored Pre-proline 0 C--O 1.235 0.324 0 CA-C-O 120.789 0.328 . . . . 0.0 110.625 -179.722 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -64.76 114.72 2.87 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 122.326 2.017 . . . . 0.0 112.382 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.44 -9.67 30.71 Favored Glycine 0 N--CA 1.446 -0.696 0 CA-C-N 115.445 -0.798 . . . . 0.0 111.594 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.607 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 100.0 m -89.89 121.69 32.23 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.364 0.602 . . . . 0.0 111.586 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.3 p -89.82 143.89 26.41 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.342 179.372 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.7 t -74.06 134.02 42.94 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.699 0.761 . . . . 0.0 110.905 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 m -147.27 69.08 1.15 Allowed 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.5 t90 -28.72 129.64 0.22 Allowed Pre-proline 0 C--O 1.232 0.157 0 CA-C-N 114.033 -1.44 . . . . 0.0 113.422 -176.086 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.449 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.9 Cg_endo -98.59 24.98 19.93 Favored 'Cis proline' 0 N--CA 1.461 -0.432 0 C-N-CA 123.695 -1.377 . . . . 0.0 113.297 0.389 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.629 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.54 147.83 33.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -177.315 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.613 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 81.2 m -83.47 122.74 28.92 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.442 179.363 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.58 HG22 ' HG3' ' A' ' 28' ' ' PRO . 25.9 p -97.76 152.63 18.94 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.952 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.718 HH21 HG21 ' A' ' 12' ' ' THR . 39.1 ttm180 -126.41 125.53 42.33 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 179.138 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 41.9 38.18 0.96 Allowed 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 113.587 0.958 . . . . 0.0 113.587 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 102.24 -0.93 50.54 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 115.472 0.949 . . . . 0.0 115.472 177.392 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.402 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.7 pt? -153.89 138.33 11.18 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 118.473 1.137 . . . . 0.0 111.263 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.58 ' HG3' HG22 ' A' ' 23' ' ' THR . 13.6 Cg_exo -68.36 104.24 1.05 Allowed 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 122.469 2.113 . . . . 0.0 112.747 -179.516 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.9 m . . . . . 0 C--N 1.323 -0.581 0 CA-C-O 121.627 0.727 . . . . 0.0 109.801 179.292 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.567 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 5.9 m . . . . . 0 CA--C 1.518 -0.285 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.78 32.21 83.4 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -178.29 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.577 ' OE2' ' HA ' ' A' ' 10' ' ' CYS . 27.3 tt0 -126.78 152.8 46.41 Favored 'General case' 0 N--CA 1.442 -0.843 0 CA-C-N 114.079 -1.06 . . . . 0.0 110.388 -177.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.643 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 29.1 p -111.83 141.33 45.6 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.778 178.824 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.669 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 23.3 p -115.61 46.73 1.45 Allowed 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.818 0.818 . . . . 0.0 109.341 178.163 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.415 HG23 ' HB ' ' A' ' 4' ' ' THR . 9.9 t -57.78 -33.04 44.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 114.593 -1.185 . . . . 0.0 109.723 179.5 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.97 18.06 58.08 Favored Glycine 0 N--CA 1.447 -0.575 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.945 178.433 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 64.49 36.22 92.9 Favored Glycine 0 C--N 1.333 0.367 0 C-N-CA 121.274 -0.489 . . . . 0.0 112.768 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.6 154.77 43.9 Favored 'General case' 0 C--N 1.324 -0.515 0 O-C-N 122.749 -0.265 . . . . 0.0 110.31 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.577 ' HA ' ' OE2' ' A' ' 3' ' ' GLU . 86.2 m -139.57 133.98 31.51 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.664 179.037 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -89.19 -40.19 13.05 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.423 -179.351 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.678 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.5 m -60.95 119.67 47.02 Favored Pre-proline 0 C--O 1.237 0.402 0 CA-C-O 120.864 0.364 . . . . 0.0 110.668 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -64.72 114.16 2.63 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 122.478 2.118 . . . . 0.0 112.633 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 111.21 -6.91 28.78 Favored Glycine 0 N--CA 1.445 -0.717 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.659 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.678 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 75.3 m -91.54 122.76 34.41 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.48 0.657 . . . . 0.0 111.929 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.6 p -91.51 144.22 25.78 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.024 -0.989 . . . . 0.0 109.922 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.1 t -73.05 134.35 44.56 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.784 0.802 . . . . 0.0 111.116 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.9 m -146.79 67.37 1.16 Allowed 'General case' 0 C--N 1.31 -1.125 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 178.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.407 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.6 t90 -28.07 129.37 0.21 Allowed Pre-proline 0 N--CA 1.463 0.18 0 CA-C-N 113.86 -1.518 . . . . 0.0 113.386 -176.019 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.5 Cg_endo -98.42 26.77 17.85 Favored 'Cis proline' 0 N--CA 1.461 -0.421 0 C-N-CA 123.719 -1.367 . . . . 0.0 113.3 0.269 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.643 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.1 m -132.21 147.71 32.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 113.782 1.03 . . . . 0.0 113.782 -177.367 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.669 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 95.3 m -83.97 124.95 31.57 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.673 179.516 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.471 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 32.9 p -103.75 155.64 18.44 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.651 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.567 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 36.1 ttp85 -135.85 124.24 23.39 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.126 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 62.41 29.15 17.15 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.732 -178.523 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.92 3.2 77.02 Favored Glycine 0 CA--C 1.522 0.517 0 CA-C-N 115.81 -0.632 . . . . 0.0 114.108 179.063 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.419 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.8 pt? -145.86 140.59 15.81 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 117.775 0.788 . . . . 0.0 110.611 179.456 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 24.2 Cg_exo -63.54 104.02 0.42 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.509 2.139 . . . . 0.0 113.021 -178.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.3 t . . . . . 0 C--N 1.326 -0.443 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.043 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.654 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 21.8 m . . . . . 0 CA--C 1.518 -0.252 0 CA-C-O 120.701 0.286 . . . . 0.0 110.252 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 67.09 31.3 77.38 Favored Glycine 0 C--N 1.333 0.406 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 -177.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -131.76 150.8 52.04 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 114.241 -0.98 . . . . 0.0 110.431 -178.105 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.614 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.8 p -112.73 141.44 46.52 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.441 178.732 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.616 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 23.7 p -114.88 45.86 1.52 Allowed 'General case' 0 C--N 1.317 -0.829 0 CA-C-O 121.788 0.804 . . . . 0.0 109.494 178.335 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.415 HG23 ' HB ' ' A' ' 4' ' ' THR . 11.5 t -56.5 -32.49 36.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 114.646 -1.161 . . . . 0.0 109.778 179.487 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.57 21.68 44.07 Favored Glycine 0 N--CA 1.448 -0.567 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.969 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.82 40.19 98.92 Favored Glycine 0 C--N 1.334 0.44 0 C-N-CA 121.385 -0.436 . . . . 0.0 112.738 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.56 147.24 32.93 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.662 0.268 . . . . 0.0 111.448 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.544 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 84.6 m -143.46 127.67 17.64 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 178.817 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -91.9 -28.33 17.35 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.206 -179.52 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.677 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.4 m -62.71 122.83 76.68 Favored Pre-proline 0 C--O 1.234 0.268 0 CA-C-O 120.88 0.372 . . . . 0.0 110.348 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 24.4 Cg_exo -63.75 115.31 3.0 Favored 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 122.267 1.978 . . . . 0.0 113.065 -179.321 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.53 5.75 51.29 Favored Glycine 0 N--CA 1.444 -0.776 0 CA-C-N 115.175 -0.921 . . . . 0.0 111.932 179.581 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.677 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 99.6 m -101.45 122.45 43.8 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.54 0.686 . . . . 0.0 111.963 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.4 p -94.19 147.59 23.02 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-N 114.929 -1.032 . . . . 0.0 110.083 179.158 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.3 t -74.53 134.32 42.22 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.696 0.76 . . . . 0.0 111.129 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 26.0 m -147.46 67.46 1.13 Allowed 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 178.816 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.463 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.6 t90 -27.99 129.32 0.21 Allowed Pre-proline 0 N--CA 1.462 0.164 0 CA-C-N 113.963 -1.471 . . . . 0.0 113.449 -176.187 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.5 Cg_endo -98.41 24.46 20.9 Favored 'Cis proline' 0 N--CA 1.46 -0.496 0 C-N-CA 123.71 -1.371 . . . . 0.0 113.342 0.315 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.614 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.24 148.2 33.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 N-CA-C 113.658 0.985 . . . . 0.0 113.658 -177.399 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.616 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.3 m -83.89 126.53 33.07 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.619 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.437 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 22.2 p -103.06 151.6 22.35 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.003 -179.822 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.654 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 38.5 ttp85 -133.68 132.07 40.25 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.089 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 18.9 p30 52.43 28.36 5.81 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 124.019 0.927 . . . . 0.0 112.627 -178.594 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 97.48 5.58 57.82 Favored Glycine 0 CA--C 1.521 0.441 0 N-CA-C 114.782 0.673 . . . . 0.0 114.782 177.345 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.413 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 2.9 pp -154.18 146.85 17.64 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 118.103 0.952 . . . . 0.0 111.111 179.702 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 17.0 Cg_exo -66.33 107.21 1.15 Allowed 'Trans proline' 0 N--CA 1.462 -0.359 0 C-N-CA 122.611 2.207 . . . . 0.0 111.95 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.5 p . . . . . 0 C--N 1.32 -0.681 0 CA-C-O 122.63 1.205 . . . . 0.0 109.182 -179.964 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.584 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 13.1 m . . . . . 0 CA--C 1.518 -0.25 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.3 28.85 73.98 Favored Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -177.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -127.5 151.38 48.94 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-N 114.231 -0.984 . . . . 0.0 110.572 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.625 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.0 p -113.05 143.45 44.3 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.253 178.651 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.629 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 24.9 p -116.85 47.26 1.5 Allowed 'General case' 0 C--N 1.318 -0.787 0 CA-C-O 121.874 0.845 . . . . 0.0 109.369 178.525 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.2 t -57.1 -32.22 39.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 114.482 -1.235 . . . . 0.0 109.524 179.323 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.92 21.13 47.69 Favored Glycine 0 N--CA 1.447 -0.588 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.85 178.346 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.37 40.11 98.19 Favored Glycine 0 C--N 1.335 0.484 0 C-N-CA 121.503 -0.379 . . . . 0.0 112.786 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.24 144.92 27.99 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.617 0.246 . . . . 0.0 111.461 -179.229 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.497 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 79.6 m -135.74 131.83 36.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.72 179.418 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.6 m-80 -88.2 -36.03 17.02 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.735 -179.411 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.708 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.1 m -61.64 119.62 48.95 Favored Pre-proline 0 C--O 1.235 0.305 0 CA-C-O 120.974 0.416 . . . . 0.0 110.7 -179.535 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -63.7 114.05 2.4 Favored 'Trans proline' 0 N--CA 1.459 -0.545 0 C-N-CA 122.462 2.108 . . . . 0.0 112.873 -179.233 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 108.36 -2.48 32.83 Favored Glycine 0 N--CA 1.444 -0.786 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.759 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.708 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 81.6 m -94.33 122.5 36.94 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.375 0.607 . . . . 0.0 111.82 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.1 p -91.8 144.01 25.93 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.088 179.151 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.5 t -73.57 134.07 43.67 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.698 0.761 . . . . 0.0 111.091 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.6 m -147.28 68.2 1.14 Allowed 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 106.377 -1.712 . . . . 0.0 106.377 178.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.458 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.4 t90 -28.54 129.54 0.22 Allowed Pre-proline 0 C--O 1.232 0.166 0 CA-C-N 113.964 -1.471 . . . . 0.0 113.419 -176.091 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.3 Cg_endo -98.49 24.64 20.54 Favored 'Cis proline' 0 N--CA 1.461 -0.428 0 C-N-CA 123.747 -1.355 . . . . 0.0 113.318 0.423 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.625 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.18 147.79 33.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 113.714 1.005 . . . . 0.0 113.714 -177.299 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.629 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.0 m -83.66 123.57 29.95 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.578 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.612 HG22 ' HG3' ' A' ' 28' ' ' PRO . 27.2 p -99.58 152.84 19.58 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.56 179.873 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.584 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 30.9 ttt180 -129.09 128.39 43.43 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.062 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 41.92 38.62 1.07 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 113.616 0.969 . . . . 0.0 113.616 -179.602 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.28 2.19 55.73 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 115.611 1.004 . . . . 0.0 115.611 177.231 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.4 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.9 pt? -157.76 139.19 9.77 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 118.532 1.166 . . . . 0.0 111.222 179.835 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.612 ' HG3' HG22 ' A' ' 23' ' ' THR . 13.2 Cg_exo -68.61 103.92 1.05 Allowed 'Trans proline' 0 N--CA 1.462 -0.379 0 C-N-CA 122.418 2.079 . . . . 0.0 112.585 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.0 m . . . . . 0 C--N 1.322 -0.609 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.0 179.506 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.46 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 15.4 m . . . . . 0 CA--C 1.517 -0.303 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.76 31.09 79.77 Favored Glycine 0 C--N 1.333 0.41 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -177.821 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -134.38 148.81 50.74 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 113.983 -1.108 . . . . 0.0 110.349 -177.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 17.4 p -112.42 144.66 41.49 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.557 179.328 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.599 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.0 p -116.33 46.96 1.49 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.809 0.814 . . . . 0.0 109.402 178.515 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -56.96 -32.81 40.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 114.638 -1.165 . . . . 0.0 109.505 179.344 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.35 21.94 43.44 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.947 178.318 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.39 40.31 98.47 Favored Glycine 0 C--N 1.334 0.472 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.684 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.77 144.63 27.15 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.735 0.302 . . . . 0.0 111.518 -179.218 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.559 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 78.1 m -136.95 133.12 35.3 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 179.319 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.3 m-80 -87.89 -32.27 19.04 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.18 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.607 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.7 m -63.56 117.06 30.93 Favored Pre-proline 0 C--O 1.236 0.352 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.706 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_exo -65.46 114.96 3.1 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 122.436 2.091 . . . . 0.0 112.372 -179.608 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.65 -7.55 31.86 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 115.472 -0.786 . . . . 0.0 111.533 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.607 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 86.3 m -91.21 121.78 33.28 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.461 0.648 . . . . 0.0 111.586 -179.84 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.7 p -89.99 141.78 28.33 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.201 179.324 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.0 t -72.02 133.87 45.55 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.607 0.717 . . . . 0.0 110.917 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.1 m -146.96 68.7 1.16 Allowed 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 179.052 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.453 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.1 t90 -28.65 129.98 0.21 Allowed Pre-proline 0 N--CA 1.462 0.14 0 CA-C-N 114.008 -1.451 . . . . 0.0 113.368 -176.172 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 63.8 Cg_endo -97.88 22.71 24.17 Favored 'Cis proline' 0 N--CA 1.462 -0.378 0 C-N-CA 123.667 -1.389 . . . . 0.0 113.403 0.3 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.608 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -128.95 147.15 33.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -177.402 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.599 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.0 m -82.3 123.94 29.51 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.333 179.451 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.532 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 22.8 p -95.31 142.84 27.24 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.119 0.485 . . . . 0.0 110.495 179.416 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.46 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 49.9 ttp180 -103.49 111.87 24.51 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.699 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 20.6 p30 46.88 32.17 1.72 Allowed 'General case' 0 N--CA 1.471 0.619 0 O-C-N 124.334 1.021 . . . . 0.0 113.065 -178.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 122.86 -27.44 5.93 Favored Glycine 0 CA--C 1.521 0.468 0 C-N-CA 119.977 -1.106 . . . . 0.0 114.754 177.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -134.91 138.67 30.12 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 117.899 0.849 . . . . 0.0 111.306 -178.727 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.532 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 33.4 Cg_exo -60.64 103.75 0.24 Allowed 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.872 2.382 . . . . 0.0 113.269 -178.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.5 t . . . . . 0 C--N 1.325 -0.475 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 178.897 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.602 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 12.5 m . . . . . 0 CA--C 1.517 -0.297 0 CA-C-O 120.798 0.332 . . . . 0.0 110.128 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.99 30.7 77.53 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -177.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -130.29 150.99 51.28 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 114.211 -0.994 . . . . 0.0 110.608 -178.141 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.619 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.6 p -112.21 141.83 45.43 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.48 178.734 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.629 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 24.8 p -115.32 47.42 1.31 Allowed 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 121.87 0.843 . . . . 0.0 109.253 178.182 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.406 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.2 t -57.22 -32.04 39.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 114.599 -1.182 . . . . 0.0 109.453 179.486 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.68 21.13 47.71 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.855 178.326 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.17 39.9 97.8 Favored Glycine 0 C--N 1.335 0.492 0 C-N-CA 121.45 -0.405 . . . . 0.0 112.746 179.772 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.85 144.57 27.01 Favored 'General case' 0 C--N 1.324 -0.532 0 O-C-N 122.823 -0.222 . . . . 0.0 111.495 -179.361 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.522 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 81.7 m -135.04 133.44 39.37 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.826 179.543 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 33.1 m-20 -89.81 -34.82 16.0 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.657 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.678 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.3 m -61.19 120.11 51.81 Favored Pre-proline 0 C--O 1.235 0.324 0 CA-C-O 120.95 0.405 . . . . 0.0 110.638 -179.589 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -63.92 113.49 2.2 Favored 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 122.425 2.083 . . . . 0.0 113.002 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 107.75 -1.53 34.06 Favored Glycine 0 N--CA 1.443 -0.854 0 CA-C-N 115.208 -0.905 . . . . 0.0 111.796 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.678 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 94.0 m -95.16 122.96 38.37 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.46 0.648 . . . . 0.0 111.844 -179.723 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.9 p -92.57 145.46 24.42 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 114.966 -1.016 . . . . 0.0 110.063 179.182 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.8 t -74.3 134.29 42.57 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.729 0.776 . . . . 0.0 111.175 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.7 m -147.49 68.12 1.13 Allowed 'General case' 0 C--N 1.311 -1.065 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.7 t90 -28.36 129.57 0.21 Allowed Pre-proline 0 N--CA 1.463 0.203 0 CA-C-N 113.936 -1.484 . . . . 0.0 113.41 -176.129 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 65.1 Cg_endo -98.44 24.27 21.14 Favored 'Cis proline' 0 C--N 1.346 0.404 0 C-N-CA 123.678 -1.384 . . . . 0.0 113.24 0.315 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.619 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.1 m -129.93 148.45 33.2 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -177.316 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.629 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 82.6 m -84.1 124.56 31.24 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.655 179.657 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.603 HG22 ' HG3' ' A' ' 28' ' ' PRO . 25.7 p -100.26 150.48 22.51 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.514 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.602 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 36.9 ttt180 -126.78 128.67 46.95 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 179.161 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 41.74 38.51 0.97 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 113.75 1.019 . . . . 0.0 113.75 -179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.91 3.39 55.94 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 115.598 0.999 . . . . 0.0 115.598 177.26 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.8 pt? -158.17 138.73 9.16 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 118.465 1.132 . . . . 0.0 111.255 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.603 ' HG3' HG22 ' A' ' 23' ' ' THR . 13.2 Cg_exo -68.51 103.56 0.98 Allowed 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.511 2.141 . . . . 0.0 112.485 -179.59 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.6 m . . . . . 0 C--N 1.321 -0.638 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.929 179.554 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.486 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 6.4 m . . . . . 0 CA--C 1.518 -0.285 0 CA-C-O 120.573 0.225 . . . . 0.0 110.572 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.81 30.74 78.76 Favored Glycine 0 C--N 1.334 0.43 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -178.213 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -126.71 152.42 46.83 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 114.24 -0.98 . . . . 0.0 110.363 -178.29 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.63 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.5 p -113.35 143.64 44.12 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.514 178.667 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.609 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.8 p -118.07 47.88 1.5 Allowed 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.85 0.833 . . . . 0.0 109.238 178.576 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.3 t -57.26 -32.44 40.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 114.506 -1.225 . . . . 0.0 109.597 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.04 20.53 50.46 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.9 178.389 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.78 39.62 97.7 Favored Glycine 0 C--N 1.336 0.558 0 C-N-CA 121.42 -0.419 . . . . 0.0 112.77 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.69 144.79 27.35 Favored 'General case' 0 C--N 1.323 -0.551 0 O-C-N 122.793 -0.239 . . . . 0.0 111.363 -179.24 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.514 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.0 m -134.26 132.82 40.11 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.863 179.555 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -86.01 -36.53 19.7 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.559 -179.71 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.699 HG21 HH21 ' A' ' 24' ' ' ARG . 3.3 m -63.35 117.85 37.99 Favored Pre-proline 0 C--O 1.235 0.326 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.754 -179.565 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -64.92 115.0 3.02 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 122.336 2.024 . . . . 0.0 112.354 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 111.21 -9.6 28.97 Favored Glycine 0 N--CA 1.445 -0.742 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.511 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.611 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 79.5 m -90.75 121.64 32.81 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.338 0.59 . . . . 0.0 111.539 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 3.2 p -89.64 143.2 27.0 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.256 -0.883 . . . . 0.0 110.223 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.3 t -73.5 134.15 43.8 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.765 0.793 . . . . 0.0 110.922 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.8 m -146.98 68.8 1.16 Allowed 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 178.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.4 t90 -28.53 129.68 0.21 Allowed Pre-proline 0 C--O 1.232 0.17 0 CA-C-N 113.909 -1.496 . . . . 0.0 113.476 -176.077 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.0 Cg_endo -98.41 25.62 19.34 Favored 'Cis proline' 0 N--CA 1.461 -0.434 0 C-N-CA 123.753 -1.353 . . . . 0.0 113.25 0.362 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.63 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.98 147.68 33.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 -177.287 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.609 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 79.2 m -83.46 122.13 28.11 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.426 179.291 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.471 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 35.4 p -100.17 148.85 24.15 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.176 0.512 . . . . 0.0 111.048 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.699 HH21 HG21 ' A' ' 12' ' ' THR . 39.9 ttm180 -114.45 112.23 22.66 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.33 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.4 m-20 60.31 33.42 20.86 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.41 -178.318 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.59 -17.67 58.86 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 120.686 -0.769 . . . . 0.0 114.158 179.238 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.449 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.4 pt? -123.06 133.47 24.52 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 117.943 0.872 . . . . 0.0 110.76 -179.648 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 24.6 Cg_exo -62.96 104.82 0.41 Allowed 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 122.854 2.369 . . . . 0.0 113.475 -178.761 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 4.4 t . . . . . 0 C--N 1.327 -0.404 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 178.905 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.606 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 30.5 m . . . . . 0 CA--C 1.516 -0.357 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.11 33.13 86.23 Favored Glycine 0 CA--C 1.507 -0.451 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 -177.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -138.03 147.4 44.11 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 113.963 -1.119 . . . . 0.0 110.453 -177.707 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.609 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 25.3 p -110.06 143.34 40.23 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.857 179.496 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.585 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 29.6 p -116.07 46.68 1.51 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.71 0.767 . . . . 0.0 109.277 177.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.403 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.8 t -56.32 -32.65 35.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 114.712 -1.131 . . . . 0.0 109.691 179.385 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.44 23.05 37.79 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.854 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.98 40.5 98.55 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 121.477 -0.392 . . . . 0.0 112.638 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.23 144.0 27.38 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.75 0.31 . . . . 0.0 111.531 -179.268 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.578 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.3 m -136.91 132.96 35.19 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.367 179.31 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.6 m-80 -87.42 -31.72 19.91 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.097 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.726 HG21 HH21 ' A' ' 24' ' ' ARG . 2.0 m -63.84 117.17 32.83 Favored Pre-proline 0 C--O 1.236 0.345 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.852 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_exo -65.13 116.04 3.64 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 122.344 2.03 . . . . 0.0 112.261 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 107.78 -8.03 36.51 Favored Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.784 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.586 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 90.2 m -90.51 122.43 33.33 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.303 0.573 . . . . 0.0 111.639 -179.842 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.2 p -89.81 143.35 26.87 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.184 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.1 t -73.24 134.28 44.24 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.683 0.754 . . . . 0.0 111.02 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 m -147.06 68.66 1.16 Allowed 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 179.064 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.8 t90 -28.29 129.57 0.21 Allowed Pre-proline 0 C--O 1.232 0.17 0 CA-C-N 113.952 -1.476 . . . . 0.0 113.521 -176.272 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.9 Cg_endo -98.14 23.12 23.21 Favored 'Cis proline' 0 N--CA 1.461 -0.422 0 C-N-CA 123.56 -1.433 . . . . 0.0 113.414 0.381 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.609 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.68 147.36 33.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 N-CA-C 113.66 0.985 . . . . 0.0 113.66 -177.503 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.585 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 76.0 m -82.29 125.61 31.17 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.482 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 30.2 p -101.03 145.89 28.14 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.104 0.478 . . . . 0.0 110.889 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.726 HH21 HG21 ' A' ' 12' ' ' THR . 37.6 ttm180 -117.09 116.66 27.75 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 178.528 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.9 m-20 60.24 32.58 20.85 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 123.567 0.542 . . . . 0.0 110.681 -178.463 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 92.65 -12.22 70.31 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 120.84 -0.695 . . . . 0.0 114.373 179.012 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -124.94 134.8 26.02 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 118.113 0.957 . . . . 0.0 111.052 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.464 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 15.9 Cg_exo -67.24 103.17 0.74 Allowed 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.671 2.248 . . . . 0.0 113.046 -179.318 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.3 m . . . . . 0 C--N 1.322 -0.614 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.625 179.113 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.2 m . . . . . 0 N--CA 1.455 -0.225 0 CA-C-O 120.82 0.343 . . . . 0.0 110.532 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.59 23.96 70.78 Favored Glycine 0 N--CA 1.45 -0.391 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 -178.572 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -117.51 152.15 35.66 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 114.015 -1.092 . . . . 0.0 109.702 -178.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.614 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.8 p -112.92 143.44 44.2 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 120.799 0.333 . . . . 0.0 110.884 179.471 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.585 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.8 p -117.07 46.93 1.58 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.756 0.789 . . . . 0.0 109.274 178.344 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.402 HG23 ' HB ' ' A' ' 4' ' ' THR . 11.6 t -56.83 -32.69 39.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 114.55 -1.204 . . . . 0.0 109.631 179.307 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.65 21.51 45.74 Favored Glycine 0 N--CA 1.447 -0.615 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.836 178.303 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.66 39.32 97.24 Favored Glycine 0 C--N 1.335 0.527 0 C-N-CA 121.484 -0.389 . . . . 0.0 112.807 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.16 144.08 25.45 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.65 0.262 . . . . 0.0 111.585 -179.269 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.576 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.6 m -134.33 135.89 43.07 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.495 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 45.8 m-20 -91.02 -31.49 16.28 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.691 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -63.23 117.71 36.23 Favored Pre-proline 0 C--O 1.237 0.418 0 CA-C-O 120.992 0.425 . . . . 0.0 110.69 -179.762 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -63.87 117.61 4.6 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 122.295 1.997 . . . . 0.0 112.554 -179.588 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.24 0.93 47.72 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.429 -0.805 . . . . 0.0 112.051 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.691 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 99.9 m -97.06 122.24 39.84 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.288 0.566 . . . . 0.0 111.262 -179.889 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.5 p -89.84 141.28 28.79 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.358 179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.3 t -72.39 134.1 45.26 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.68 0.752 . . . . 0.0 110.754 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.3 m -147.02 67.47 1.15 Allowed 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.423 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.8 t90 -27.94 129.64 0.2 Allowed Pre-proline 0 C--N 1.34 0.169 0 CA-C-N 113.917 -1.492 . . . . 0.0 113.526 -176.099 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.423 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.5 Cg_endo -97.67 23.41 23.52 Favored 'Cis proline' 0 N--CA 1.461 -0.404 0 C-N-CA 123.574 -1.428 . . . . 0.0 113.364 0.317 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.614 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.62 146.3 34.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 N-CA-C 113.671 0.989 . . . . 0.0 113.671 -177.301 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.585 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.7 m -82.64 123.86 29.65 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.505 -0.771 . . . . 0.0 110.43 179.5 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 21.1 p -95.71 144.64 25.94 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.213 0.53 . . . . 0.0 111.076 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.9 103.88 15.84 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 178.237 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 48.03 29.92 1.89 Allowed 'General case' 0 N--CA 1.472 0.661 0 O-C-N 124.249 0.968 . . . . 0.0 112.811 -178.362 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.57 -31.6 3.73 Favored Glycine 0 CA--C 1.522 0.473 0 C-N-CA 119.974 -1.108 . . . . 0.0 114.411 178.282 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.433 ' H ' HD23 ' A' ' 27' ' ' LEU . 1.8 pt? -126.91 135.87 27.99 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 117.756 0.778 . . . . 0.0 111.393 -178.794 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.409 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 39.2 Cg_exo -60.63 104.41 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.848 2.365 . . . . 0.0 113.293 -179.072 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.8 t . . . . . 0 C--N 1.325 -0.497 0 CA-C-O 121.942 0.877 . . . . 0.0 108.882 179.534 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 9.5 m . . . . . 0 N--CA 1.452 -0.329 0 CA-C-O 120.671 0.272 . . . . 0.0 110.368 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.41 28.17 73.29 Favored Glycine 0 C--N 1.334 0.459 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 -178.354 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -125.18 150.0 47.38 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 114.148 -1.026 . . . . 0.0 110.016 -178.378 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.604 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.3 p -111.48 143.72 41.86 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.557 179.097 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.594 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.0 p -116.14 47.49 1.39 Allowed 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.835 0.826 . . . . 0.0 109.281 178.475 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.403 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.4 t -57.2 -32.28 40.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 114.503 -1.226 . . . . 0.0 109.487 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.07 20.65 49.97 Favored Glycine 0 N--CA 1.448 -0.529 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.766 178.285 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.93 39.03 96.99 Favored Glycine 0 C--N 1.336 0.547 0 C-N-CA 121.602 -0.332 . . . . 0.0 112.775 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.13 144.28 25.6 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.698 0.285 . . . . 0.0 111.562 -179.345 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.551 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 72.6 m -133.7 135.35 43.98 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.32 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 48.4 m-20 -93.98 -29.7 15.11 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.441 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.749 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -63.38 121.67 71.23 Favored Pre-proline 0 C--O 1.237 0.404 0 CA-C-O 121.15 0.5 . . . . 0.0 111.014 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.2 Cg_exo -64.45 118.54 5.5 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.396 2.064 . . . . 0.0 112.641 -179.752 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.61 8.93 51.38 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.076 -0.965 . . . . 0.0 111.864 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.749 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 71.1 m -105.18 123.42 47.8 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.485 0.66 . . . . 0.0 111.958 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.3 p -94.07 142.51 27.31 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.144 179.274 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.1 t -72.8 134.23 44.83 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.624 0.726 . . . . 0.0 111.217 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.9 m -147.5 67.88 1.13 Allowed 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 106.502 -1.666 . . . . 0.0 106.502 178.837 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.1 t90 -28.02 129.6 0.21 Allowed Pre-proline 0 N--CA 1.462 0.174 0 CA-C-N 113.936 -1.484 . . . . 0.0 113.517 -176.205 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 64.2 Cg_endo -97.98 23.47 22.95 Favored 'Cis proline' 0 N--CA 1.462 -0.34 0 C-N-CA 123.625 -1.406 . . . . 0.0 113.312 0.356 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.604 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.9 146.98 33.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 -177.378 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.0 m -83.02 121.98 27.73 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.621 179.615 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.483 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 35.5 p -98.3 146.43 25.67 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.37 179.56 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 13.5 ttt180 -109.21 114.65 28.53 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.483 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 20.1 p30 47.58 31.29 1.99 Allowed 'General case' 0 N--CA 1.472 0.662 0 O-C-N 124.269 0.981 . . . . 0.0 113.041 -178.686 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.9 -27.39 6.21 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 120.035 -1.079 . . . . 0.0 114.602 177.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.463 ' O ' HG23 ' A' ' 29' ' ' VAL . 2.2 pt? -137.1 141.92 36.27 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 117.782 0.791 . . . . 0.0 111.17 -178.813 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.483 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 33.5 Cg_exo -58.07 105.88 0.23 Allowed 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 122.874 2.382 . . . . 0.0 113.539 -178.927 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.463 HG23 ' O ' ' A' ' 27' ' ' LEU . 10.7 t . . . . . 0 C--N 1.325 -0.498 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 178.453 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 19.0 m . . . . . 0 CA--C 1.518 -0.262 0 CA-C-O 120.562 0.22 . . . . 0.0 110.583 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.89 32.92 85.78 Favored Glycine 0 C--N 1.334 0.469 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -178.359 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -132.56 148.81 52.38 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 114.245 -0.978 . . . . 0.0 110.286 -178.178 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.606 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 25.7 p -108.83 143.05 38.52 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.076 179.511 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.6 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.8 p -116.27 46.94 1.49 Allowed 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.791 0.805 . . . . 0.0 109.295 177.918 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.9 t -56.44 -32.62 36.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 114.639 -1.164 . . . . 0.0 109.803 179.579 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.11 22.66 39.82 Favored Glycine 0 N--CA 1.447 -0.606 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.944 178.369 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.21 40.25 98.31 Favored Glycine 0 C--N 1.336 0.572 0 C-N-CA 121.414 -0.422 . . . . 0.0 112.598 179.857 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.28 144.07 27.37 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.683 0.278 . . . . 0.0 111.566 -179.195 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.552 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 84.5 m -136.02 133.05 37.06 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.355 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -88.3 -32.51 18.42 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.126 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.792 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.0 OUTLIER -64.97 118.32 47.93 Favored Pre-proline 0 C--O 1.237 0.426 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.05 -179.56 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -64.96 118.38 5.38 Favored 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 122.354 2.036 . . . . 0.0 112.485 -179.838 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 104.38 2.56 44.27 Favored Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.704 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.792 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 70.8 m -99.44 121.93 41.83 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.305 0.574 . . . . 0.0 111.77 -179.818 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.1 p -89.87 140.39 29.65 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.96 179.068 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.4 t -72.16 133.91 45.41 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.678 0.752 . . . . 0.0 110.891 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.7 m -147.06 68.83 1.16 Allowed 'General case' 0 C--N 1.311 -1.076 0 N-CA-C 106.519 -1.66 . . . . 0.0 106.519 179.161 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.424 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.1 t90 -28.45 129.48 0.21 Allowed Pre-proline 0 C--O 1.232 0.154 0 CA-C-N 113.987 -1.461 . . . . 0.0 113.445 -176.119 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.0 Cg_endo -98.29 24.26 21.35 Favored 'Cis proline' 0 N--CA 1.46 -0.457 0 C-N-CA 123.672 -1.387 . . . . 0.0 113.328 0.419 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.606 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.52 147.26 33.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 113.767 1.025 . . . . 0.0 113.767 -177.297 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.6 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 72.7 m -82.33 124.45 30.0 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.322 -0.853 . . . . 0.0 110.269 179.341 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.425 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 32.3 p -101.63 149.95 23.6 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.313 0.578 . . . . 0.0 111.574 -179.536 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 15.9 tpp85 -105.89 103.52 13.03 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 70.9 m-20 58.45 34.67 24.15 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 123.379 0.425 . . . . 0.0 110.547 -178.592 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 102.01 -24.05 32.54 Favored Glycine 0 CA--C 1.522 0.524 0 C-N-CA 120.49 -0.862 . . . . 0.0 114.13 179.368 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.437 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.2 pt? -118.12 130.59 24.64 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 117.964 0.882 . . . . 0.0 110.709 -179.602 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 31.1 Cg_exo -59.22 105.91 0.27 Allowed 'Trans proline' 0 CA--C 1.526 0.109 0 C-N-CA 123.153 2.569 . . . . 0.0 113.722 -178.836 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 27' ' ' LEU . 5.9 t . . . . . 0 C--N 1.327 -0.408 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 178.604 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.442 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 12.7 m . . . . . 0 N--CA 1.452 -0.356 0 CA-C-O 120.793 0.33 . . . . 0.0 110.4 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.22 29.67 75.9 Favored Glycine 0 C--N 1.333 0.405 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 -178.228 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.414 ' CD ' ' H ' ' A' ' 11' ' ' ASN . 38.6 tt0 -129.76 149.62 51.42 Favored 'General case' 0 N--CA 1.445 -0.698 0 CA-C-N 114.043 -1.079 . . . . 0.0 110.045 -178.362 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.606 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.0 p -110.28 144.34 39.12 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.705 179.313 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.585 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.9 p -116.82 46.93 1.55 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.811 0.815 . . . . 0.0 109.316 178.45 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.4 t -56.83 -32.57 39.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 114.683 -1.144 . . . . 0.0 109.671 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.63 21.23 47.2 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.84 178.319 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.73 39.86 98.01 Favored Glycine 0 C--N 1.335 0.486 0 C-N-CA 121.455 -0.403 . . . . 0.0 112.669 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.8 144.57 27.08 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.645 0.26 . . . . 0.0 111.553 -179.256 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.537 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 80.1 m -135.52 134.1 39.13 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.969 -0.559 . . . . 0.0 109.523 179.505 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.414 ' H ' ' CD ' ' A' ' 3' ' ' GLU . 62.8 m-80 -91.77 -31.43 15.77 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.216 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.707 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -63.2 121.17 67.74 Favored Pre-proline 0 C--O 1.236 0.365 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.122 -179.317 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.5 Cg_exo -64.17 118.51 5.46 Favored 'Trans proline' 0 N--CA 1.457 -0.67 0 C-N-CA 122.365 2.044 . . . . 0.0 112.688 -179.771 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.9 5.48 54.98 Favored Glycine 0 N--CA 1.446 -0.642 0 CA-C-N 115.2 -0.909 . . . . 0.0 112.013 179.657 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.707 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 86.1 m -102.14 120.87 41.16 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.607 0.718 . . . . 0.0 112.12 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 3.0 p -90.97 144.99 25.1 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.794 178.801 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.5 t -73.75 134.41 43.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.738 0.78 . . . . 0.0 111.066 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.8 m -146.78 67.71 1.16 Allowed 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 178.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.2 t90 -28.21 129.45 0.21 Allowed Pre-proline 0 C--O 1.232 0.172 0 CA-C-N 113.958 -1.474 . . . . 0.0 113.392 -176.118 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.6 Cg_endo -98.3 24.65 20.78 Favored 'Cis proline' 0 N--CA 1.462 -0.376 0 C-N-CA 123.676 -1.385 . . . . 0.0 113.324 0.357 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.606 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -130.81 148.2 33.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -177.314 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.585 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.5 m -83.53 128.54 34.59 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.586 179.518 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.4 p -108.29 149.9 28.03 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.042 -179.719 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.442 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 20.7 ttp180 -131.64 126.07 33.75 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.849 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.5 m-20 62.17 28.57 17.15 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.708 -178.693 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.99 5.32 77.29 Favored Glycine 0 CA--C 1.523 0.533 0 CA-C-N 115.715 -0.675 . . . . 0.0 114.101 179.087 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.41 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.8 pt? -148.21 142.65 16.65 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 117.851 0.825 . . . . 0.0 110.748 179.527 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 27.4 Cg_exo -62.6 104.58 0.37 Allowed 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.601 2.201 . . . . 0.0 112.926 -179.083 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.404 HG23 ' HG ' ' A' ' 27' ' ' LEU . 5.2 t . . . . . 0 C--N 1.324 -0.512 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 178.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.686 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 23.7 m . . . . . 0 CA--C 1.518 -0.287 0 CA-C-O 120.867 0.365 . . . . 0.0 110.083 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.74 31.4 79.72 Favored Glycine 0 C--N 1.334 0.469 0 N-CA-C 109.199 -1.561 . . . . 0.0 109.199 -177.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -134.6 148.21 50.38 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 113.957 -1.122 . . . . 0.0 110.32 -177.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.604 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.3 p -110.29 142.77 41.45 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.811 179.422 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.596 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.8 p -115.24 46.65 1.42 Allowed 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.722 0.772 . . . . 0.0 109.261 177.995 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.42 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.6 t -56.56 -32.42 36.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 114.666 -1.152 . . . . 0.0 109.652 179.385 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.71 22.41 41.1 Favored Glycine 0 N--CA 1.447 -0.596 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.858 178.327 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.03 40.06 97.97 Favored Glycine 0 C--N 1.335 0.475 0 C-N-CA 121.499 -0.382 . . . . 0.0 112.734 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.56 143.94 25.92 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.694 0.283 . . . . 0.0 111.581 -179.202 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.584 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 68.4 m -136.14 134.84 38.7 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.471 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 44.9 m-20 -91.2 -30.23 16.77 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.358 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.688 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.7 m -62.55 118.66 43.23 Favored Pre-proline 0 C--O 1.235 0.293 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.718 -179.78 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.9 Cg_exo -64.13 115.02 2.89 Favored 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.394 2.063 . . . . 0.0 112.851 -179.385 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.33 0.9 40.91 Favored Glycine 0 N--CA 1.445 -0.707 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.786 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.688 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 86.2 m -96.9 123.65 40.66 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.398 0.618 . . . . 0.0 111.82 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.9 p -92.66 144.05 25.7 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.074 179.15 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.3 t -73.44 134.26 43.92 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.607 0.718 . . . . 0.0 111.017 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.3 m -147.3 67.68 1.14 Allowed 'General case' 0 C--N 1.312 -1.061 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 179.025 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.7 t90 -28.11 129.45 0.21 Allowed Pre-proline 0 C--O 1.232 0.17 0 CA-C-N 114.067 -1.424 . . . . 0.0 113.448 -176.228 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 63.7 Cg_endo -98.08 22.94 23.55 Favored 'Cis proline' 0 N--CA 1.461 -0.419 0 C-N-CA 123.671 -1.387 . . . . 0.0 113.391 0.321 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.604 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.37 148.24 33.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 113.627 0.973 . . . . 0.0 113.627 -177.433 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.596 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.3 m -83.61 127.65 33.91 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.761 179.743 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.469 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 21.2 p -101.55 150.75 22.75 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.774 179.786 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.686 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 33.8 ttt180 -132.63 124.13 27.72 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.534 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 59.84 30.6 20.15 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.058 0.456 . . . . 0.0 111.203 -179.294 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.81 7.58 74.43 Favored Glycine 0 CA--C 1.523 0.579 0 C-N-CA 121.095 -0.574 . . . . 0.0 114.29 178.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.5 pt? -148.32 137.6 12.15 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 117.875 0.838 . . . . 0.0 110.674 179.182 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.469 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 16.9 Cg_exo -66.77 103.45 0.71 Allowed 'Trans proline' 0 N--CA 1.465 -0.185 0 C-N-CA 122.541 2.161 . . . . 0.0 112.656 -179.26 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.3 m . . . . . 0 C--N 1.323 -0.559 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.986 179.414 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.541 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 7.9 m . . . . . 0 CA--C 1.517 -0.307 0 CA-C-O 120.56 0.219 . . . . 0.0 110.568 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.07 31.52 81.11 Favored Glycine 0 C--N 1.334 0.441 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -178.264 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -129.42 151.81 49.65 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 114.152 -1.024 . . . . 0.0 110.519 -178.118 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.632 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.3 p -112.41 141.85 45.65 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.678 178.821 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.626 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.0 p -116.11 47.85 1.33 Allowed 'General case' 0 C--N 1.318 -0.797 0 CA-C-O 121.873 0.844 . . . . 0.0 109.264 177.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.2 t -57.24 -32.2 40.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 114.573 -1.194 . . . . 0.0 109.703 179.559 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -96.88 20.68 49.76 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.856 178.307 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.54 39.29 97.14 Favored Glycine 0 C--N 1.335 0.512 0 C-N-CA 121.468 -0.396 . . . . 0.0 112.662 179.829 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.22 144.2 26.39 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.62 0.248 . . . . 0.0 111.266 -179.248 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.536 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 76.7 m -133.32 133.93 43.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.022 -0.536 . . . . 0.0 109.952 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 33.7 m-20 -87.45 -35.02 18.49 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.441 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.717 HG21 HH21 ' A' ' 24' ' ' ARG . 3.6 m -63.17 118.12 40.0 Favored Pre-proline 0 C--O 1.236 0.365 0 CA-C-O 120.748 0.309 . . . . 0.0 110.747 -179.751 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -65.17 114.88 3.02 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.338 2.025 . . . . 0.0 112.297 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.24 -8.52 30.96 Favored Glycine 0 N--CA 1.445 -0.701 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.601 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.581 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 96.5 m -91.43 121.98 33.62 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.366 0.603 . . . . 0.0 111.619 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.7 p -89.76 144.38 26.02 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.251 179.348 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.0 t -74.28 134.16 42.61 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.615 0.721 . . . . 0.0 111.016 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.9 m -147.29 68.77 1.14 Allowed 'General case' 0 C--N 1.311 -1.072 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.019 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.1 t90 -28.32 129.65 0.21 Allowed Pre-proline 0 C--O 1.232 0.178 0 CA-C-N 113.978 -1.465 . . . . 0.0 113.399 -176.207 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 65.4 Cg_endo -98.42 24.91 20.26 Favored 'Cis proline' 0 N--CA 1.461 -0.441 0 C-N-CA 123.694 -1.377 . . . . 0.0 113.263 0.31 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.632 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.64 147.98 33.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 N-CA-C 113.688 0.996 . . . . 0.0 113.688 -177.386 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.626 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.9 m -83.4 123.04 29.28 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.453 179.44 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 28.1 p -99.0 147.14 25.31 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.193 0.52 . . . . 0.0 111.108 -179.732 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.717 HH21 HG21 ' A' ' 12' ' ' THR . 40.5 ttm180 -114.14 112.86 23.88 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.386 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 60.43 33.06 20.71 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.438 -178.262 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.51 -16.97 60.19 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.75 -0.738 . . . . 0.0 114.207 179.175 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.432 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.4 pt? -123.91 133.99 25.04 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 117.935 0.868 . . . . 0.0 110.743 -179.651 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 24.5 Cg_exo -62.82 104.14 0.37 Allowed 'Trans proline' 0 N--CA 1.466 -0.115 0 C-N-CA 122.838 2.359 . . . . 0.0 113.523 -178.858 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 4.3 t . . . . . 0 C--N 1.327 -0.402 0 CA-C-O 122.108 0.956 . . . . 0.0 108.592 178.916 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 35.3 m . . . . . 0 CA--C 1.519 -0.239 0 CA-C-O 120.729 0.299 . . . . 0.0 110.698 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.64 32.65 83.81 Favored Glycine 0 C--N 1.335 0.475 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -178.222 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.418 ' CD ' ' H ' ' A' ' 11' ' ' ASN . 38.4 tt0 -137.75 148.41 45.57 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 114.205 -0.997 . . . . 0.0 110.405 -178.101 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.615 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 27.1 p -108.85 142.91 38.74 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.897 179.355 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.604 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.3 p -116.28 46.86 1.5 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.777 0.798 . . . . 0.0 109.277 177.846 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.8 t -56.62 -32.75 38.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 114.607 -1.179 . . . . 0.0 109.795 179.566 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.84 22.7 39.64 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.919 178.443 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.87 40.48 98.36 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 121.446 -0.407 . . . . 0.0 112.615 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -147.85 144.07 27.88 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.654 0.264 . . . . 0.0 111.355 -179.195 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.56 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 79.3 m -136.58 133.76 36.72 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.993 -0.549 . . . . 0.0 109.718 179.555 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.418 ' H ' ' CD ' ' A' ' 3' ' ' GLU . 62.6 m-80 -91.12 -31.35 16.26 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.947 179.757 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.637 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -62.55 118.96 46.08 Favored Pre-proline 0 C--O 1.237 0.398 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.846 -179.547 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.8 Cg_exo -64.08 118.92 5.84 Favored 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 122.231 1.954 . . . . 0.0 112.739 -179.619 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.42 10.77 53.32 Favored Glycine 0 N--CA 1.446 -0.688 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.977 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.637 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 95.5 m -105.48 121.52 44.1 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.456 0.646 . . . . 0.0 111.723 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 8.0 p -89.76 143.25 26.95 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 115.102 -0.953 . . . . 0.0 109.898 179.07 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.0 t -72.61 134.19 45.04 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.668 0.747 . . . . 0.0 110.954 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.9 m -146.09 67.58 1.19 Allowed 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.424 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.6 t90 -27.94 129.39 0.21 Allowed Pre-proline 0 C--O 1.233 0.201 0 CA-C-N 113.919 -1.491 . . . . 0.0 113.528 -176.202 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.9 Cg_endo -98.04 24.82 20.89 Favored 'Cis proline' 0 N--CA 1.462 -0.346 0 C-N-CA 123.658 -1.392 . . . . 0.0 113.307 0.468 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.615 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -131.61 146.9 32.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -177.413 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.604 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 78.3 m -81.66 132.11 35.29 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.224 179.343 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 63.0 p -117.16 147.39 42.5 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.017 0.437 . . . . 0.0 111.608 -178.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 54.0 ttm-85 -108.56 114.27 27.96 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 177.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 16.1 m120 61.33 35.25 18.1 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.143 0.497 . . . . 0.0 109.683 -178.252 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 72.83 27.82 68.22 Favored Glycine 0 N--CA 1.452 -0.269 0 CA-C-N 115.69 -0.686 . . . . 0.0 112.244 -179.276 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.4 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 10.1 tt -140.95 120.03 8.31 Favored Pre-proline 0 C--N 1.328 -0.355 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.937 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 22.1 Cg_exo -64.98 102.85 0.45 Allowed 'Trans proline' 0 N--CA 1.465 -0.148 0 C-N-CA 122.524 2.149 . . . . 0.0 112.841 -179.268 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.1 p . . . . . 0 C--N 1.322 -0.622 0 CA-C-O 122.055 0.931 . . . . 0.0 109.736 179.701 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 11.6 m . . . . . 0 CA--C 1.519 -0.241 0 CA-C-O 120.816 0.341 . . . . 0.0 110.47 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.44 31.96 82.6 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 109.476 -1.449 . . . . 0.0 109.476 -178.071 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -132.71 148.95 52.34 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 114.127 -1.036 . . . . 0.0 110.359 -177.899 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.61 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 25.7 p -110.12 142.72 41.23 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.891 179.34 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.594 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 29.9 p -115.72 46.97 1.42 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.655 0.74 . . . . 0.0 109.283 177.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.406 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.9 t -56.54 -32.64 37.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.685 179.492 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.05 22.0 43.13 Favored Glycine 0 N--CA 1.447 -0.617 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.836 178.443 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.27 39.58 97.41 Favored Glycine 0 C--N 1.335 0.518 0 C-N-CA 121.511 -0.376 . . . . 0.0 112.683 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -149.68 143.77 25.7 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.664 0.268 . . . . 0.0 111.557 -179.308 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 78.9 m -134.7 135.24 41.85 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 179.491 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 44.1 m-20 -90.31 -30.84 17.22 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.63 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.5 m -62.95 117.97 37.84 Favored Pre-proline 0 C--O 1.236 0.35 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.655 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.6 Cg_exo -64.37 116.48 3.78 Favored 'Trans proline' 0 N--CA 1.457 -0.658 0 C-N-CA 122.386 2.058 . . . . 0.0 112.662 -179.414 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.3 2.31 47.8 Favored Glycine 0 N--CA 1.445 -0.75 0 CA-C-N 115.373 -0.831 . . . . 0.0 112.107 179.635 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.63 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 88.9 m -97.78 123.13 41.6 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.334 0.588 . . . . 0.0 111.497 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.8 p -90.07 141.58 28.53 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.293 179.467 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.8 t -73.06 134.28 44.52 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.663 0.744 . . . . 0.0 110.95 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.2 m -147.19 68.61 1.15 Allowed 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.056 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.426 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.7 t90 -28.14 129.6 0.21 Allowed Pre-proline 0 N--CA 1.463 0.187 0 CA-C-N 113.962 -1.472 . . . . 0.0 113.421 -176.252 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.426 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 68.8 Cg_endo -98.03 23.31 23.11 Favored 'Cis proline' 0 N--CA 1.461 -0.439 0 C-N-CA 123.62 -1.408 . . . . 0.0 113.275 0.307 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.61 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -129.99 147.02 33.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -177.4 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 77.3 m -82.05 125.34 30.71 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.494 179.464 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.523 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 32.4 p -101.06 146.47 27.41 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.156 0.503 . . . . 0.0 111.195 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.435 ' HG2' ' SG ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -101.79 107.86 19.19 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 177.879 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 17.7 p30 49.36 28.83 2.49 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 124.319 1.012 . . . . 0.0 112.776 -178.421 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 124.33 -29.62 4.99 Favored Glycine 0 CA--C 1.521 0.451 0 C-N-CA 120.035 -1.079 . . . . 0.0 114.518 178.141 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.427 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.7 pt? -125.81 135.46 27.05 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 117.776 0.788 . . . . 0.0 111.109 -179.007 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 35.0 Cg_exo -60.85 104.75 0.28 Allowed 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.861 2.374 . . . . 0.0 113.404 -178.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 27' ' ' LEU . 6.1 t . . . . . 0 C--N 1.325 -0.475 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 178.874 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.671 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 8.9 m . . . . . 0 CA--C 1.518 -0.268 0 CA-C-O 120.763 0.316 . . . . 0.0 110.25 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.27 31.72 81.47 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -177.817 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -133.51 148.31 51.67 Favored 'General case' 0 N--CA 1.444 -0.766 0 CA-C-N 113.928 -1.136 . . . . 0.0 110.509 -177.72 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.6 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.4 p -110.45 142.86 41.6 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.808 179.325 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.582 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.6 p -115.36 46.95 1.38 Allowed 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.739 0.78 . . . . 0.0 109.278 178.071 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.408 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.8 t -56.55 -32.42 36.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 114.624 -1.171 . . . . 0.0 109.658 179.474 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.23 21.88 43.73 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 115.617 -0.72 . . . . 0.0 111.811 178.384 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.36 39.52 97.37 Favored Glycine 0 C--N 1.335 0.524 0 C-N-CA 121.527 -0.368 . . . . 0.0 112.668 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.03 143.86 25.43 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.684 0.278 . . . . 0.0 111.597 -179.294 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.582 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 70.4 m -134.78 135.01 41.51 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.421 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.1 m-20 -88.58 -31.1 18.79 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.615 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.7 m -63.59 117.72 37.49 Favored Pre-proline 0 C--O 1.236 0.381 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.752 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_exo -65.05 115.66 3.41 Favored 'Trans proline' 0 N--CA 1.459 -0.536 0 C-N-CA 122.316 2.011 . . . . 0.0 112.438 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 108.87 -8.73 34.01 Favored Glycine 0 N--CA 1.446 -0.681 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.738 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.615 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 88.2 m -89.98 122.69 33.23 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.42 0.629 . . . . 0.0 111.762 -179.677 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.0 p -90.67 144.35 25.83 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.078 -0.964 . . . . 0.0 110.113 179.212 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.4 t -74.06 134.27 42.96 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.592 0.71 . . . . 0.0 111.092 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 m -147.45 68.27 1.13 Allowed 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 106.517 -1.661 . . . . 0.0 106.517 179.053 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.451 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.8 t90 -28.16 129.44 0.21 Allowed Pre-proline 0 N--CA 1.463 0.191 0 CA-C-N 114.007 -1.451 . . . . 0.0 113.437 -176.256 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.451 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.9 Cg_endo -98.36 23.18 22.77 Favored 'Cis proline' 0 C--N 1.345 0.388 0 C-N-CA 123.617 -1.41 . . . . 0.0 113.257 0.334 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.6 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -129.48 148.64 33.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -177.447 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.572 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 73.5 m -83.55 126.19 32.55 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.723 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.513 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 20.1 p -99.68 148.2 24.6 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.771 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.671 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 57.9 ttp180 -130.4 131.94 45.52 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.024 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.6 p-10 44.59 36.4 1.72 Allowed 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 113.324 0.861 . . . . 0.0 113.324 -179.413 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.17 0.84 55.89 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 115.621 1.008 . . . . 0.0 115.621 177.272 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -161.61 144.97 9.41 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 118.473 1.137 . . . . 0.0 111.046 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.513 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 20.8 Cg_exo -65.14 104.32 0.59 Allowed 'Trans proline' 0 N--CA 1.464 -0.255 0 C-N-CA 122.444 2.096 . . . . 0.0 112.904 -179.109 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.9 t . . . . . 0 C--N 1.325 -0.498 0 CA-C-O 122.063 0.935 . . . . 0.0 108.551 179.112 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.693 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 16.6 m . . . . . 0 CA--C 1.516 -0.33 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.5 30.28 76.24 Favored Glycine 0 N--CA 1.45 -0.422 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -177.89 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -130.24 152.69 49.38 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 114.126 -1.037 . . . . 0.0 110.544 -178.199 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.63 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.3 p -115.24 143.34 45.4 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.241 178.44 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.639 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.8 p -115.73 47.46 1.35 Allowed 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.915 0.865 . . . . 0.0 109.362 178.666 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -57.52 -32.23 41.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 114.552 -1.204 . . . . 0.0 109.481 179.387 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -96.51 19.9 52.69 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.828 178.281 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.9 39.73 97.91 Favored Glycine 0 C--N 1.335 0.48 0 C-N-CA 121.524 -0.37 . . . . 0.0 112.746 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.04 144.96 26.12 Favored 'General case' 0 C--N 1.324 -0.528 0 O-C-N 122.734 -0.274 . . . . 0.0 111.472 -179.275 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.529 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 85.6 m -134.62 133.57 40.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.088 -0.505 . . . . 0.0 109.81 179.539 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 34.2 m-20 -90.14 -34.04 16.02 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.676 -179.667 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.673 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.1 m -61.98 121.19 63.82 Favored Pre-proline 0 C--O 1.236 0.366 0 CA-C-O 120.943 0.401 . . . . 0.0 110.654 -179.673 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -64.58 114.79 2.87 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.44 2.093 . . . . 0.0 112.691 -179.535 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 106.08 0.94 38.74 Favored Glycine 0 N--CA 1.445 -0.705 0 CA-C-N 115.465 -0.789 . . . . 0.0 111.68 179.764 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.673 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 84.2 m -98.91 119.74 38.19 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 121.46 0.648 . . . . 0.0 111.658 -179.8 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.8 p -90.59 144.82 25.39 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.023 179.095 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.7 t -72.84 134.4 44.85 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.697 0.761 . . . . 0.0 111.109 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.1 m -147.13 66.96 1.14 Allowed 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 106.217 -1.771 . . . . 0.0 106.217 178.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.9 t90 -28.24 129.53 0.21 Allowed Pre-proline 0 C--O 1.233 0.195 0 CA-C-N 113.89 -1.504 . . . . 0.0 113.436 -176.142 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 64.6 Cg_endo -98.32 24.19 21.41 Favored 'Cis proline' 0 N--CA 1.461 -0.384 0 C-N-CA 123.645 -1.398 . . . . 0.0 113.284 0.43 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.63 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -129.15 147.76 33.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 -177.409 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.639 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 91.8 m -84.37 123.76 30.55 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.737 179.663 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.54 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 34.6 p -100.08 146.46 26.75 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.338 179.531 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.693 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 25.5 ttp85 -117.4 122.05 42.75 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.879 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 21.6 p30 46.82 32.3 1.74 Allowed 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.342 1.057 . . . . 0.0 113.595 -179.031 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.48 -17.44 14.02 Favored Glycine 0 CA--C 1.522 0.489 0 C-N-CA 119.92 -1.133 . . . . 0.0 115.325 177.133 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -144.13 144.36 25.83 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-N 118.367 1.083 . . . . 0.0 111.669 -178.91 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.54 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 16.9 Cg_exo -65.93 103.61 0.62 Allowed 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 122.623 2.215 . . . . 0.0 112.479 -179.738 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.49 HG23 ' HB3' ' A' ' 24' ' ' ARG . 3.6 m . . . . . 0 C--N 1.321 -0.651 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.231 179.22 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.549 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 11.6 m . . . . . 0 CA--C 1.517 -0.323 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.71 31.17 80.02 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 109.241 -1.543 . . . . 0.0 109.241 -178.099 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.407 ' CD ' ' H ' ' A' ' 11' ' ' ASN . 38.4 tt0 -132.76 149.08 52.32 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 114.0 -1.1 . . . . 0.0 110.147 -177.888 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.604 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.1 p -110.9 144.41 39.99 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.629 179.308 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.583 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.7 p -116.64 46.86 1.54 Allowed 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.789 0.804 . . . . 0.0 109.282 178.56 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -56.85 -32.59 39.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 114.587 -1.188 . . . . 0.0 109.531 179.45 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.39 21.78 44.24 Favored Glycine 0 N--CA 1.446 -0.64 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.906 178.368 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.41 40.08 98.17 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 121.431 -0.414 . . . . 0.0 112.832 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.73 144.7 27.24 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.69 0.281 . . . . 0.0 111.514 -179.23 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.544 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.4 m -136.41 133.42 36.67 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.3 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ASN . . . . . 0.407 ' H ' ' CD ' ' A' ' 3' ' ' GLU . 64.7 m-80 -88.34 -32.21 18.52 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.189 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.659 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.6 m -63.25 118.85 47.37 Favored Pre-proline 0 C--O 1.236 0.382 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.816 -179.618 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -64.76 115.8 3.44 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.438 2.092 . . . . 0.0 112.553 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 106.4 -3.62 37.33 Favored Glycine 0 N--CA 1.445 -0.707 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.89 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.659 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 93.1 m -93.91 121.14 35.07 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.377 0.608 . . . . 0.0 111.822 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.4 p -89.88 143.87 26.43 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.053 178.897 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.6 t -73.26 134.36 44.23 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.7 0.762 . . . . 0.0 111.009 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.5 m -147.01 68.08 1.16 Allowed 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 106.378 -1.712 . . . . 0.0 106.378 178.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.3 t90 -28.3 129.52 0.21 Allowed Pre-proline 0 C--O 1.232 0.147 0 CA-C-N 113.874 -1.512 . . . . 0.0 113.413 -176.205 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.462 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.0 Cg_endo -98.37 24.34 21.14 Favored 'Cis proline' 0 N--CA 1.46 -0.466 0 C-N-CA 123.696 -1.377 . . . . 0.0 113.324 0.34 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.604 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -130.32 148.27 33.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -177.325 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.5 m -83.59 127.23 33.58 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.602 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.437 HG22 ' HG3' ' A' ' 28' ' ' PRO . 32.1 p -105.46 149.04 26.52 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.762 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.549 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 41.3 ttp85 -130.86 123.94 30.14 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.253 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 79.4 m-20 62.11 29.31 17.55 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.779 -178.465 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.42 5.18 75.95 Favored Glycine 0 CA--C 1.523 0.549 0 CA-C-N 115.704 -0.68 . . . . 0.0 114.055 179.112 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.417 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.7 pt? -147.23 139.13 13.73 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 117.845 0.822 . . . . 0.0 110.765 179.415 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.437 ' HG3' HG22 ' A' ' 23' ' ' THR . 23.4 Cg_exo -64.3 104.81 0.54 Allowed 'Trans proline' 0 N--CA 1.466 -0.142 0 C-N-CA 122.63 2.22 . . . . 0.0 112.878 -178.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.2 t . . . . . 0 C--N 1.326 -0.435 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.062 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.544 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 4.0 m . . . . . 0 CA--C 1.518 -0.276 0 CA-C-O 120.793 0.33 . . . . 0.0 110.501 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.3 31.09 79.71 Favored Glycine 0 C--N 1.334 0.435 0 N-CA-C 109.439 -1.465 . . . . 0.0 109.439 -178.186 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -128.79 149.33 50.77 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 113.883 -1.159 . . . . 0.0 109.793 -177.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.587 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 27.2 p -109.74 142.6 40.73 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.136 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.583 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 29.8 p -116.54 45.31 1.83 Allowed 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.64 0.734 . . . . 0.0 109.296 177.771 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.44 HG23 ' HB ' ' A' ' 4' ' ' THR . 11.4 t -55.75 -33.33 33.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 114.735 -1.121 . . . . 0.0 109.906 179.477 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.74 22.59 39.71 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.708 -0.678 . . . . 0.0 112.011 178.57 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.99 40.24 99.06 Favored Glycine 0 C--N 1.334 0.461 0 C-N-CA 121.3 -0.476 . . . . 0.0 112.63 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -146.2 146.17 30.7 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.822 0.344 . . . . 0.0 111.565 -179.357 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 80.1 m -141.33 130.53 23.48 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 178.763 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -89.31 -27.19 20.69 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.48 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.594 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.8 m -65.56 117.48 41.43 Favored Pre-proline 0 C--O 1.237 0.423 0 CA-C-O 120.949 0.404 . . . . 0.0 110.259 179.771 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -64.14 114.04 2.48 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 122.315 2.01 . . . . 0.0 113.149 -179.064 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 107.28 -5.41 35.8 Favored Glycine 0 N--CA 1.442 -0.936 0 CA-C-N 115.282 -0.872 . . . . 0.0 112.014 179.609 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.594 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 99.5 m -89.9 123.11 33.55 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.403 0.62 . . . . 0.0 111.49 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.6 p -90.01 141.54 28.57 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.305 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 50.7 t -71.94 134.52 46.03 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.706 0.765 . . . . 0.0 110.911 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.3 m -147.08 68.1 1.15 Allowed 'General case' 0 C--N 1.312 -1.043 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 179.192 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.422 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.7 t90 -27.73 129.26 0.2 Allowed Pre-proline 0 C--O 1.232 0.154 0 CA-C-N 113.976 -1.465 . . . . 0.0 113.516 -176.121 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.422 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 62.6 Cg_endo -97.91 23.14 23.54 Favored 'Cis proline' 0 N--CA 1.462 -0.376 0 C-N-CA 123.675 -1.386 . . . . 0.0 113.282 0.368 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.587 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.4 m -130.05 146.44 34.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 113.803 1.038 . . . . 0.0 113.803 -177.316 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 82.2 m -81.6 126.9 32.3 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.355 179.417 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.446 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 24.7 p -101.68 145.76 28.65 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.294 0.569 . . . . 0.0 111.426 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.544 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 27.1 tpt180 -117.48 117.28 29.03 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.212 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 63.5 m-20 60.48 32.23 20.47 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.465 -178.583 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.45 -12.73 69.08 Favored Glycine 0 CA--C 1.524 0.618 0 C-N-CA 120.808 -0.711 . . . . 0.0 114.214 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.415 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.5 pt? -129.21 137.14 30.34 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 118.113 0.956 . . . . 0.0 110.95 -179.814 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.446 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 24.7 Cg_exo -63.03 103.8 0.37 Allowed 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.679 2.252 . . . . 0.0 113.252 -178.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.5 t . . . . . 0 C--N 1.325 -0.458 0 CA-C-O 121.958 0.885 . . . . 0.0 108.931 179.424 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.603 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 18.6 m . . . . . 0 CA--C 1.516 -0.334 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.46 30.85 78.52 Favored Glycine 0 CA--C 1.507 -0.455 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -178.052 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -131.06 150.91 51.93 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 114.214 -0.993 . . . . 0.0 110.676 -178.07 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.629 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.7 p -113.54 143.82 43.9 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.374 178.612 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.613 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.5 p -117.34 47.75 1.46 Allowed 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.838 0.828 . . . . 0.0 109.337 178.564 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.6 t -57.26 -32.31 40.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 114.458 -1.246 . . . . 0.0 109.51 179.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.13 20.67 49.9 Favored Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.873 178.358 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.55 39.86 97.93 Favored Glycine 0 C--N 1.335 0.525 0 C-N-CA 121.458 -0.401 . . . . 0.0 112.728 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.78 144.73 27.2 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.623 0.249 . . . . 0.0 111.455 -179.357 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.516 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.8 m -134.6 132.44 39.04 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.806 179.532 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -86.65 -36.17 18.93 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.585 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.718 HG21 HH21 ' A' ' 24' ' ' ARG . 3.6 m -62.34 118.36 39.54 Favored Pre-proline 0 C--O 1.235 0.324 0 CA-C-O 120.789 0.328 . . . . 0.0 110.625 -179.722 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -64.76 114.72 2.87 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 122.326 2.017 . . . . 0.0 112.382 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.44 -9.67 30.71 Favored Glycine 0 N--CA 1.446 -0.696 0 CA-C-N 115.445 -0.798 . . . . 0.0 111.594 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.607 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 100.0 m -89.89 121.69 32.23 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.364 0.602 . . . . 0.0 111.586 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.3 p -89.82 143.89 26.41 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.342 179.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.7 t -74.06 134.02 42.94 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.699 0.761 . . . . 0.0 110.905 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 m -147.27 69.08 1.15 Allowed 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.5 t90 -28.72 129.64 0.22 Allowed Pre-proline 0 C--O 1.232 0.157 0 CA-C-N 114.033 -1.44 . . . . 0.0 113.422 -176.086 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.449 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.9 Cg_endo -98.59 24.98 19.93 Favored 'Cis proline' 0 N--CA 1.461 -0.432 0 C-N-CA 123.695 -1.377 . . . . 0.0 113.297 0.389 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.629 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.54 147.83 33.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -177.315 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.613 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 81.2 m -83.47 122.74 28.92 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.442 179.363 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.9 p -97.76 152.63 18.94 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.952 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.718 HH21 HG21 ' A' ' 12' ' ' THR . 39.1 ttm180 -126.41 125.53 42.33 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 179.138 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 41.9 38.18 0.96 Allowed 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 113.587 0.958 . . . . 0.0 113.587 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.645 0 N-CA-C 115.472 0.949 . . . . 0.0 115.472 177.392 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.567 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 5.9 m . . . . . 0 CA--C 1.518 -0.285 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.78 32.21 83.4 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -178.29 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.577 ' OE2' ' HA ' ' A' ' 10' ' ' CYS . 27.3 tt0 -126.78 152.8 46.41 Favored 'General case' 0 N--CA 1.442 -0.843 0 CA-C-N 114.079 -1.06 . . . . 0.0 110.388 -177.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.643 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 29.1 p -111.83 141.33 45.6 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.778 178.824 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.669 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 23.3 p -115.61 46.73 1.45 Allowed 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.818 0.818 . . . . 0.0 109.341 178.163 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.415 HG23 ' HB ' ' A' ' 4' ' ' THR . 9.9 t -57.78 -33.04 44.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 114.593 -1.185 . . . . 0.0 109.723 179.5 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.97 18.06 58.08 Favored Glycine 0 N--CA 1.447 -0.575 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.945 178.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 64.49 36.22 92.9 Favored Glycine 0 C--N 1.333 0.367 0 C-N-CA 121.274 -0.489 . . . . 0.0 112.768 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.6 154.77 43.9 Favored 'General case' 0 C--N 1.324 -0.515 0 O-C-N 122.749 -0.265 . . . . 0.0 110.31 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.577 ' HA ' ' OE2' ' A' ' 3' ' ' GLU . 86.2 m -139.57 133.98 31.51 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.664 179.037 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -89.19 -40.19 13.05 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.423 -179.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.678 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.5 m -60.95 119.67 47.02 Favored Pre-proline 0 C--O 1.237 0.402 0 CA-C-O 120.864 0.364 . . . . 0.0 110.668 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -64.72 114.16 2.63 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 122.478 2.118 . . . . 0.0 112.633 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 111.21 -6.91 28.78 Favored Glycine 0 N--CA 1.445 -0.717 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.659 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.678 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 75.3 m -91.54 122.76 34.41 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.48 0.657 . . . . 0.0 111.929 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.6 p -91.51 144.22 25.78 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.024 -0.989 . . . . 0.0 109.922 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.1 t -73.05 134.35 44.56 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.784 0.802 . . . . 0.0 111.116 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.9 m -146.79 67.37 1.16 Allowed 'General case' 0 C--N 1.31 -1.125 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 178.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.407 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.6 t90 -28.07 129.37 0.21 Allowed Pre-proline 0 N--CA 1.463 0.18 0 CA-C-N 113.86 -1.518 . . . . 0.0 113.386 -176.019 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.5 Cg_endo -98.42 26.77 17.85 Favored 'Cis proline' 0 N--CA 1.461 -0.421 0 C-N-CA 123.719 -1.367 . . . . 0.0 113.3 0.269 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.643 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.1 m -132.21 147.71 32.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 113.782 1.03 . . . . 0.0 113.782 -177.367 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.669 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 95.3 m -83.97 124.95 31.57 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.673 179.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.413 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 32.9 p -103.75 155.64 18.44 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.651 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.567 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 36.1 ttp85 -135.85 124.24 23.39 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.126 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 62.41 29.15 17.15 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.732 -178.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.517 0 CA-C-N 115.81 -0.632 . . . . 0.0 114.108 179.063 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.654 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 21.8 m . . . . . 0 CA--C 1.518 -0.252 0 CA-C-O 120.701 0.286 . . . . 0.0 110.252 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 67.09 31.3 77.38 Favored Glycine 0 C--N 1.333 0.406 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 -177.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -131.76 150.8 52.04 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 114.241 -0.98 . . . . 0.0 110.431 -178.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.614 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.8 p -112.73 141.44 46.52 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.441 178.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.616 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 23.7 p -114.88 45.86 1.52 Allowed 'General case' 0 C--N 1.317 -0.829 0 CA-C-O 121.788 0.804 . . . . 0.0 109.494 178.335 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.415 HG23 ' HB ' ' A' ' 4' ' ' THR . 11.5 t -56.5 -32.49 36.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 114.646 -1.161 . . . . 0.0 109.778 179.487 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.57 21.68 44.07 Favored Glycine 0 N--CA 1.448 -0.567 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.969 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.82 40.19 98.92 Favored Glycine 0 C--N 1.334 0.44 0 C-N-CA 121.385 -0.436 . . . . 0.0 112.738 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.56 147.24 32.93 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.662 0.268 . . . . 0.0 111.448 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.544 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 84.6 m -143.46 127.67 17.64 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 178.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -91.9 -28.33 17.35 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.206 -179.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.677 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.4 m -62.71 122.83 76.68 Favored Pre-proline 0 C--O 1.234 0.268 0 CA-C-O 120.88 0.372 . . . . 0.0 110.348 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 24.4 Cg_exo -63.75 115.31 3.0 Favored 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 122.267 1.978 . . . . 0.0 113.065 -179.321 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.53 5.75 51.29 Favored Glycine 0 N--CA 1.444 -0.776 0 CA-C-N 115.175 -0.921 . . . . 0.0 111.932 179.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.677 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 99.6 m -101.45 122.45 43.8 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.54 0.686 . . . . 0.0 111.963 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.4 p -94.19 147.59 23.02 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-N 114.929 -1.032 . . . . 0.0 110.083 179.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.3 t -74.53 134.32 42.22 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.696 0.76 . . . . 0.0 111.129 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 26.0 m -147.46 67.46 1.13 Allowed 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 178.816 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.463 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.6 t90 -27.99 129.32 0.21 Allowed Pre-proline 0 N--CA 1.462 0.164 0 CA-C-N 113.963 -1.471 . . . . 0.0 113.449 -176.187 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.5 Cg_endo -98.41 24.46 20.9 Favored 'Cis proline' 0 N--CA 1.46 -0.496 0 C-N-CA 123.71 -1.371 . . . . 0.0 113.342 0.315 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.614 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.24 148.2 33.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 N-CA-C 113.658 0.985 . . . . 0.0 113.658 -177.399 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.616 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.3 m -83.89 126.53 33.07 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.619 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.437 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 22.2 p -103.06 151.6 22.35 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.003 -179.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.654 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 38.5 ttp85 -133.68 132.07 40.25 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.089 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 18.9 p30 52.43 28.36 5.81 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 124.019 0.927 . . . . 0.0 112.627 -178.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.441 0 N-CA-C 114.782 0.673 . . . . 0.0 114.782 177.345 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.584 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 13.1 m . . . . . 0 CA--C 1.518 -0.25 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.3 28.85 73.98 Favored Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -177.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -127.5 151.38 48.94 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-N 114.231 -0.984 . . . . 0.0 110.572 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.625 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.0 p -113.05 143.45 44.3 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.253 178.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.629 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 24.9 p -116.85 47.26 1.5 Allowed 'General case' 0 C--N 1.318 -0.787 0 CA-C-O 121.874 0.845 . . . . 0.0 109.369 178.525 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.2 t -57.1 -32.22 39.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 114.482 -1.235 . . . . 0.0 109.524 179.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.92 21.13 47.69 Favored Glycine 0 N--CA 1.447 -0.588 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.85 178.346 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.37 40.11 98.19 Favored Glycine 0 C--N 1.335 0.484 0 C-N-CA 121.503 -0.379 . . . . 0.0 112.786 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.24 144.92 27.99 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.617 0.246 . . . . 0.0 111.461 -179.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.497 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 79.6 m -135.74 131.83 36.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.72 179.418 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.6 m-80 -88.2 -36.03 17.02 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.735 -179.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.708 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.1 m -61.64 119.62 48.95 Favored Pre-proline 0 C--O 1.235 0.305 0 CA-C-O 120.974 0.416 . . . . 0.0 110.7 -179.535 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -63.7 114.05 2.4 Favored 'Trans proline' 0 N--CA 1.459 -0.545 0 C-N-CA 122.462 2.108 . . . . 0.0 112.873 -179.233 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 108.36 -2.48 32.83 Favored Glycine 0 N--CA 1.444 -0.786 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.759 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.708 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 81.6 m -94.33 122.5 36.94 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.375 0.607 . . . . 0.0 111.82 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.1 p -91.8 144.01 25.93 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.088 179.151 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.5 t -73.57 134.07 43.67 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.698 0.761 . . . . 0.0 111.091 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.6 m -147.28 68.2 1.14 Allowed 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 106.377 -1.712 . . . . 0.0 106.377 178.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.458 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.4 t90 -28.54 129.54 0.22 Allowed Pre-proline 0 C--O 1.232 0.166 0 CA-C-N 113.964 -1.471 . . . . 0.0 113.419 -176.091 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.3 Cg_endo -98.49 24.64 20.54 Favored 'Cis proline' 0 N--CA 1.461 -0.428 0 C-N-CA 123.747 -1.355 . . . . 0.0 113.318 0.423 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.625 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.18 147.79 33.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 113.714 1.005 . . . . 0.0 113.714 -177.299 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.629 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.0 m -83.66 123.57 29.95 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.578 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 27.2 p -99.58 152.84 19.58 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.56 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.584 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 30.9 ttt180 -129.09 128.39 43.43 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.062 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 41.92 38.62 1.07 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 113.616 0.969 . . . . 0.0 113.616 -179.602 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.596 0 N-CA-C 115.611 1.004 . . . . 0.0 115.611 177.231 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.46 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 15.4 m . . . . . 0 CA--C 1.517 -0.303 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.76 31.09 79.77 Favored Glycine 0 C--N 1.333 0.41 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -177.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -134.38 148.81 50.74 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 113.983 -1.108 . . . . 0.0 110.349 -177.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 17.4 p -112.42 144.66 41.49 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.557 179.328 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.599 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.0 p -116.33 46.96 1.49 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.809 0.814 . . . . 0.0 109.402 178.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -56.96 -32.81 40.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 114.638 -1.165 . . . . 0.0 109.505 179.344 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.35 21.94 43.44 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.947 178.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.39 40.31 98.47 Favored Glycine 0 C--N 1.334 0.472 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.684 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.77 144.63 27.15 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.735 0.302 . . . . 0.0 111.518 -179.218 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.559 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 78.1 m -136.95 133.12 35.3 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 179.319 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.3 m-80 -87.89 -32.27 19.04 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.18 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.607 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.7 m -63.56 117.06 30.93 Favored Pre-proline 0 C--O 1.236 0.352 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.706 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_exo -65.46 114.96 3.1 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 122.436 2.091 . . . . 0.0 112.372 -179.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.65 -7.55 31.86 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 115.472 -0.786 . . . . 0.0 111.533 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.607 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 86.3 m -91.21 121.78 33.28 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.461 0.648 . . . . 0.0 111.586 -179.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.7 p -89.99 141.78 28.33 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.201 179.324 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.0 t -72.02 133.87 45.55 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.607 0.717 . . . . 0.0 110.917 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.1 m -146.96 68.7 1.16 Allowed 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 179.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.453 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.1 t90 -28.65 129.98 0.21 Allowed Pre-proline 0 N--CA 1.462 0.14 0 CA-C-N 114.008 -1.451 . . . . 0.0 113.368 -176.172 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 63.8 Cg_endo -97.88 22.71 24.17 Favored 'Cis proline' 0 N--CA 1.462 -0.378 0 C-N-CA 123.667 -1.389 . . . . 0.0 113.403 0.3 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.608 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -128.95 147.15 33.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -177.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.599 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.0 m -82.3 123.94 29.51 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.333 179.451 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 22.8 p -95.31 142.84 27.24 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.119 0.485 . . . . 0.0 110.495 179.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.46 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 49.9 ttp180 -103.49 111.87 24.51 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.699 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 20.6 p30 46.88 32.17 1.72 Allowed 'General case' 0 N--CA 1.471 0.619 0 O-C-N 124.334 1.021 . . . . 0.0 113.065 -178.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.468 0 C-N-CA 119.977 -1.106 . . . . 0.0 114.754 177.935 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.602 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 12.5 m . . . . . 0 CA--C 1.517 -0.297 0 CA-C-O 120.798 0.332 . . . . 0.0 110.128 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.99 30.7 77.53 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -177.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -130.29 150.99 51.28 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 114.211 -0.994 . . . . 0.0 110.608 -178.141 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.619 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.6 p -112.21 141.83 45.43 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.48 178.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.629 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 24.8 p -115.32 47.42 1.31 Allowed 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 121.87 0.843 . . . . 0.0 109.253 178.182 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.406 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.2 t -57.22 -32.04 39.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 114.599 -1.182 . . . . 0.0 109.453 179.486 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.68 21.13 47.71 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.855 178.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.17 39.9 97.8 Favored Glycine 0 C--N 1.335 0.492 0 C-N-CA 121.45 -0.405 . . . . 0.0 112.746 179.772 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.85 144.57 27.01 Favored 'General case' 0 C--N 1.324 -0.532 0 O-C-N 122.823 -0.222 . . . . 0.0 111.495 -179.361 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.522 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 81.7 m -135.04 133.44 39.37 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.826 179.543 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -89.81 -34.82 16.0 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.657 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.678 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.3 m -61.19 120.11 51.81 Favored Pre-proline 0 C--O 1.235 0.324 0 CA-C-O 120.95 0.405 . . . . 0.0 110.638 -179.589 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -63.92 113.49 2.2 Favored 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 122.425 2.083 . . . . 0.0 113.002 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 107.75 -1.53 34.06 Favored Glycine 0 N--CA 1.443 -0.854 0 CA-C-N 115.208 -0.905 . . . . 0.0 111.796 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.678 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 94.0 m -95.16 122.96 38.37 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.46 0.648 . . . . 0.0 111.844 -179.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.9 p -92.57 145.46 24.42 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 114.966 -1.016 . . . . 0.0 110.063 179.182 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.8 t -74.3 134.29 42.57 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.729 0.776 . . . . 0.0 111.175 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.7 m -147.49 68.12 1.13 Allowed 'General case' 0 C--N 1.311 -1.065 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.7 t90 -28.36 129.57 0.21 Allowed Pre-proline 0 N--CA 1.463 0.203 0 CA-C-N 113.936 -1.484 . . . . 0.0 113.41 -176.129 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 65.1 Cg_endo -98.44 24.27 21.14 Favored 'Cis proline' 0 C--N 1.346 0.404 0 C-N-CA 123.678 -1.384 . . . . 0.0 113.24 0.315 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.619 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.1 m -129.93 148.45 33.2 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -177.316 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.629 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 82.6 m -84.1 124.56 31.24 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.655 179.657 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 25.7 p -100.26 150.48 22.51 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.514 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.602 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 36.9 ttt180 -126.78 128.67 46.95 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 179.161 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 41.74 38.51 0.97 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 113.75 1.019 . . . . 0.0 113.75 -179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.63 0 N-CA-C 115.598 0.999 . . . . 0.0 115.598 177.26 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.486 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 6.4 m . . . . . 0 CA--C 1.518 -0.285 0 CA-C-O 120.573 0.225 . . . . 0.0 110.572 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.81 30.74 78.76 Favored Glycine 0 C--N 1.334 0.43 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -178.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -126.71 152.42 46.83 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 114.24 -0.98 . . . . 0.0 110.363 -178.29 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.63 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.5 p -113.35 143.64 44.12 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.514 178.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.609 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.8 p -118.07 47.88 1.5 Allowed 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.85 0.833 . . . . 0.0 109.238 178.576 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.3 t -57.26 -32.44 40.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 114.506 -1.225 . . . . 0.0 109.597 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.04 20.53 50.46 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.9 178.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.78 39.62 97.7 Favored Glycine 0 C--N 1.336 0.558 0 C-N-CA 121.42 -0.419 . . . . 0.0 112.77 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.69 144.79 27.35 Favored 'General case' 0 C--N 1.323 -0.551 0 O-C-N 122.793 -0.239 . . . . 0.0 111.363 -179.24 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.514 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.0 m -134.26 132.82 40.11 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.863 179.555 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -86.01 -36.53 19.7 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.559 -179.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.699 HG21 HH21 ' A' ' 24' ' ' ARG . 3.3 m -63.35 117.85 37.99 Favored Pre-proline 0 C--O 1.235 0.326 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.754 -179.565 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -64.92 115.0 3.02 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 122.336 2.024 . . . . 0.0 112.354 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 111.21 -9.6 28.97 Favored Glycine 0 N--CA 1.445 -0.742 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.511 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.611 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 79.5 m -90.75 121.64 32.81 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.338 0.59 . . . . 0.0 111.539 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 3.2 p -89.64 143.2 27.0 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.256 -0.883 . . . . 0.0 110.223 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.3 t -73.5 134.15 43.8 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.765 0.793 . . . . 0.0 110.922 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.8 m -146.98 68.8 1.16 Allowed 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 178.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.4 t90 -28.53 129.68 0.21 Allowed Pre-proline 0 C--O 1.232 0.17 0 CA-C-N 113.909 -1.496 . . . . 0.0 113.476 -176.077 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.0 Cg_endo -98.41 25.62 19.34 Favored 'Cis proline' 0 N--CA 1.461 -0.434 0 C-N-CA 123.753 -1.353 . . . . 0.0 113.25 0.362 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.63 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.98 147.68 33.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 -177.287 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.609 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 79.2 m -83.46 122.13 28.11 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.426 179.291 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 35.4 p -100.17 148.85 24.15 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.176 0.512 . . . . 0.0 111.048 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.699 HH21 HG21 ' A' ' 12' ' ' THR . 39.9 ttm180 -114.45 112.23 22.66 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.33 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.4 m-20 60.31 33.42 20.86 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.41 -178.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.54 0 C-N-CA 120.686 -0.769 . . . . 0.0 114.158 179.238 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.606 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 30.5 m . . . . . 0 CA--C 1.516 -0.357 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.11 33.13 86.23 Favored Glycine 0 CA--C 1.507 -0.451 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 -177.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -138.03 147.4 44.11 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 113.963 -1.119 . . . . 0.0 110.453 -177.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.609 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 25.3 p -110.06 143.34 40.23 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.857 179.496 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.585 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 29.6 p -116.07 46.68 1.51 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.71 0.767 . . . . 0.0 109.277 177.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.403 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.8 t -56.32 -32.65 35.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 114.712 -1.131 . . . . 0.0 109.691 179.385 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.44 23.05 37.79 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.854 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.98 40.5 98.55 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 121.477 -0.392 . . . . 0.0 112.638 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.23 144.0 27.38 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.75 0.31 . . . . 0.0 111.531 -179.268 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.578 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.3 m -136.91 132.96 35.19 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.367 179.31 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.6 m-80 -87.42 -31.72 19.91 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.097 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.726 HG21 HH21 ' A' ' 24' ' ' ARG . 2.0 m -63.84 117.17 32.83 Favored Pre-proline 0 C--O 1.236 0.345 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.852 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_exo -65.13 116.04 3.64 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 122.344 2.03 . . . . 0.0 112.261 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 107.78 -8.03 36.51 Favored Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.784 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.586 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 90.2 m -90.51 122.43 33.33 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.303 0.573 . . . . 0.0 111.639 -179.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.2 p -89.81 143.35 26.87 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.184 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.1 t -73.24 134.28 44.24 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.683 0.754 . . . . 0.0 111.02 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 m -147.06 68.66 1.16 Allowed 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 179.064 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.8 t90 -28.29 129.57 0.21 Allowed Pre-proline 0 C--O 1.232 0.17 0 CA-C-N 113.952 -1.476 . . . . 0.0 113.521 -176.272 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.9 Cg_endo -98.14 23.12 23.21 Favored 'Cis proline' 0 N--CA 1.461 -0.422 0 C-N-CA 123.56 -1.433 . . . . 0.0 113.414 0.381 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.609 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.68 147.36 33.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 N-CA-C 113.66 0.985 . . . . 0.0 113.66 -177.503 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.585 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 76.0 m -82.29 125.61 31.17 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.482 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 30.2 p -101.03 145.89 28.14 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.104 0.478 . . . . 0.0 110.889 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.726 HH21 HG21 ' A' ' 12' ' ' THR . 37.6 ttm180 -117.09 116.66 27.75 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 178.528 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.9 m-20 60.24 32.58 20.85 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 123.567 0.542 . . . . 0.0 110.681 -178.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.623 0 C-N-CA 120.84 -0.695 . . . . 0.0 114.373 179.012 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.2 m . . . . . 0 N--CA 1.455 -0.225 0 CA-C-O 120.82 0.343 . . . . 0.0 110.532 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.59 23.96 70.78 Favored Glycine 0 N--CA 1.45 -0.391 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 -178.572 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -117.51 152.15 35.66 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 114.015 -1.092 . . . . 0.0 109.702 -178.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.614 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.8 p -112.92 143.44 44.2 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 120.799 0.333 . . . . 0.0 110.884 179.471 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.585 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.8 p -117.07 46.93 1.58 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.756 0.789 . . . . 0.0 109.274 178.344 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.402 HG23 ' HB ' ' A' ' 4' ' ' THR . 11.6 t -56.83 -32.69 39.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 114.55 -1.204 . . . . 0.0 109.631 179.307 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.65 21.51 45.74 Favored Glycine 0 N--CA 1.447 -0.615 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.836 178.303 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.66 39.32 97.24 Favored Glycine 0 C--N 1.335 0.527 0 C-N-CA 121.484 -0.389 . . . . 0.0 112.807 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.16 144.08 25.45 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.65 0.262 . . . . 0.0 111.585 -179.269 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.576 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.6 m -134.33 135.89 43.07 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.495 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -91.02 -31.49 16.28 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.691 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -63.23 117.71 36.23 Favored Pre-proline 0 C--O 1.237 0.418 0 CA-C-O 120.992 0.425 . . . . 0.0 110.69 -179.762 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -63.87 117.61 4.6 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 122.295 1.997 . . . . 0.0 112.554 -179.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.24 0.93 47.72 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.429 -0.805 . . . . 0.0 112.051 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.691 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 99.9 m -97.06 122.24 39.84 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.288 0.566 . . . . 0.0 111.262 -179.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.5 p -89.84 141.28 28.79 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.358 179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.3 t -72.39 134.1 45.26 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.68 0.752 . . . . 0.0 110.754 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.3 m -147.02 67.47 1.15 Allowed 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.423 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.8 t90 -27.94 129.64 0.2 Allowed Pre-proline 0 C--N 1.34 0.169 0 CA-C-N 113.917 -1.492 . . . . 0.0 113.526 -176.099 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.423 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.5 Cg_endo -97.67 23.41 23.52 Favored 'Cis proline' 0 N--CA 1.461 -0.404 0 C-N-CA 123.574 -1.428 . . . . 0.0 113.364 0.317 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.614 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.62 146.3 34.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 N-CA-C 113.671 0.989 . . . . 0.0 113.671 -177.301 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.585 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.7 m -82.64 123.86 29.65 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.505 -0.771 . . . . 0.0 110.43 179.5 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 21.1 p -95.71 144.64 25.94 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.213 0.53 . . . . 0.0 111.076 179.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.9 103.88 15.84 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 178.237 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 20.1 p30 48.03 29.92 1.89 Allowed 'General case' 0 N--CA 1.472 0.661 0 O-C-N 124.249 0.968 . . . . 0.0 112.811 -178.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.473 0 C-N-CA 119.974 -1.108 . . . . 0.0 114.411 178.282 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 9.5 m . . . . . 0 N--CA 1.452 -0.329 0 CA-C-O 120.671 0.272 . . . . 0.0 110.368 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.41 28.17 73.29 Favored Glycine 0 C--N 1.334 0.459 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 -178.354 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -125.18 150.0 47.38 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 114.148 -1.026 . . . . 0.0 110.016 -178.378 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.604 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.3 p -111.48 143.72 41.86 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.557 179.097 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.594 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.0 p -116.14 47.49 1.39 Allowed 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.835 0.826 . . . . 0.0 109.281 178.475 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.403 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.4 t -57.2 -32.28 40.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 114.503 -1.226 . . . . 0.0 109.487 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.07 20.65 49.97 Favored Glycine 0 N--CA 1.448 -0.529 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.766 178.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.93 39.03 96.99 Favored Glycine 0 C--N 1.336 0.547 0 C-N-CA 121.602 -0.332 . . . . 0.0 112.775 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.13 144.28 25.6 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.698 0.285 . . . . 0.0 111.562 -179.345 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.551 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 72.6 m -133.7 135.35 43.98 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.32 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -93.98 -29.7 15.11 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.441 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.749 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -63.38 121.67 71.23 Favored Pre-proline 0 C--O 1.237 0.404 0 CA-C-O 121.15 0.5 . . . . 0.0 111.014 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.2 Cg_exo -64.45 118.54 5.5 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.396 2.064 . . . . 0.0 112.641 -179.752 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.61 8.93 51.38 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.076 -0.965 . . . . 0.0 111.864 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.749 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 71.1 m -105.18 123.42 47.8 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.485 0.66 . . . . 0.0 111.958 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.3 p -94.07 142.51 27.31 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.144 179.274 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.1 t -72.8 134.23 44.83 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.624 0.726 . . . . 0.0 111.217 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.9 m -147.5 67.88 1.13 Allowed 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 106.502 -1.666 . . . . 0.0 106.502 178.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.1 t90 -28.02 129.6 0.21 Allowed Pre-proline 0 N--CA 1.462 0.174 0 CA-C-N 113.936 -1.484 . . . . 0.0 113.517 -176.205 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 64.2 Cg_endo -97.98 23.47 22.95 Favored 'Cis proline' 0 N--CA 1.462 -0.34 0 C-N-CA 123.625 -1.406 . . . . 0.0 113.312 0.356 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.604 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.9 146.98 33.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 -177.378 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.0 m -83.02 121.98 27.73 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.621 179.615 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 35.5 p -98.3 146.43 25.67 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.37 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 13.5 ttt180 -109.21 114.65 28.53 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.483 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 20.1 p30 47.58 31.29 1.99 Allowed 'General case' 0 N--CA 1.472 0.662 0 O-C-N 124.269 0.981 . . . . 0.0 113.041 -178.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.475 0 C-N-CA 120.035 -1.079 . . . . 0.0 114.602 177.852 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 19.0 m . . . . . 0 CA--C 1.518 -0.262 0 CA-C-O 120.562 0.22 . . . . 0.0 110.583 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.89 32.92 85.78 Favored Glycine 0 C--N 1.334 0.469 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -178.359 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -132.56 148.81 52.38 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 114.245 -0.978 . . . . 0.0 110.286 -178.178 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.606 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 25.7 p -108.83 143.05 38.52 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.076 179.511 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.6 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.8 p -116.27 46.94 1.49 Allowed 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.791 0.805 . . . . 0.0 109.295 177.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.9 t -56.44 -32.62 36.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 114.639 -1.164 . . . . 0.0 109.803 179.579 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.11 22.66 39.82 Favored Glycine 0 N--CA 1.447 -0.606 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.944 178.369 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.21 40.25 98.31 Favored Glycine 0 C--N 1.336 0.572 0 C-N-CA 121.414 -0.422 . . . . 0.0 112.598 179.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.28 144.07 27.37 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.683 0.278 . . . . 0.0 111.566 -179.195 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.552 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 84.5 m -136.02 133.05 37.06 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.355 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -88.3 -32.51 18.42 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.126 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.792 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.0 OUTLIER -64.97 118.32 47.93 Favored Pre-proline 0 C--O 1.237 0.426 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.05 -179.56 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -64.96 118.38 5.38 Favored 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 122.354 2.036 . . . . 0.0 112.485 -179.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 104.38 2.56 44.27 Favored Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.704 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.792 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 70.8 m -99.44 121.93 41.83 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.305 0.574 . . . . 0.0 111.77 -179.818 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.1 p -89.87 140.39 29.65 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.96 179.068 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.4 t -72.16 133.91 45.41 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.678 0.752 . . . . 0.0 110.891 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.7 m -147.06 68.83 1.16 Allowed 'General case' 0 C--N 1.311 -1.076 0 N-CA-C 106.519 -1.66 . . . . 0.0 106.519 179.161 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.424 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.1 t90 -28.45 129.48 0.21 Allowed Pre-proline 0 C--O 1.232 0.154 0 CA-C-N 113.987 -1.461 . . . . 0.0 113.445 -176.119 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.0 Cg_endo -98.29 24.26 21.35 Favored 'Cis proline' 0 N--CA 1.46 -0.457 0 C-N-CA 123.672 -1.387 . . . . 0.0 113.328 0.419 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.606 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.52 147.26 33.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 113.767 1.025 . . . . 0.0 113.767 -177.297 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.6 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 72.7 m -82.33 124.45 30.0 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.322 -0.853 . . . . 0.0 110.269 179.341 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.3 p -101.63 149.95 23.6 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.313 0.578 . . . . 0.0 111.574 -179.536 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 15.9 tpp85 -105.89 103.52 13.03 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 70.9 m-20 58.45 34.67 24.15 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 123.379 0.425 . . . . 0.0 110.547 -178.592 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.524 0 C-N-CA 120.49 -0.862 . . . . 0.0 114.13 179.368 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.442 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 12.7 m . . . . . 0 N--CA 1.452 -0.356 0 CA-C-O 120.793 0.33 . . . . 0.0 110.4 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.22 29.67 75.9 Favored Glycine 0 C--N 1.333 0.405 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 -178.228 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.414 ' CD ' ' H ' ' A' ' 11' ' ' ASN . 38.6 tt0 -129.76 149.62 51.42 Favored 'General case' 0 N--CA 1.445 -0.698 0 CA-C-N 114.043 -1.079 . . . . 0.0 110.045 -178.362 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.606 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.0 p -110.28 144.34 39.12 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.705 179.313 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.585 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.9 p -116.82 46.93 1.55 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.811 0.815 . . . . 0.0 109.316 178.45 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.4 t -56.83 -32.57 39.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 114.683 -1.144 . . . . 0.0 109.671 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.63 21.23 47.2 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.84 178.319 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.73 39.86 98.01 Favored Glycine 0 C--N 1.335 0.486 0 C-N-CA 121.455 -0.403 . . . . 0.0 112.669 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.8 144.57 27.08 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.645 0.26 . . . . 0.0 111.553 -179.256 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.537 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 80.1 m -135.52 134.1 39.13 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.969 -0.559 . . . . 0.0 109.523 179.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . 0.414 ' H ' ' CD ' ' A' ' 3' ' ' GLU . 62.8 m-80 -91.77 -31.43 15.77 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.216 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.707 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -63.2 121.17 67.74 Favored Pre-proline 0 C--O 1.236 0.365 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.122 -179.317 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.5 Cg_exo -64.17 118.51 5.46 Favored 'Trans proline' 0 N--CA 1.457 -0.67 0 C-N-CA 122.365 2.044 . . . . 0.0 112.688 -179.771 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.9 5.48 54.98 Favored Glycine 0 N--CA 1.446 -0.642 0 CA-C-N 115.2 -0.909 . . . . 0.0 112.013 179.657 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.707 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 86.1 m -102.14 120.87 41.16 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.607 0.718 . . . . 0.0 112.12 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 3.0 p -90.97 144.99 25.1 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.794 178.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.5 t -73.75 134.41 43.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.738 0.78 . . . . 0.0 111.066 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.8 m -146.78 67.71 1.16 Allowed 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 178.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.2 t90 -28.21 129.45 0.21 Allowed Pre-proline 0 C--O 1.232 0.172 0 CA-C-N 113.958 -1.474 . . . . 0.0 113.392 -176.118 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.6 Cg_endo -98.3 24.65 20.78 Favored 'Cis proline' 0 N--CA 1.462 -0.376 0 C-N-CA 123.676 -1.385 . . . . 0.0 113.324 0.357 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.606 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -130.81 148.2 33.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -177.314 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.585 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.5 m -83.53 128.54 34.59 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.586 179.518 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.4 p -108.29 149.9 28.03 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.042 -179.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.442 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 20.7 ttp180 -131.64 126.07 33.75 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.849 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.5 m-20 62.17 28.57 17.15 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.708 -178.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.533 0 CA-C-N 115.715 -0.675 . . . . 0.0 114.101 179.087 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.686 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 23.7 m . . . . . 0 CA--C 1.518 -0.287 0 CA-C-O 120.867 0.365 . . . . 0.0 110.083 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.74 31.4 79.72 Favored Glycine 0 C--N 1.334 0.469 0 N-CA-C 109.199 -1.561 . . . . 0.0 109.199 -177.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -134.6 148.21 50.38 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 113.957 -1.122 . . . . 0.0 110.32 -177.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.604 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.3 p -110.29 142.77 41.45 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.811 179.422 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.596 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.8 p -115.24 46.65 1.42 Allowed 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.722 0.772 . . . . 0.0 109.261 177.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.42 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.6 t -56.56 -32.42 36.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 114.666 -1.152 . . . . 0.0 109.652 179.385 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.71 22.41 41.1 Favored Glycine 0 N--CA 1.447 -0.596 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.858 178.327 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.03 40.06 97.97 Favored Glycine 0 C--N 1.335 0.475 0 C-N-CA 121.499 -0.382 . . . . 0.0 112.734 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.56 143.94 25.92 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.694 0.283 . . . . 0.0 111.581 -179.202 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.584 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 68.4 m -136.14 134.84 38.7 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.471 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -91.2 -30.23 16.77 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.358 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.688 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.7 m -62.55 118.66 43.23 Favored Pre-proline 0 C--O 1.235 0.293 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.718 -179.78 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.9 Cg_exo -64.13 115.02 2.89 Favored 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.394 2.063 . . . . 0.0 112.851 -179.385 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.33 0.9 40.91 Favored Glycine 0 N--CA 1.445 -0.707 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.786 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.688 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 86.2 m -96.9 123.65 40.66 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.398 0.618 . . . . 0.0 111.82 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.9 p -92.66 144.05 25.7 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.074 179.15 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.3 t -73.44 134.26 43.92 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.607 0.718 . . . . 0.0 111.017 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.3 m -147.3 67.68 1.14 Allowed 'General case' 0 C--N 1.312 -1.061 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 179.025 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.7 t90 -28.11 129.45 0.21 Allowed Pre-proline 0 C--O 1.232 0.17 0 CA-C-N 114.067 -1.424 . . . . 0.0 113.448 -176.228 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 63.7 Cg_endo -98.08 22.94 23.55 Favored 'Cis proline' 0 N--CA 1.461 -0.419 0 C-N-CA 123.671 -1.387 . . . . 0.0 113.391 0.321 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.604 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.37 148.24 33.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 113.627 0.973 . . . . 0.0 113.627 -177.433 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.596 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.3 m -83.61 127.65 33.91 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.761 179.743 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 21.2 p -101.55 150.75 22.75 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.774 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.686 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 33.8 ttt180 -132.63 124.13 27.72 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.534 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 59.84 30.6 20.15 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.058 0.456 . . . . 0.0 111.203 -179.294 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.579 0 C-N-CA 121.095 -0.574 . . . . 0.0 114.29 178.968 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.541 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 7.9 m . . . . . 0 CA--C 1.517 -0.307 0 CA-C-O 120.56 0.219 . . . . 0.0 110.568 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.07 31.52 81.11 Favored Glycine 0 C--N 1.334 0.441 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -178.264 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -129.42 151.81 49.65 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 114.152 -1.024 . . . . 0.0 110.519 -178.118 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.632 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.3 p -112.41 141.85 45.65 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.678 178.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.626 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.0 p -116.11 47.85 1.33 Allowed 'General case' 0 C--N 1.318 -0.797 0 CA-C-O 121.873 0.844 . . . . 0.0 109.264 177.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.2 t -57.24 -32.2 40.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 114.573 -1.194 . . . . 0.0 109.703 179.559 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -96.88 20.68 49.76 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.856 178.307 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.54 39.29 97.14 Favored Glycine 0 C--N 1.335 0.512 0 C-N-CA 121.468 -0.396 . . . . 0.0 112.662 179.829 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.22 144.2 26.39 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.62 0.248 . . . . 0.0 111.266 -179.248 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.536 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 76.7 m -133.32 133.93 43.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.022 -0.536 . . . . 0.0 109.952 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -87.45 -35.02 18.49 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.441 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.717 HG21 HH21 ' A' ' 24' ' ' ARG . 3.6 m -63.17 118.12 40.0 Favored Pre-proline 0 C--O 1.236 0.365 0 CA-C-O 120.748 0.309 . . . . 0.0 110.747 -179.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -65.17 114.88 3.02 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.338 2.025 . . . . 0.0 112.297 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.24 -8.52 30.96 Favored Glycine 0 N--CA 1.445 -0.701 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.601 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.581 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 96.5 m -91.43 121.98 33.62 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.366 0.603 . . . . 0.0 111.619 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.7 p -89.76 144.38 26.02 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.251 179.348 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.0 t -74.28 134.16 42.61 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.615 0.721 . . . . 0.0 111.016 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.9 m -147.29 68.77 1.14 Allowed 'General case' 0 C--N 1.311 -1.072 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.019 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.1 t90 -28.32 129.65 0.21 Allowed Pre-proline 0 C--O 1.232 0.178 0 CA-C-N 113.978 -1.465 . . . . 0.0 113.399 -176.207 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 65.4 Cg_endo -98.42 24.91 20.26 Favored 'Cis proline' 0 N--CA 1.461 -0.441 0 C-N-CA 123.694 -1.377 . . . . 0.0 113.263 0.31 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.632 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.64 147.98 33.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 N-CA-C 113.688 0.996 . . . . 0.0 113.688 -177.386 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.626 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.9 m -83.4 123.04 29.28 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.453 179.44 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 28.1 p -99.0 147.14 25.31 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.193 0.52 . . . . 0.0 111.108 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.717 HH21 HG21 ' A' ' 12' ' ' THR . 40.5 ttm180 -114.14 112.86 23.88 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.386 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 60.43 33.06 20.71 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.438 -178.262 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.532 0 C-N-CA 120.75 -0.738 . . . . 0.0 114.207 179.175 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 35.3 m . . . . . 0 CA--C 1.519 -0.239 0 CA-C-O 120.729 0.299 . . . . 0.0 110.698 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.64 32.65 83.81 Favored Glycine 0 C--N 1.335 0.475 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -178.222 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.418 ' CD ' ' H ' ' A' ' 11' ' ' ASN . 38.4 tt0 -137.75 148.41 45.57 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 114.205 -0.997 . . . . 0.0 110.405 -178.101 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.615 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 27.1 p -108.85 142.91 38.74 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.897 179.355 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.604 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.3 p -116.28 46.86 1.5 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.777 0.798 . . . . 0.0 109.277 177.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.8 t -56.62 -32.75 38.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 114.607 -1.179 . . . . 0.0 109.795 179.566 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.84 22.7 39.64 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.919 178.443 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.87 40.48 98.36 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 121.446 -0.407 . . . . 0.0 112.615 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -147.85 144.07 27.88 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.654 0.264 . . . . 0.0 111.355 -179.195 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.56 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 79.3 m -136.58 133.76 36.72 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.993 -0.549 . . . . 0.0 109.718 179.555 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . 0.418 ' H ' ' CD ' ' A' ' 3' ' ' GLU . 62.6 m-80 -91.12 -31.35 16.26 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.947 179.757 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.637 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -62.55 118.96 46.08 Favored Pre-proline 0 C--O 1.237 0.398 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.846 -179.547 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.8 Cg_exo -64.08 118.92 5.84 Favored 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 122.231 1.954 . . . . 0.0 112.739 -179.619 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.42 10.77 53.32 Favored Glycine 0 N--CA 1.446 -0.688 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.977 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.637 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 95.5 m -105.48 121.52 44.1 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.456 0.646 . . . . 0.0 111.723 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 8.0 p -89.76 143.25 26.95 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 115.102 -0.953 . . . . 0.0 109.898 179.07 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.0 t -72.61 134.19 45.04 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.668 0.747 . . . . 0.0 110.954 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.9 m -146.09 67.58 1.19 Allowed 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.424 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.6 t90 -27.94 129.39 0.21 Allowed Pre-proline 0 C--O 1.233 0.201 0 CA-C-N 113.919 -1.491 . . . . 0.0 113.528 -176.202 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.9 Cg_endo -98.04 24.82 20.89 Favored 'Cis proline' 0 N--CA 1.462 -0.346 0 C-N-CA 123.658 -1.392 . . . . 0.0 113.307 0.468 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.615 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -131.61 146.9 32.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -177.413 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.604 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 78.3 m -81.66 132.11 35.29 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.224 179.343 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 63.0 p -117.16 147.39 42.5 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.017 0.437 . . . . 0.0 111.608 -178.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 54.0 ttm-85 -108.56 114.27 27.96 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 177.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 54.8 m-20 61.33 35.25 18.1 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.143 0.497 . . . . 0.0 109.683 -178.252 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.269 0 CA-C-N 115.69 -0.686 . . . . 0.0 112.244 -179.276 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 11.6 m . . . . . 0 CA--C 1.519 -0.241 0 CA-C-O 120.816 0.341 . . . . 0.0 110.47 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.44 31.96 82.6 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 109.476 -1.449 . . . . 0.0 109.476 -178.071 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -132.71 148.95 52.34 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 114.127 -1.036 . . . . 0.0 110.359 -177.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.61 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 25.7 p -110.12 142.72 41.23 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.891 179.34 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.594 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 29.9 p -115.72 46.97 1.42 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.655 0.74 . . . . 0.0 109.283 177.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.406 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.9 t -56.54 -32.64 37.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.685 179.492 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.05 22.0 43.13 Favored Glycine 0 N--CA 1.447 -0.617 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.836 178.443 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.27 39.58 97.41 Favored Glycine 0 C--N 1.335 0.518 0 C-N-CA 121.511 -0.376 . . . . 0.0 112.683 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -149.68 143.77 25.7 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.664 0.268 . . . . 0.0 111.557 -179.308 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 78.9 m -134.7 135.24 41.85 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 179.491 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -90.31 -30.84 17.22 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.63 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.5 m -62.95 117.97 37.84 Favored Pre-proline 0 C--O 1.236 0.35 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.655 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.6 Cg_exo -64.37 116.48 3.78 Favored 'Trans proline' 0 N--CA 1.457 -0.658 0 C-N-CA 122.386 2.058 . . . . 0.0 112.662 -179.414 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.3 2.31 47.8 Favored Glycine 0 N--CA 1.445 -0.75 0 CA-C-N 115.373 -0.831 . . . . 0.0 112.107 179.635 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.63 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 88.9 m -97.78 123.13 41.6 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.334 0.588 . . . . 0.0 111.497 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.8 p -90.07 141.58 28.53 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.293 179.467 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.8 t -73.06 134.28 44.52 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.663 0.744 . . . . 0.0 110.95 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.2 m -147.19 68.61 1.15 Allowed 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.056 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.426 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.7 t90 -28.14 129.6 0.21 Allowed Pre-proline 0 N--CA 1.463 0.187 0 CA-C-N 113.962 -1.472 . . . . 0.0 113.421 -176.252 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.426 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 68.8 Cg_endo -98.03 23.31 23.11 Favored 'Cis proline' 0 N--CA 1.461 -0.439 0 C-N-CA 123.62 -1.408 . . . . 0.0 113.275 0.307 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.61 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -129.99 147.02 33.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -177.4 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 77.3 m -82.05 125.34 30.71 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.494 179.464 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.4 p -101.06 146.47 27.41 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.156 0.503 . . . . 0.0 111.195 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.435 ' HG2' ' SG ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -101.79 107.86 19.19 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 177.879 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 17.7 p30 49.36 28.83 2.49 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 124.319 1.012 . . . . 0.0 112.776 -178.421 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.451 0 C-N-CA 120.035 -1.079 . . . . 0.0 114.518 178.141 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.671 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 8.9 m . . . . . 0 CA--C 1.518 -0.268 0 CA-C-O 120.763 0.316 . . . . 0.0 110.25 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.27 31.72 81.47 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -177.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -133.51 148.31 51.67 Favored 'General case' 0 N--CA 1.444 -0.766 0 CA-C-N 113.928 -1.136 . . . . 0.0 110.509 -177.72 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.6 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.4 p -110.45 142.86 41.6 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.808 179.325 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.582 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.6 p -115.36 46.95 1.38 Allowed 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.739 0.78 . . . . 0.0 109.278 178.071 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.408 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.8 t -56.55 -32.42 36.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 114.624 -1.171 . . . . 0.0 109.658 179.474 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.23 21.88 43.73 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 115.617 -0.72 . . . . 0.0 111.811 178.384 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.36 39.52 97.37 Favored Glycine 0 C--N 1.335 0.524 0 C-N-CA 121.527 -0.368 . . . . 0.0 112.668 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.03 143.86 25.43 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.684 0.278 . . . . 0.0 111.597 -179.294 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.582 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 70.4 m -134.78 135.01 41.51 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.421 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -88.58 -31.1 18.79 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.615 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.7 m -63.59 117.72 37.49 Favored Pre-proline 0 C--O 1.236 0.381 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.752 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_exo -65.05 115.66 3.41 Favored 'Trans proline' 0 N--CA 1.459 -0.536 0 C-N-CA 122.316 2.011 . . . . 0.0 112.438 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 108.87 -8.73 34.01 Favored Glycine 0 N--CA 1.446 -0.681 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.738 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.615 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 88.2 m -89.98 122.69 33.23 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.42 0.629 . . . . 0.0 111.762 -179.677 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.0 p -90.67 144.35 25.83 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.078 -0.964 . . . . 0.0 110.113 179.212 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.4 t -74.06 134.27 42.96 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.592 0.71 . . . . 0.0 111.092 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 m -147.45 68.27 1.13 Allowed 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 106.517 -1.661 . . . . 0.0 106.517 179.053 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.451 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.8 t90 -28.16 129.44 0.21 Allowed Pre-proline 0 N--CA 1.463 0.191 0 CA-C-N 114.007 -1.451 . . . . 0.0 113.437 -176.256 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.451 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.9 Cg_endo -98.36 23.18 22.77 Favored 'Cis proline' 0 C--N 1.345 0.388 0 C-N-CA 123.617 -1.41 . . . . 0.0 113.257 0.334 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.6 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -129.48 148.64 33.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -177.447 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.572 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 73.5 m -83.55 126.19 32.55 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.723 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 20.1 p -99.68 148.2 24.6 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.771 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.671 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 57.9 ttp180 -130.4 131.94 45.52 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.024 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.6 p-10 44.59 36.4 1.72 Allowed 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 113.324 0.861 . . . . 0.0 113.324 -179.413 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.633 0 N-CA-C 115.621 1.008 . . . . 0.0 115.621 177.272 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.693 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 16.6 m . . . . . 0 CA--C 1.516 -0.33 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.5 30.28 76.24 Favored Glycine 0 N--CA 1.45 -0.422 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -177.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -130.24 152.69 49.38 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 114.126 -1.037 . . . . 0.0 110.544 -178.199 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.63 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.3 p -115.24 143.34 45.4 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.241 178.44 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.639 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.8 p -115.73 47.46 1.35 Allowed 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.915 0.865 . . . . 0.0 109.362 178.666 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -57.52 -32.23 41.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 114.552 -1.204 . . . . 0.0 109.481 179.387 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -96.51 19.9 52.69 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.828 178.281 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.9 39.73 97.91 Favored Glycine 0 C--N 1.335 0.48 0 C-N-CA 121.524 -0.37 . . . . 0.0 112.746 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.04 144.96 26.12 Favored 'General case' 0 C--N 1.324 -0.528 0 O-C-N 122.734 -0.274 . . . . 0.0 111.472 -179.275 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.529 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 85.6 m -134.62 133.57 40.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.088 -0.505 . . . . 0.0 109.81 179.539 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -90.14 -34.04 16.02 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.676 -179.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.673 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.1 m -61.98 121.19 63.82 Favored Pre-proline 0 C--O 1.236 0.366 0 CA-C-O 120.943 0.401 . . . . 0.0 110.654 -179.673 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -64.58 114.79 2.87 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.44 2.093 . . . . 0.0 112.691 -179.535 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 106.08 0.94 38.74 Favored Glycine 0 N--CA 1.445 -0.705 0 CA-C-N 115.465 -0.789 . . . . 0.0 111.68 179.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.673 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 84.2 m -98.91 119.74 38.19 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 121.46 0.648 . . . . 0.0 111.658 -179.8 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.8 p -90.59 144.82 25.39 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.023 179.095 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.7 t -72.84 134.4 44.85 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.697 0.761 . . . . 0.0 111.109 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.1 m -147.13 66.96 1.14 Allowed 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 106.217 -1.771 . . . . 0.0 106.217 178.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.9 t90 -28.24 129.53 0.21 Allowed Pre-proline 0 C--O 1.233 0.195 0 CA-C-N 113.89 -1.504 . . . . 0.0 113.436 -176.142 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 64.6 Cg_endo -98.32 24.19 21.41 Favored 'Cis proline' 0 N--CA 1.461 -0.384 0 C-N-CA 123.645 -1.398 . . . . 0.0 113.284 0.43 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.63 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -129.15 147.76 33.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 -177.409 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.639 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 91.8 m -84.37 123.76 30.55 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.737 179.663 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 34.6 p -100.08 146.46 26.75 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.338 179.531 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.693 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 25.5 ttp85 -117.4 122.05 42.75 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 21.6 p30 46.82 32.3 1.74 Allowed 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.342 1.057 . . . . 0.0 113.595 -179.031 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.489 0 C-N-CA 119.92 -1.133 . . . . 0.0 115.325 177.133 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.549 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 11.6 m . . . . . 0 CA--C 1.517 -0.323 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.71 31.17 80.02 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 109.241 -1.543 . . . . 0.0 109.241 -178.099 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.407 ' CD ' ' H ' ' A' ' 11' ' ' ASN . 38.4 tt0 -132.76 149.08 52.32 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 114.0 -1.1 . . . . 0.0 110.147 -177.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.604 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.1 p -110.9 144.41 39.99 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.629 179.308 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.583 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.7 p -116.64 46.86 1.54 Allowed 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.789 0.804 . . . . 0.0 109.282 178.56 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -56.85 -32.59 39.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 114.587 -1.188 . . . . 0.0 109.531 179.45 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.39 21.78 44.24 Favored Glycine 0 N--CA 1.446 -0.64 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.906 178.368 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.41 40.08 98.17 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 121.431 -0.414 . . . . 0.0 112.832 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.73 144.7 27.24 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.69 0.281 . . . . 0.0 111.514 -179.23 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.544 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.4 m -136.41 133.42 36.67 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.3 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . 0.407 ' H ' ' CD ' ' A' ' 3' ' ' GLU . 64.7 m-80 -88.34 -32.21 18.52 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.189 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.659 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.6 m -63.25 118.85 47.37 Favored Pre-proline 0 C--O 1.236 0.382 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.816 -179.618 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -64.76 115.8 3.44 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.438 2.092 . . . . 0.0 112.553 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 106.4 -3.62 37.33 Favored Glycine 0 N--CA 1.445 -0.707 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.89 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.659 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 93.1 m -93.91 121.14 35.07 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.377 0.608 . . . . 0.0 111.822 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.4 p -89.88 143.87 26.43 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.053 178.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.6 t -73.26 134.36 44.23 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.7 0.762 . . . . 0.0 111.009 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.5 m -147.01 68.08 1.16 Allowed 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 106.378 -1.712 . . . . 0.0 106.378 178.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.3 t90 -28.3 129.52 0.21 Allowed Pre-proline 0 C--O 1.232 0.147 0 CA-C-N 113.874 -1.512 . . . . 0.0 113.413 -176.205 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.462 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.0 Cg_endo -98.37 24.34 21.14 Favored 'Cis proline' 0 N--CA 1.46 -0.466 0 C-N-CA 123.696 -1.377 . . . . 0.0 113.324 0.34 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.604 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -130.32 148.27 33.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -177.325 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.5 m -83.59 127.23 33.58 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.602 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.1 p -105.46 149.04 26.52 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.762 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.549 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 41.3 ttp85 -130.86 123.94 30.14 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.253 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 79.4 m-20 62.11 29.31 17.55 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.779 -178.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.549 0 CA-C-N 115.704 -0.68 . . . . 0.0 114.055 179.112 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.544 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 4.0 m . . . . . 0 CA--C 1.518 -0.276 0 CA-C-O 120.793 0.33 . . . . 0.0 110.501 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.3 31.09 79.71 Favored Glycine 0 C--N 1.334 0.435 0 N-CA-C 109.439 -1.465 . . . . 0.0 109.439 -178.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -128.79 149.33 50.77 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 113.883 -1.159 . . . . 0.0 109.793 -177.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.587 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 27.2 p -109.74 142.6 40.73 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.136 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.583 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 29.8 p -116.54 45.31 1.83 Allowed 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.64 0.734 . . . . 0.0 109.296 177.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.44 HG23 ' HB ' ' A' ' 4' ' ' THR . 11.4 t -55.75 -33.33 33.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 114.735 -1.121 . . . . 0.0 109.906 179.477 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.74 22.59 39.71 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.708 -0.678 . . . . 0.0 112.011 178.57 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.99 40.24 99.06 Favored Glycine 0 C--N 1.334 0.461 0 C-N-CA 121.3 -0.476 . . . . 0.0 112.63 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -146.2 146.17 30.7 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.822 0.344 . . . . 0.0 111.565 -179.357 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 80.1 m -141.33 130.53 23.48 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 178.763 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -89.31 -27.19 20.69 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.48 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.594 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.8 m -65.56 117.48 41.43 Favored Pre-proline 0 C--O 1.237 0.423 0 CA-C-O 120.949 0.404 . . . . 0.0 110.259 179.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -64.14 114.04 2.48 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 122.315 2.01 . . . . 0.0 113.149 -179.064 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 107.28 -5.41 35.8 Favored Glycine 0 N--CA 1.442 -0.936 0 CA-C-N 115.282 -0.872 . . . . 0.0 112.014 179.609 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.594 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 99.5 m -89.9 123.11 33.55 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.403 0.62 . . . . 0.0 111.49 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.6 p -90.01 141.54 28.57 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.305 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 50.7 t -71.94 134.52 46.03 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.706 0.765 . . . . 0.0 110.911 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.3 m -147.08 68.1 1.15 Allowed 'General case' 0 C--N 1.312 -1.043 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 179.192 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.422 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.7 t90 -27.73 129.26 0.2 Allowed Pre-proline 0 C--O 1.232 0.154 0 CA-C-N 113.976 -1.465 . . . . 0.0 113.516 -176.121 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.422 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 62.6 Cg_endo -97.91 23.14 23.54 Favored 'Cis proline' 0 N--CA 1.462 -0.376 0 C-N-CA 123.675 -1.386 . . . . 0.0 113.282 0.368 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.587 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.4 m -130.05 146.44 34.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 113.803 1.038 . . . . 0.0 113.803 -177.316 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 82.2 m -81.6 126.9 32.3 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.355 179.417 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 24.7 p -101.68 145.76 28.65 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.294 0.569 . . . . 0.0 111.426 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.544 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 27.1 tpt180 -117.48 117.28 29.03 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.212 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 63.5 m-20 60.48 32.23 20.47 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.465 -178.583 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.618 0 C-N-CA 120.808 -0.711 . . . . 0.0 114.214 179.14 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.603 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 18.6 m . . . . . 0 CA--C 1.516 -0.334 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.46 30.85 78.52 Favored Glycine 0 CA--C 1.507 -0.455 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -178.052 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -131.06 150.91 51.93 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 114.214 -0.993 . . . . 0.0 110.676 -178.07 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.629 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.7 p -113.54 143.82 43.9 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.374 178.612 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.613 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.5 p -117.34 47.75 1.46 Allowed 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.838 0.828 . . . . 0.0 109.337 178.564 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.6 t -57.26 -32.31 40.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 114.458 -1.246 . . . . 0.0 109.51 179.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.13 20.67 49.9 Favored Glycine 0 N--CA 1.447 -0.589 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.873 178.358 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.55 39.86 97.93 Favored Glycine 0 C--N 1.335 0.525 0 C-N-CA 121.458 -0.401 . . . . 0.0 112.728 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.78 144.73 27.2 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.623 0.249 . . . . 0.0 111.455 -179.357 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.516 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.8 m -134.6 132.44 39.04 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.806 179.532 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -86.65 -36.17 18.93 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.585 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.718 HG21 HH21 ' A' ' 24' ' ' ARG . 3.6 m -62.34 118.36 39.54 Favored Pre-proline 0 C--O 1.235 0.324 0 CA-C-O 120.789 0.328 . . . . 0.0 110.625 -179.722 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -64.76 114.72 2.87 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 122.326 2.017 . . . . 0.0 112.382 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.44 -9.67 30.71 Favored Glycine 0 N--CA 1.446 -0.696 0 CA-C-N 115.445 -0.798 . . . . 0.0 111.594 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.607 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 100.0 m -89.89 121.69 32.23 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.364 0.602 . . . . 0.0 111.586 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.3 p -89.82 143.89 26.41 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.342 179.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.7 t -74.06 134.02 42.94 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.699 0.761 . . . . 0.0 110.905 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 m -147.27 69.08 1.15 Allowed 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.5 t90 -28.72 129.64 0.22 Allowed Pre-proline 0 C--O 1.232 0.157 0 CA-C-N 114.033 -1.44 . . . . 0.0 113.422 -176.086 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.449 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.9 Cg_endo -98.59 24.98 19.93 Favored 'Cis proline' 0 N--CA 1.461 -0.432 0 C-N-CA 123.695 -1.377 . . . . 0.0 113.297 0.389 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.629 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.54 147.83 33.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -177.315 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.613 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 81.2 m -83.47 122.74 28.92 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.442 179.363 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.58 HG22 ' HG3' ' A' ' 28' ' ' PRO . 25.9 p -97.76 152.63 18.94 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.952 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.718 HH21 HG21 ' A' ' 12' ' ' THR . 39.1 ttm180 -126.41 125.53 42.33 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 179.138 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 41.9 38.18 0.96 Allowed 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 113.587 0.958 . . . . 0.0 113.587 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 102.24 -0.93 50.54 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 115.472 0.949 . . . . 0.0 115.472 177.392 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.402 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.7 pt? -153.89 138.33 11.18 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 118.473 1.137 . . . . 0.0 111.263 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.58 ' HG3' HG22 ' A' ' 23' ' ' THR . 13.6 Cg_exo -68.36 104.24 1.05 Allowed 'Trans proline' 0 N--CA 1.462 -0.354 0 C-N-CA 122.469 2.113 . . . . 0.0 112.747 -179.516 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.9 m . . . . . 0 C--N 1.323 -0.581 0 CA-C-O 121.627 0.727 . . . . 0.0 109.801 179.292 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.567 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 5.9 m . . . . . 0 CA--C 1.518 -0.285 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.78 32.21 83.4 Favored Glycine 0 C--N 1.336 0.543 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -178.29 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.577 ' OE2' ' HA ' ' A' ' 10' ' ' CYS . 27.3 tt0 -126.78 152.8 46.41 Favored 'General case' 0 N--CA 1.442 -0.843 0 CA-C-N 114.079 -1.06 . . . . 0.0 110.388 -177.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.643 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 29.1 p -111.83 141.33 45.6 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.778 178.824 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.669 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 23.3 p -115.61 46.73 1.45 Allowed 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.818 0.818 . . . . 0.0 109.341 178.163 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.415 HG23 ' HB ' ' A' ' 4' ' ' THR . 9.9 t -57.78 -33.04 44.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 114.593 -1.185 . . . . 0.0 109.723 179.5 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.97 18.06 58.08 Favored Glycine 0 N--CA 1.447 -0.575 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.945 178.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 64.49 36.22 92.9 Favored Glycine 0 C--N 1.333 0.367 0 C-N-CA 121.274 -0.489 . . . . 0.0 112.768 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.6 154.77 43.9 Favored 'General case' 0 C--N 1.324 -0.515 0 O-C-N 122.749 -0.265 . . . . 0.0 110.31 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.577 ' HA ' ' OE2' ' A' ' 3' ' ' GLU . 86.2 m -139.57 133.98 31.51 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.664 179.037 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -89.19 -40.19 13.05 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.423 -179.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.678 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.5 m -60.95 119.67 47.02 Favored Pre-proline 0 C--O 1.237 0.402 0 CA-C-O 120.864 0.364 . . . . 0.0 110.668 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -64.72 114.16 2.63 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 122.478 2.118 . . . . 0.0 112.633 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 111.21 -6.91 28.78 Favored Glycine 0 N--CA 1.445 -0.717 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.659 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.678 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 75.3 m -91.54 122.76 34.41 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.48 0.657 . . . . 0.0 111.929 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.6 p -91.51 144.22 25.78 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.024 -0.989 . . . . 0.0 109.922 178.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.1 t -73.05 134.35 44.56 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.784 0.802 . . . . 0.0 111.116 -179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.9 m -146.79 67.37 1.16 Allowed 'General case' 0 C--N 1.31 -1.125 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 178.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.407 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.6 t90 -28.07 129.37 0.21 Allowed Pre-proline 0 N--CA 1.463 0.18 0 CA-C-N 113.86 -1.518 . . . . 0.0 113.386 -176.019 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.407 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.5 Cg_endo -98.42 26.77 17.85 Favored 'Cis proline' 0 N--CA 1.461 -0.421 0 C-N-CA 123.719 -1.367 . . . . 0.0 113.3 0.269 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.643 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.1 m -132.21 147.71 32.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 113.782 1.03 . . . . 0.0 113.782 -177.367 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.669 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 95.3 m -83.97 124.95 31.57 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.673 179.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.471 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 32.9 p -103.75 155.64 18.44 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.651 -179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.567 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 36.1 ttp85 -135.85 124.24 23.39 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 179.126 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 78.5 m-20 62.41 29.15 17.15 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.732 -178.523 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.92 3.2 77.02 Favored Glycine 0 CA--C 1.522 0.517 0 CA-C-N 115.81 -0.632 . . . . 0.0 114.108 179.063 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.419 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.8 pt? -145.86 140.59 15.81 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 117.775 0.788 . . . . 0.0 110.611 179.456 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 24.2 Cg_exo -63.54 104.02 0.42 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.509 2.139 . . . . 0.0 113.021 -178.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.3 t . . . . . 0 C--N 1.326 -0.443 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.043 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.654 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 21.8 m . . . . . 0 CA--C 1.518 -0.252 0 CA-C-O 120.701 0.286 . . . . 0.0 110.252 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 67.09 31.3 77.38 Favored Glycine 0 C--N 1.333 0.406 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 -177.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -131.76 150.8 52.04 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 114.241 -0.98 . . . . 0.0 110.431 -178.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.614 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.8 p -112.73 141.44 46.52 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.441 178.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.616 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 23.7 p -114.88 45.86 1.52 Allowed 'General case' 0 C--N 1.317 -0.829 0 CA-C-O 121.788 0.804 . . . . 0.0 109.494 178.335 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.415 HG23 ' HB ' ' A' ' 4' ' ' THR . 11.5 t -56.5 -32.49 36.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 114.646 -1.161 . . . . 0.0 109.778 179.487 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.57 21.68 44.07 Favored Glycine 0 N--CA 1.448 -0.567 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.969 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.82 40.19 98.92 Favored Glycine 0 C--N 1.334 0.44 0 C-N-CA 121.385 -0.436 . . . . 0.0 112.738 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.56 147.24 32.93 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.662 0.268 . . . . 0.0 111.448 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.544 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 84.6 m -143.46 127.67 17.64 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 178.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -91.9 -28.33 17.35 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.206 -179.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.677 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.4 m -62.71 122.83 76.68 Favored Pre-proline 0 C--O 1.234 0.268 0 CA-C-O 120.88 0.372 . . . . 0.0 110.348 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 24.4 Cg_exo -63.75 115.31 3.0 Favored 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 122.267 1.978 . . . . 0.0 113.065 -179.321 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.53 5.75 51.29 Favored Glycine 0 N--CA 1.444 -0.776 0 CA-C-N 115.175 -0.921 . . . . 0.0 111.932 179.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.677 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 99.6 m -101.45 122.45 43.8 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.54 0.686 . . . . 0.0 111.963 -179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.4 p -94.19 147.59 23.02 Favored 'General case' 0 N--CA 1.447 -0.576 0 CA-C-N 114.929 -1.032 . . . . 0.0 110.083 179.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.3 t -74.53 134.32 42.22 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.696 0.76 . . . . 0.0 111.129 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 26.0 m -147.46 67.46 1.13 Allowed 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 178.816 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.463 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.6 t90 -27.99 129.32 0.21 Allowed Pre-proline 0 N--CA 1.462 0.164 0 CA-C-N 113.963 -1.471 . . . . 0.0 113.449 -176.187 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.5 Cg_endo -98.41 24.46 20.9 Favored 'Cis proline' 0 N--CA 1.46 -0.496 0 C-N-CA 123.71 -1.371 . . . . 0.0 113.342 0.315 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.614 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.24 148.2 33.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 N-CA-C 113.658 0.985 . . . . 0.0 113.658 -177.399 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.616 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.3 m -83.89 126.53 33.07 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.619 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.437 ' O ' ' HA ' ' A' ' 15' ' ' CYS . 22.2 p -103.06 151.6 22.35 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.003 -179.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.654 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 38.5 ttp85 -133.68 132.07 40.25 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.089 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 18.9 p30 52.43 28.36 5.81 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 124.019 0.927 . . . . 0.0 112.627 -178.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 97.48 5.58 57.82 Favored Glycine 0 CA--C 1.521 0.441 0 N-CA-C 114.782 0.673 . . . . 0.0 114.782 177.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.413 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 2.9 pp -154.18 146.85 17.64 Favored Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 118.103 0.952 . . . . 0.0 111.111 179.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 17.0 Cg_exo -66.33 107.21 1.15 Allowed 'Trans proline' 0 N--CA 1.462 -0.359 0 C-N-CA 122.611 2.207 . . . . 0.0 111.95 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.5 p . . . . . 0 C--N 1.32 -0.681 0 CA-C-O 122.63 1.205 . . . . 0.0 109.182 -179.964 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.584 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 13.1 m . . . . . 0 CA--C 1.518 -0.25 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.3 28.85 73.98 Favored Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -177.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -127.5 151.38 48.94 Favored 'General case' 0 N--CA 1.444 -0.742 0 CA-C-N 114.231 -0.984 . . . . 0.0 110.572 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.625 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.0 p -113.05 143.45 44.3 Favored 'General case' 0 C--N 1.318 -0.789 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.253 178.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.629 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 24.9 p -116.85 47.26 1.5 Allowed 'General case' 0 C--N 1.318 -0.787 0 CA-C-O 121.874 0.845 . . . . 0.0 109.369 178.525 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.2 t -57.1 -32.22 39.47 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 114.482 -1.235 . . . . 0.0 109.524 179.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.92 21.13 47.69 Favored Glycine 0 N--CA 1.447 -0.588 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.85 178.346 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.37 40.11 98.19 Favored Glycine 0 C--N 1.335 0.484 0 C-N-CA 121.503 -0.379 . . . . 0.0 112.786 179.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.24 144.92 27.99 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.617 0.246 . . . . 0.0 111.461 -179.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.497 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 79.6 m -135.74 131.83 36.07 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.72 179.418 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.6 m-80 -88.2 -36.03 17.02 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.735 -179.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.708 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.1 m -61.64 119.62 48.95 Favored Pre-proline 0 C--O 1.235 0.305 0 CA-C-O 120.974 0.416 . . . . 0.0 110.7 -179.535 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_exo -63.7 114.05 2.4 Favored 'Trans proline' 0 N--CA 1.459 -0.545 0 C-N-CA 122.462 2.108 . . . . 0.0 112.873 -179.233 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 108.36 -2.48 32.83 Favored Glycine 0 N--CA 1.444 -0.786 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.759 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.708 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 81.6 m -94.33 122.5 36.94 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.375 0.607 . . . . 0.0 111.82 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.1 p -91.8 144.01 25.93 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.088 179.151 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.5 t -73.57 134.07 43.67 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.698 0.761 . . . . 0.0 111.091 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.6 m -147.28 68.2 1.14 Allowed 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 106.377 -1.712 . . . . 0.0 106.377 178.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.458 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.4 t90 -28.54 129.54 0.22 Allowed Pre-proline 0 C--O 1.232 0.166 0 CA-C-N 113.964 -1.471 . . . . 0.0 113.419 -176.091 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.3 Cg_endo -98.49 24.64 20.54 Favored 'Cis proline' 0 N--CA 1.461 -0.428 0 C-N-CA 123.747 -1.355 . . . . 0.0 113.318 0.423 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.625 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.18 147.79 33.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 113.714 1.005 . . . . 0.0 113.714 -177.299 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.629 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.0 m -83.66 123.57 29.95 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.578 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.612 HG22 ' HG3' ' A' ' 28' ' ' PRO . 27.2 p -99.58 152.84 19.58 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.56 179.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.584 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 30.9 ttt180 -129.09 128.39 43.43 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.062 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.2 p-10 41.92 38.62 1.07 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 113.616 0.969 . . . . 0.0 113.616 -179.602 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.28 2.19 55.73 Favored Glycine 0 CA--C 1.524 0.596 0 N-CA-C 115.611 1.004 . . . . 0.0 115.611 177.231 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.4 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.9 pt? -157.76 139.19 9.77 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-N 118.532 1.166 . . . . 0.0 111.222 179.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.612 ' HG3' HG22 ' A' ' 23' ' ' THR . 13.2 Cg_exo -68.61 103.92 1.05 Allowed 'Trans proline' 0 N--CA 1.462 -0.379 0 C-N-CA 122.418 2.079 . . . . 0.0 112.585 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 15.0 m . . . . . 0 C--N 1.322 -0.609 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.0 179.506 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.46 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 15.4 m . . . . . 0 CA--C 1.517 -0.303 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.76 31.09 79.77 Favored Glycine 0 C--N 1.333 0.41 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -177.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -134.38 148.81 50.74 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 113.983 -1.108 . . . . 0.0 110.349 -177.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 17.4 p -112.42 144.66 41.49 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.557 179.328 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.599 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.0 p -116.33 46.96 1.49 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.809 0.814 . . . . 0.0 109.402 178.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -56.96 -32.81 40.52 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 114.638 -1.165 . . . . 0.0 109.505 179.344 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.35 21.94 43.44 Favored Glycine 0 N--CA 1.448 -0.557 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.947 178.318 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.39 40.31 98.47 Favored Glycine 0 C--N 1.334 0.472 0 C-N-CA 121.47 -0.395 . . . . 0.0 112.684 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.77 144.63 27.15 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.735 0.302 . . . . 0.0 111.518 -179.218 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.559 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 78.1 m -136.95 133.12 35.3 Favored 'General case' 0 C--N 1.327 -0.394 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 179.319 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.3 m-80 -87.89 -32.27 19.04 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.18 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.607 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.7 m -63.56 117.06 30.93 Favored Pre-proline 0 C--O 1.236 0.352 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.706 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_exo -65.46 114.96 3.1 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 122.436 2.091 . . . . 0.0 112.372 -179.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.65 -7.55 31.86 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 115.472 -0.786 . . . . 0.0 111.533 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.607 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 86.3 m -91.21 121.78 33.28 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.461 0.648 . . . . 0.0 111.586 -179.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.7 p -89.99 141.78 28.33 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.201 179.324 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.0 t -72.02 133.87 45.55 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.607 0.717 . . . . 0.0 110.917 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.1 m -146.96 68.7 1.16 Allowed 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 179.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.453 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.1 t90 -28.65 129.98 0.21 Allowed Pre-proline 0 N--CA 1.462 0.14 0 CA-C-N 114.008 -1.451 . . . . 0.0 113.368 -176.172 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 63.8 Cg_endo -97.88 22.71 24.17 Favored 'Cis proline' 0 N--CA 1.462 -0.378 0 C-N-CA 123.667 -1.389 . . . . 0.0 113.403 0.3 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.608 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -128.95 147.15 33.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -177.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.599 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.0 m -82.3 123.94 29.51 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.672 -0.694 . . . . 0.0 110.333 179.451 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.532 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 22.8 p -95.31 142.84 27.24 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.119 0.485 . . . . 0.0 110.495 179.416 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.46 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 49.9 ttp180 -103.49 111.87 24.51 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 178.699 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 20.6 p30 46.88 32.17 1.72 Allowed 'General case' 0 N--CA 1.471 0.619 0 O-C-N 124.334 1.021 . . . . 0.0 113.065 -178.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 122.86 -27.44 5.93 Favored Glycine 0 CA--C 1.521 0.468 0 C-N-CA 119.977 -1.106 . . . . 0.0 114.754 177.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -134.91 138.67 30.12 Favored Pre-proline 0 C--N 1.326 -0.428 0 CA-C-N 117.899 0.849 . . . . 0.0 111.306 -178.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.532 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 33.4 Cg_exo -60.64 103.75 0.24 Allowed 'Trans proline' 0 C--N 1.343 0.274 0 C-N-CA 122.872 2.382 . . . . 0.0 113.269 -178.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.5 t . . . . . 0 C--N 1.325 -0.475 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 178.897 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.602 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 12.5 m . . . . . 0 CA--C 1.517 -0.297 0 CA-C-O 120.798 0.332 . . . . 0.0 110.128 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.99 30.7 77.53 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -177.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -130.29 150.99 51.28 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 114.211 -0.994 . . . . 0.0 110.608 -178.141 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.619 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.6 p -112.21 141.83 45.43 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.48 178.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.629 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 24.8 p -115.32 47.42 1.31 Allowed 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 121.87 0.843 . . . . 0.0 109.253 178.182 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.406 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.2 t -57.22 -32.04 39.44 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 114.599 -1.182 . . . . 0.0 109.453 179.486 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.68 21.13 47.71 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.666 -0.697 . . . . 0.0 111.855 178.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.17 39.9 97.8 Favored Glycine 0 C--N 1.335 0.492 0 C-N-CA 121.45 -0.405 . . . . 0.0 112.746 179.772 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.85 144.57 27.01 Favored 'General case' 0 C--N 1.324 -0.532 0 O-C-N 122.823 -0.222 . . . . 0.0 111.495 -179.361 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.522 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 81.7 m -135.04 133.44 39.37 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.826 179.543 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -89.81 -34.82 16.0 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.657 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.678 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.3 m -61.19 120.11 51.81 Favored Pre-proline 0 C--O 1.235 0.324 0 CA-C-O 120.95 0.405 . . . . 0.0 110.638 -179.589 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -63.92 113.49 2.2 Favored 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 122.425 2.083 . . . . 0.0 113.002 -179.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 107.75 -1.53 34.06 Favored Glycine 0 N--CA 1.443 -0.854 0 CA-C-N 115.208 -0.905 . . . . 0.0 111.796 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.678 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 94.0 m -95.16 122.96 38.37 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.46 0.648 . . . . 0.0 111.844 -179.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.9 p -92.57 145.46 24.42 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 114.966 -1.016 . . . . 0.0 110.063 179.182 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.8 t -74.3 134.29 42.57 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.729 0.776 . . . . 0.0 111.175 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.7 m -147.49 68.12 1.13 Allowed 'General case' 0 C--N 1.311 -1.065 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.7 t90 -28.36 129.57 0.21 Allowed Pre-proline 0 N--CA 1.463 0.203 0 CA-C-N 113.936 -1.484 . . . . 0.0 113.41 -176.129 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 65.1 Cg_endo -98.44 24.27 21.14 Favored 'Cis proline' 0 C--N 1.346 0.404 0 C-N-CA 123.678 -1.384 . . . . 0.0 113.24 0.315 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.619 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.1 m -129.93 148.45 33.2 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 113.651 0.982 . . . . 0.0 113.651 -177.316 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.629 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 82.6 m -84.1 124.56 31.24 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.655 179.657 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.603 HG22 ' HG3' ' A' ' 28' ' ' PRO . 25.7 p -100.26 150.48 22.51 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.514 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.602 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 36.9 ttt180 -126.78 128.67 46.95 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 179.161 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 41.74 38.51 0.97 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 113.75 1.019 . . . . 0.0 113.75 -179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 99.91 3.39 55.94 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 115.598 0.999 . . . . 0.0 115.598 177.26 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.8 pt? -158.17 138.73 9.16 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 118.465 1.132 . . . . 0.0 111.255 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.603 ' HG3' HG22 ' A' ' 23' ' ' THR . 13.2 Cg_exo -68.51 103.56 0.98 Allowed 'Trans proline' 0 N--CA 1.461 -0.421 0 C-N-CA 122.511 2.141 . . . . 0.0 112.485 -179.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.6 m . . . . . 0 C--N 1.321 -0.638 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.929 179.554 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.486 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 6.4 m . . . . . 0 CA--C 1.518 -0.285 0 CA-C-O 120.573 0.225 . . . . 0.0 110.572 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.81 30.74 78.76 Favored Glycine 0 C--N 1.334 0.43 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 -178.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -126.71 152.42 46.83 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 114.24 -0.98 . . . . 0.0 110.363 -178.29 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.63 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.5 p -113.35 143.64 44.12 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.514 178.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.609 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.8 p -118.07 47.88 1.5 Allowed 'General case' 0 C--N 1.319 -0.728 0 CA-C-O 121.85 0.833 . . . . 0.0 109.238 178.576 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.3 t -57.26 -32.44 40.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 114.506 -1.225 . . . . 0.0 109.597 179.518 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.04 20.53 50.46 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.9 178.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.78 39.62 97.7 Favored Glycine 0 C--N 1.336 0.558 0 C-N-CA 121.42 -0.419 . . . . 0.0 112.77 179.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.69 144.79 27.35 Favored 'General case' 0 C--N 1.323 -0.551 0 O-C-N 122.793 -0.239 . . . . 0.0 111.363 -179.24 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.514 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.0 m -134.26 132.82 40.11 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.103 -0.499 . . . . 0.0 109.863 179.555 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -86.01 -36.53 19.7 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.559 -179.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.699 HG21 HH21 ' A' ' 24' ' ' ARG . 3.3 m -63.35 117.85 37.99 Favored Pre-proline 0 C--O 1.235 0.326 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.754 -179.565 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -64.92 115.0 3.02 Favored 'Trans proline' 0 N--CA 1.458 -0.616 0 C-N-CA 122.336 2.024 . . . . 0.0 112.354 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 111.21 -9.6 28.97 Favored Glycine 0 N--CA 1.445 -0.742 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.511 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.611 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 79.5 m -90.75 121.64 32.81 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.338 0.59 . . . . 0.0 111.539 -179.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 3.2 p -89.64 143.2 27.0 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.256 -0.883 . . . . 0.0 110.223 179.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.3 t -73.5 134.15 43.8 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.765 0.793 . . . . 0.0 110.922 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.8 m -146.98 68.8 1.16 Allowed 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 178.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.429 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.4 t90 -28.53 129.68 0.21 Allowed Pre-proline 0 C--O 1.232 0.17 0 CA-C-N 113.909 -1.496 . . . . 0.0 113.476 -176.077 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.0 Cg_endo -98.41 25.62 19.34 Favored 'Cis proline' 0 N--CA 1.461 -0.434 0 C-N-CA 123.753 -1.353 . . . . 0.0 113.25 0.362 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.63 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.98 147.68 33.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 113.762 1.023 . . . . 0.0 113.762 -177.287 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.609 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 79.2 m -83.46 122.13 28.11 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.426 179.291 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.471 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 35.4 p -100.17 148.85 24.15 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 121.176 0.512 . . . . 0.0 111.048 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.699 HH21 HG21 ' A' ' 12' ' ' THR . 39.9 ttm180 -114.45 112.23 22.66 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 178.33 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.4 m-20 60.31 33.42 20.86 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.41 -178.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.59 -17.67 58.86 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 120.686 -0.769 . . . . 0.0 114.158 179.238 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.449 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.4 pt? -123.06 133.47 24.52 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 117.943 0.872 . . . . 0.0 110.76 -179.648 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 24.6 Cg_exo -62.96 104.82 0.41 Allowed 'Trans proline' 0 N--CA 1.465 -0.163 0 C-N-CA 122.854 2.369 . . . . 0.0 113.475 -178.761 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 4.4 t . . . . . 0 C--N 1.327 -0.404 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 178.905 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.606 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 30.5 m . . . . . 0 CA--C 1.516 -0.357 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.11 33.13 86.23 Favored Glycine 0 CA--C 1.507 -0.451 0 N-CA-C 109.197 -1.561 . . . . 0.0 109.197 -177.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -138.03 147.4 44.11 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 113.963 -1.119 . . . . 0.0 110.453 -177.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.609 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 25.3 p -110.06 143.34 40.23 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.857 179.496 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.585 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 29.6 p -116.07 46.68 1.51 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.71 0.767 . . . . 0.0 109.277 177.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.403 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.8 t -56.32 -32.65 35.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 114.712 -1.131 . . . . 0.0 109.691 179.385 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.44 23.05 37.79 Favored Glycine 0 N--CA 1.447 -0.602 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.854 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.98 40.5 98.55 Favored Glycine 0 C--N 1.335 0.507 0 C-N-CA 121.477 -0.392 . . . . 0.0 112.638 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.23 144.0 27.38 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.75 0.31 . . . . 0.0 111.531 -179.268 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.578 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.3 m -136.91 132.96 35.19 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.367 179.31 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.6 m-80 -87.42 -31.72 19.91 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.097 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.726 HG21 HH21 ' A' ' 24' ' ' ARG . 2.0 m -63.84 117.17 32.83 Favored Pre-proline 0 C--O 1.236 0.345 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.852 -179.673 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_exo -65.13 116.04 3.64 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 122.344 2.03 . . . . 0.0 112.261 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 107.78 -8.03 36.51 Favored Glycine 0 N--CA 1.445 -0.715 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.784 -179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.586 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 90.2 m -90.51 122.43 33.33 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.303 0.573 . . . . 0.0 111.639 -179.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.2 p -89.81 143.35 26.87 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.184 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.1 t -73.24 134.28 44.24 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.683 0.754 . . . . 0.0 111.02 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.4 m -147.06 68.66 1.16 Allowed 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 179.064 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.8 t90 -28.29 129.57 0.21 Allowed Pre-proline 0 C--O 1.232 0.17 0 CA-C-N 113.952 -1.476 . . . . 0.0 113.521 -176.272 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.9 Cg_endo -98.14 23.12 23.21 Favored 'Cis proline' 0 N--CA 1.461 -0.422 0 C-N-CA 123.56 -1.433 . . . . 0.0 113.414 0.381 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.609 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.68 147.36 33.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 N-CA-C 113.66 0.985 . . . . 0.0 113.66 -177.503 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.585 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 76.0 m -82.29 125.61 31.17 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.482 179.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 30.2 p -101.03 145.89 28.14 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.104 0.478 . . . . 0.0 110.889 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.726 HH21 HG21 ' A' ' 12' ' ' THR . 37.6 ttm180 -117.09 116.66 27.75 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 178.528 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.9 m-20 60.24 32.58 20.85 Favored 'General case' 0 C--N 1.325 -0.487 0 O-C-N 123.567 0.542 . . . . 0.0 110.681 -178.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 92.65 -12.22 70.31 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 120.84 -0.695 . . . . 0.0 114.373 179.012 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.2 pt? -124.94 134.8 26.02 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 118.113 0.957 . . . . 0.0 111.052 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.464 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 15.9 Cg_exo -67.24 103.17 0.74 Allowed 'Trans proline' 0 N--CA 1.463 -0.321 0 C-N-CA 122.671 2.248 . . . . 0.0 113.046 -179.318 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.3 m . . . . . 0 C--N 1.322 -0.614 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.625 179.113 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.2 m . . . . . 0 N--CA 1.455 -0.225 0 CA-C-O 120.82 0.343 . . . . 0.0 110.532 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.59 23.96 70.78 Favored Glycine 0 N--CA 1.45 -0.391 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 -178.572 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -117.51 152.15 35.66 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 114.015 -1.092 . . . . 0.0 109.702 -178.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.614 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.8 p -112.92 143.44 44.2 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 120.799 0.333 . . . . 0.0 110.884 179.471 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.585 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.8 p -117.07 46.93 1.58 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 121.756 0.789 . . . . 0.0 109.274 178.344 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.402 HG23 ' HB ' ' A' ' 4' ' ' THR . 11.6 t -56.83 -32.69 39.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 114.55 -1.204 . . . . 0.0 109.631 179.307 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.65 21.51 45.74 Favored Glycine 0 N--CA 1.447 -0.615 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.836 178.303 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.66 39.32 97.24 Favored Glycine 0 C--N 1.335 0.527 0 C-N-CA 121.484 -0.389 . . . . 0.0 112.807 179.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.16 144.08 25.45 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 120.65 0.262 . . . . 0.0 111.585 -179.269 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.576 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.6 m -134.33 135.89 43.07 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.495 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -91.02 -31.49 16.28 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.691 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -63.23 117.71 36.23 Favored Pre-proline 0 C--O 1.237 0.418 0 CA-C-O 120.992 0.425 . . . . 0.0 110.69 -179.762 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -63.87 117.61 4.6 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 122.295 1.997 . . . . 0.0 112.554 -179.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.24 0.93 47.72 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.429 -0.805 . . . . 0.0 112.051 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.691 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 99.9 m -97.06 122.24 39.84 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-O 121.288 0.566 . . . . 0.0 111.262 -179.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.5 p -89.84 141.28 28.79 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.358 179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.3 t -72.39 134.1 45.26 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.68 0.752 . . . . 0.0 110.754 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.3 m -147.02 67.47 1.15 Allowed 'General case' 0 C--N 1.311 -1.094 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.423 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.8 t90 -27.94 129.64 0.2 Allowed Pre-proline 0 C--N 1.34 0.169 0 CA-C-N 113.917 -1.492 . . . . 0.0 113.526 -176.099 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.423 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.5 Cg_endo -97.67 23.41 23.52 Favored 'Cis proline' 0 N--CA 1.461 -0.404 0 C-N-CA 123.574 -1.428 . . . . 0.0 113.364 0.317 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.614 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.62 146.3 34.38 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 N-CA-C 113.671 0.989 . . . . 0.0 113.671 -177.301 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.585 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.7 m -82.64 123.86 29.65 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.505 -0.771 . . . . 0.0 110.43 179.5 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 21.1 p -95.71 144.64 25.94 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.213 0.53 . . . . 0.0 111.076 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.9 103.88 15.84 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 178.237 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 20.1 p30 48.03 29.92 1.89 Allowed 'General case' 0 N--CA 1.472 0.661 0 O-C-N 124.249 0.968 . . . . 0.0 112.811 -178.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.57 -31.6 3.73 Favored Glycine 0 CA--C 1.522 0.473 0 C-N-CA 119.974 -1.108 . . . . 0.0 114.411 178.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.433 ' H ' HD23 ' A' ' 27' ' ' LEU . 1.8 pt? -126.91 135.87 27.99 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 117.756 0.778 . . . . 0.0 111.393 -178.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.409 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 39.2 Cg_exo -60.63 104.41 0.26 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.848 2.365 . . . . 0.0 113.293 -179.072 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 25.8 t . . . . . 0 C--N 1.325 -0.497 0 CA-C-O 121.942 0.877 . . . . 0.0 108.882 179.534 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 9.5 m . . . . . 0 N--CA 1.452 -0.329 0 CA-C-O 120.671 0.272 . . . . 0.0 110.368 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.41 28.17 73.29 Favored Glycine 0 C--N 1.334 0.459 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 -178.354 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -125.18 150.0 47.38 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 114.148 -1.026 . . . . 0.0 110.016 -178.378 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.604 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 18.3 p -111.48 143.72 41.86 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.557 179.097 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.594 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.0 p -116.14 47.49 1.39 Allowed 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.835 0.826 . . . . 0.0 109.281 178.475 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.403 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.4 t -57.2 -32.28 40.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 114.503 -1.226 . . . . 0.0 109.487 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.07 20.65 49.97 Favored Glycine 0 N--CA 1.448 -0.529 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.766 178.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.93 39.03 96.99 Favored Glycine 0 C--N 1.336 0.547 0 C-N-CA 121.602 -0.332 . . . . 0.0 112.775 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.13 144.28 25.6 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 120.698 0.285 . . . . 0.0 111.562 -179.345 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.551 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 72.6 m -133.7 135.35 43.98 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 179.32 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -93.98 -29.7 15.11 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.441 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.749 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -63.38 121.67 71.23 Favored Pre-proline 0 C--O 1.237 0.404 0 CA-C-O 121.15 0.5 . . . . 0.0 111.014 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.2 Cg_exo -64.45 118.54 5.5 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.396 2.064 . . . . 0.0 112.641 -179.752 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.61 8.93 51.38 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.076 -0.965 . . . . 0.0 111.864 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.749 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 71.1 m -105.18 123.42 47.8 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.485 0.66 . . . . 0.0 111.958 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.3 p -94.07 142.51 27.31 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.144 179.274 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.1 t -72.8 134.23 44.83 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.624 0.726 . . . . 0.0 111.217 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.9 m -147.5 67.88 1.13 Allowed 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 106.502 -1.666 . . . . 0.0 106.502 178.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.1 t90 -28.02 129.6 0.21 Allowed Pre-proline 0 N--CA 1.462 0.174 0 CA-C-N 113.936 -1.484 . . . . 0.0 113.517 -176.205 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 64.2 Cg_endo -97.98 23.47 22.95 Favored 'Cis proline' 0 N--CA 1.462 -0.34 0 C-N-CA 123.625 -1.406 . . . . 0.0 113.312 0.356 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.604 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.9 146.98 33.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 -177.378 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.0 m -83.02 121.98 27.73 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.621 179.615 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.483 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 35.5 p -98.3 146.43 25.67 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.37 179.56 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 13.5 ttt180 -109.21 114.65 28.53 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.483 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 20.1 p30 47.58 31.29 1.99 Allowed 'General case' 0 N--CA 1.472 0.662 0 O-C-N 124.269 0.981 . . . . 0.0 113.041 -178.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 121.9 -27.39 6.21 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 120.035 -1.079 . . . . 0.0 114.602 177.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.463 ' O ' HG23 ' A' ' 29' ' ' VAL . 2.2 pt? -137.1 141.92 36.27 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 117.782 0.791 . . . . 0.0 111.17 -178.813 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.483 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 33.5 Cg_exo -58.07 105.88 0.23 Allowed 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 122.874 2.382 . . . . 0.0 113.539 -178.927 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.463 HG23 ' O ' ' A' ' 27' ' ' LEU . 10.7 t . . . . . 0 C--N 1.325 -0.498 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 178.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 19.0 m . . . . . 0 CA--C 1.518 -0.262 0 CA-C-O 120.562 0.22 . . . . 0.0 110.583 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 63.89 32.92 85.78 Favored Glycine 0 C--N 1.334 0.469 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -178.359 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -132.56 148.81 52.38 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 114.245 -0.978 . . . . 0.0 110.286 -178.178 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.606 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 25.7 p -108.83 143.05 38.52 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.076 179.511 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.6 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.8 p -116.27 46.94 1.49 Allowed 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.791 0.805 . . . . 0.0 109.295 177.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.9 t -56.44 -32.62 36.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 114.639 -1.164 . . . . 0.0 109.803 179.579 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.11 22.66 39.82 Favored Glycine 0 N--CA 1.447 -0.606 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.944 178.369 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.21 40.25 98.31 Favored Glycine 0 C--N 1.336 0.572 0 C-N-CA 121.414 -0.422 . . . . 0.0 112.598 179.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.28 144.07 27.37 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 120.683 0.278 . . . . 0.0 111.566 -179.195 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.552 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 84.5 m -136.02 133.05 37.06 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.355 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -88.3 -32.51 18.42 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.126 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.792 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.0 OUTLIER -64.97 118.32 47.93 Favored Pre-proline 0 C--O 1.237 0.426 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.05 -179.56 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -64.96 118.38 5.38 Favored 'Trans proline' 0 N--CA 1.457 -0.627 0 C-N-CA 122.354 2.036 . . . . 0.0 112.485 -179.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 104.38 2.56 44.27 Favored Glycine 0 N--CA 1.446 -0.673 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.704 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.792 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 70.8 m -99.44 121.93 41.83 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.305 0.574 . . . . 0.0 111.77 -179.818 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.1 p -89.87 140.39 29.65 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.269 -0.878 . . . . 0.0 109.96 179.068 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.4 t -72.16 133.91 45.41 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.678 0.752 . . . . 0.0 110.891 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.7 m -147.06 68.83 1.16 Allowed 'General case' 0 C--N 1.311 -1.076 0 N-CA-C 106.519 -1.66 . . . . 0.0 106.519 179.161 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.424 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.1 t90 -28.45 129.48 0.21 Allowed Pre-proline 0 C--O 1.232 0.154 0 CA-C-N 113.987 -1.461 . . . . 0.0 113.445 -176.119 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.0 Cg_endo -98.29 24.26 21.35 Favored 'Cis proline' 0 N--CA 1.46 -0.457 0 C-N-CA 123.672 -1.387 . . . . 0.0 113.328 0.419 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.606 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.52 147.26 33.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 113.767 1.025 . . . . 0.0 113.767 -177.297 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.6 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 72.7 m -82.33 124.45 30.0 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.322 -0.853 . . . . 0.0 110.269 179.341 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.425 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 32.3 p -101.63 149.95 23.6 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.313 0.578 . . . . 0.0 111.574 -179.536 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 15.9 tpp85 -105.89 103.52 13.03 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 70.9 m-20 58.45 34.67 24.15 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 123.379 0.425 . . . . 0.0 110.547 -178.592 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 102.01 -24.05 32.54 Favored Glycine 0 CA--C 1.522 0.524 0 C-N-CA 120.49 -0.862 . . . . 0.0 114.13 179.368 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.437 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.2 pt? -118.12 130.59 24.64 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-N 117.964 0.882 . . . . 0.0 110.709 -179.602 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 31.1 Cg_exo -59.22 105.91 0.27 Allowed 'Trans proline' 0 CA--C 1.526 0.109 0 C-N-CA 123.153 2.569 . . . . 0.0 113.722 -178.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 27' ' ' LEU . 5.9 t . . . . . 0 C--N 1.327 -0.408 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 178.604 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.442 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 12.7 m . . . . . 0 N--CA 1.452 -0.356 0 CA-C-O 120.793 0.33 . . . . 0.0 110.4 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.22 29.67 75.9 Favored Glycine 0 C--N 1.333 0.405 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 -178.228 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.414 ' CD ' ' H ' ' A' ' 11' ' ' ASN . 38.6 tt0 -129.76 149.62 51.42 Favored 'General case' 0 N--CA 1.445 -0.698 0 CA-C-N 114.043 -1.079 . . . . 0.0 110.045 -178.362 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.606 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.0 p -110.28 144.34 39.12 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.705 179.313 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.585 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.9 p -116.82 46.93 1.55 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.811 0.815 . . . . 0.0 109.316 178.45 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.4 t -56.83 -32.57 39.02 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 114.683 -1.144 . . . . 0.0 109.671 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -97.63 21.23 47.2 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.84 178.319 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.73 39.86 98.01 Favored Glycine 0 C--N 1.335 0.486 0 C-N-CA 121.455 -0.403 . . . . 0.0 112.669 179.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -148.8 144.57 27.08 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.645 0.26 . . . . 0.0 111.553 -179.256 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.537 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 80.1 m -135.52 134.1 39.13 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.969 -0.559 . . . . 0.0 109.523 179.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.414 ' H ' ' CD ' ' A' ' 3' ' ' GLU . 62.8 m-80 -91.77 -31.43 15.77 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.216 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.707 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -63.2 121.17 67.74 Favored Pre-proline 0 C--O 1.236 0.365 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.122 -179.317 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.5 Cg_exo -64.17 118.51 5.46 Favored 'Trans proline' 0 N--CA 1.457 -0.67 0 C-N-CA 122.365 2.044 . . . . 0.0 112.688 -179.771 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 99.9 5.48 54.98 Favored Glycine 0 N--CA 1.446 -0.642 0 CA-C-N 115.2 -0.909 . . . . 0.0 112.013 179.657 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.707 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 86.1 m -102.14 120.87 41.16 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.607 0.718 . . . . 0.0 112.12 -179.722 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 3.0 p -90.97 144.99 25.1 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.794 178.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.5 t -73.75 134.41 43.46 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.738 0.78 . . . . 0.0 111.066 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.8 m -146.78 67.71 1.16 Allowed 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 178.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.2 t90 -28.21 129.45 0.21 Allowed Pre-proline 0 C--O 1.232 0.172 0 CA-C-N 113.958 -1.474 . . . . 0.0 113.392 -176.118 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.6 Cg_endo -98.3 24.65 20.78 Favored 'Cis proline' 0 N--CA 1.462 -0.376 0 C-N-CA 123.676 -1.385 . . . . 0.0 113.324 0.357 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.606 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -130.81 148.2 33.09 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -177.314 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.585 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.5 m -83.53 128.54 34.59 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-N 115.536 -0.756 . . . . 0.0 110.586 179.518 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 32.4 p -108.29 149.9 28.03 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.042 -179.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.442 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 20.7 ttp180 -131.64 126.07 33.75 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 178.849 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.5 m-20 62.17 28.57 17.15 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.708 -178.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.99 5.32 77.29 Favored Glycine 0 CA--C 1.523 0.533 0 CA-C-N 115.715 -0.675 . . . . 0.0 114.101 179.087 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.41 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.8 pt? -148.21 142.65 16.65 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 117.851 0.825 . . . . 0.0 110.748 179.527 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 27.4 Cg_exo -62.6 104.58 0.37 Allowed 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.601 2.201 . . . . 0.0 112.926 -179.083 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.404 HG23 ' HG ' ' A' ' 27' ' ' LEU . 5.2 t . . . . . 0 C--N 1.324 -0.512 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 178.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.686 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 23.7 m . . . . . 0 CA--C 1.518 -0.287 0 CA-C-O 120.867 0.365 . . . . 0.0 110.083 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.74 31.4 79.72 Favored Glycine 0 C--N 1.334 0.469 0 N-CA-C 109.199 -1.561 . . . . 0.0 109.199 -177.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -134.6 148.21 50.38 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 113.957 -1.122 . . . . 0.0 110.32 -177.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.604 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.3 p -110.29 142.77 41.45 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.811 179.422 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.596 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.8 p -115.24 46.65 1.42 Allowed 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.722 0.772 . . . . 0.0 109.261 177.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.42 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.6 t -56.56 -32.42 36.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 114.666 -1.152 . . . . 0.0 109.652 179.385 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.71 22.41 41.1 Favored Glycine 0 N--CA 1.447 -0.596 0 CA-C-N 115.625 -0.716 . . . . 0.0 111.858 178.327 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.03 40.06 97.97 Favored Glycine 0 C--N 1.335 0.475 0 C-N-CA 121.499 -0.382 . . . . 0.0 112.734 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.56 143.94 25.92 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 120.694 0.283 . . . . 0.0 111.581 -179.202 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.584 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 68.4 m -136.14 134.84 38.7 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.471 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -91.2 -30.23 16.77 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 116.554 -0.294 . . . . 0.0 110.358 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.688 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.7 m -62.55 118.66 43.23 Favored Pre-proline 0 C--O 1.235 0.293 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.718 -179.78 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.9 Cg_exo -64.13 115.02 2.89 Favored 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.394 2.063 . . . . 0.0 112.851 -179.385 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.33 0.9 40.91 Favored Glycine 0 N--CA 1.445 -0.707 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.786 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.688 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 86.2 m -96.9 123.65 40.66 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.398 0.618 . . . . 0.0 111.82 -179.852 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.9 p -92.66 144.05 25.7 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.074 179.15 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.3 t -73.44 134.26 43.92 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.607 0.718 . . . . 0.0 111.017 -179.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.3 m -147.3 67.68 1.14 Allowed 'General case' 0 C--N 1.312 -1.061 0 N-CA-C 106.523 -1.658 . . . . 0.0 106.523 179.025 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.7 t90 -28.11 129.45 0.21 Allowed Pre-proline 0 C--O 1.232 0.17 0 CA-C-N 114.067 -1.424 . . . . 0.0 113.448 -176.228 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 63.7 Cg_endo -98.08 22.94 23.55 Favored 'Cis proline' 0 N--CA 1.461 -0.419 0 C-N-CA 123.671 -1.387 . . . . 0.0 113.391 0.321 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.604 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -129.37 148.24 33.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 113.627 0.973 . . . . 0.0 113.627 -177.433 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.596 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.3 m -83.61 127.65 33.91 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.761 179.743 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.469 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 21.2 p -101.55 150.75 22.75 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.774 179.786 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.686 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 33.8 ttt180 -132.63 124.13 27.72 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.534 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 59.84 30.6 20.15 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.058 0.456 . . . . 0.0 111.203 -179.294 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.81 7.58 74.43 Favored Glycine 0 CA--C 1.523 0.579 0 C-N-CA 121.095 -0.574 . . . . 0.0 114.29 178.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.5 pt? -148.32 137.6 12.15 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 117.875 0.838 . . . . 0.0 110.674 179.182 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.469 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 16.9 Cg_exo -66.77 103.45 0.71 Allowed 'Trans proline' 0 N--CA 1.465 -0.185 0 C-N-CA 122.541 2.161 . . . . 0.0 112.656 -179.26 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.3 m . . . . . 0 C--N 1.323 -0.559 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.986 179.414 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.541 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 7.9 m . . . . . 0 CA--C 1.517 -0.307 0 CA-C-O 120.56 0.219 . . . . 0.0 110.568 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.07 31.52 81.11 Favored Glycine 0 C--N 1.334 0.441 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -178.264 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -129.42 151.81 49.65 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 114.152 -1.024 . . . . 0.0 110.519 -178.118 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.632 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.3 p -112.41 141.85 45.65 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.678 178.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.626 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 28.0 p -116.11 47.85 1.33 Allowed 'General case' 0 C--N 1.318 -0.797 0 CA-C-O 121.873 0.844 . . . . 0.0 109.264 177.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.2 t -57.24 -32.2 40.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 114.573 -1.194 . . . . 0.0 109.703 179.559 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -96.88 20.68 49.76 Favored Glycine 0 N--CA 1.447 -0.592 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.856 178.307 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.54 39.29 97.14 Favored Glycine 0 C--N 1.335 0.512 0 C-N-CA 121.468 -0.396 . . . . 0.0 112.662 179.829 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.22 144.2 26.39 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.62 0.248 . . . . 0.0 111.266 -179.248 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.536 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 76.7 m -133.32 133.93 43.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.022 -0.536 . . . . 0.0 109.952 179.596 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -87.45 -35.02 18.49 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.441 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.717 HG21 HH21 ' A' ' 24' ' ' ARG . 3.6 m -63.17 118.12 40.0 Favored Pre-proline 0 C--O 1.236 0.365 0 CA-C-O 120.748 0.309 . . . . 0.0 110.747 -179.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -65.17 114.88 3.02 Favored 'Trans proline' 0 N--CA 1.458 -0.568 0 C-N-CA 122.338 2.025 . . . . 0.0 112.297 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 110.24 -8.52 30.96 Favored Glycine 0 N--CA 1.445 -0.701 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.601 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.581 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 96.5 m -91.43 121.98 33.62 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.366 0.603 . . . . 0.0 111.619 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.7 p -89.76 144.38 26.02 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 115.208 -0.906 . . . . 0.0 110.251 179.348 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.0 t -74.28 134.16 42.61 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.615 0.721 . . . . 0.0 111.016 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.9 m -147.29 68.77 1.14 Allowed 'General case' 0 C--N 1.311 -1.072 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.019 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.1 t90 -28.32 129.65 0.21 Allowed Pre-proline 0 C--O 1.232 0.178 0 CA-C-N 113.978 -1.465 . . . . 0.0 113.399 -176.207 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 65.4 Cg_endo -98.42 24.91 20.26 Favored 'Cis proline' 0 N--CA 1.461 -0.441 0 C-N-CA 123.694 -1.377 . . . . 0.0 113.263 0.31 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.632 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -130.64 147.98 33.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 N-CA-C 113.688 0.996 . . . . 0.0 113.688 -177.386 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.626 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 75.9 m -83.4 123.04 29.28 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.453 179.44 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 28.1 p -99.0 147.14 25.31 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.193 0.52 . . . . 0.0 111.108 -179.732 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.717 HH21 HG21 ' A' ' 12' ' ' THR . 40.5 ttm180 -114.14 112.86 23.88 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 178.386 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 77.2 m-20 60.43 33.06 20.71 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.438 -178.262 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 95.51 -16.97 60.19 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.75 -0.738 . . . . 0.0 114.207 179.175 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.432 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.4 pt? -123.91 133.99 25.04 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 117.935 0.868 . . . . 0.0 110.743 -179.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.465 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 24.5 Cg_exo -62.82 104.14 0.37 Allowed 'Trans proline' 0 N--CA 1.466 -0.115 0 C-N-CA 122.838 2.359 . . . . 0.0 113.523 -178.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 4.3 t . . . . . 0 C--N 1.327 -0.402 0 CA-C-O 122.108 0.956 . . . . 0.0 108.592 178.916 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 35.3 m . . . . . 0 CA--C 1.519 -0.239 0 CA-C-O 120.729 0.299 . . . . 0.0 110.698 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.64 32.65 83.81 Favored Glycine 0 C--N 1.335 0.475 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -178.222 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.418 ' CD ' ' H ' ' A' ' 11' ' ' ASN . 38.4 tt0 -137.75 148.41 45.57 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 114.205 -0.997 . . . . 0.0 110.405 -178.101 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.615 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 27.1 p -108.85 142.91 38.74 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.897 179.355 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.604 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 30.3 p -116.28 46.86 1.5 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.777 0.798 . . . . 0.0 109.277 177.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.8 t -56.62 -32.75 38.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-N 114.607 -1.179 . . . . 0.0 109.795 179.566 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.84 22.7 39.64 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.919 178.443 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.87 40.48 98.36 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 121.446 -0.407 . . . . 0.0 112.615 179.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -147.85 144.07 27.88 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.654 0.264 . . . . 0.0 111.355 -179.195 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.56 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 79.3 m -136.58 133.76 36.72 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.993 -0.549 . . . . 0.0 109.718 179.555 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.418 ' H ' ' CD ' ' A' ' 3' ' ' GLU . 62.6 m-80 -91.12 -31.35 16.26 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.947 179.757 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.637 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.3 m -62.55 118.96 46.08 Favored Pre-proline 0 C--O 1.237 0.398 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.846 -179.547 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.8 Cg_exo -64.08 118.92 5.84 Favored 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 122.231 1.954 . . . . 0.0 112.739 -179.619 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.42 10.77 53.32 Favored Glycine 0 N--CA 1.446 -0.688 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.977 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.637 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 95.5 m -105.48 121.52 44.1 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.456 0.646 . . . . 0.0 111.723 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 8.0 p -89.76 143.25 26.95 Favored 'General case' 0 N--CA 1.446 -0.64 0 CA-C-N 115.102 -0.953 . . . . 0.0 109.898 179.07 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 54.0 t -72.61 134.19 45.04 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.668 0.747 . . . . 0.0 110.954 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.9 m -146.09 67.58 1.19 Allowed 'General case' 0 C--N 1.31 -1.142 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.424 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.6 t90 -27.94 129.39 0.21 Allowed Pre-proline 0 C--O 1.233 0.201 0 CA-C-N 113.919 -1.491 . . . . 0.0 113.528 -176.202 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.424 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.9 Cg_endo -98.04 24.82 20.89 Favored 'Cis proline' 0 N--CA 1.462 -0.346 0 C-N-CA 123.658 -1.392 . . . . 0.0 113.307 0.468 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.615 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -131.61 146.9 32.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -177.413 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.604 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 78.3 m -81.66 132.11 35.29 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.224 179.343 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 63.0 p -117.16 147.39 42.5 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.017 0.437 . . . . 0.0 111.608 -178.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 54.0 ttm-85 -108.56 114.27 27.96 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 177.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 54.8 m-20 61.33 35.25 18.1 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.143 0.497 . . . . 0.0 109.683 -178.252 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 72.83 27.82 68.22 Favored Glycine 0 N--CA 1.452 -0.269 0 CA-C-N 115.69 -0.686 . . . . 0.0 112.244 -179.276 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.4 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 10.1 tt -140.95 120.03 8.31 Favored Pre-proline 0 C--N 1.328 -0.355 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 -179.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 22.1 Cg_exo -64.98 102.85 0.45 Allowed 'Trans proline' 0 N--CA 1.465 -0.148 0 C-N-CA 122.524 2.149 . . . . 0.0 112.841 -179.268 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.1 p . . . . . 0 C--N 1.322 -0.622 0 CA-C-O 122.055 0.931 . . . . 0.0 109.736 179.701 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 11.6 m . . . . . 0 CA--C 1.519 -0.241 0 CA-C-O 120.816 0.341 . . . . 0.0 110.47 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.44 31.96 82.6 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 109.476 -1.449 . . . . 0.0 109.476 -178.071 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -132.71 148.95 52.34 Favored 'General case' 0 N--CA 1.444 -0.748 0 CA-C-N 114.127 -1.036 . . . . 0.0 110.359 -177.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.61 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 25.7 p -110.12 142.72 41.23 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.891 179.34 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.594 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 29.9 p -115.72 46.97 1.42 Allowed 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.655 0.74 . . . . 0.0 109.283 177.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.406 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.9 t -56.54 -32.64 37.31 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.685 179.492 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.05 22.0 43.13 Favored Glycine 0 N--CA 1.447 -0.617 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.836 178.443 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.27 39.58 97.41 Favored Glycine 0 C--N 1.335 0.518 0 C-N-CA 121.511 -0.376 . . . . 0.0 112.683 179.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -149.68 143.77 25.7 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.664 0.268 . . . . 0.0 111.557 -179.308 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 78.9 m -134.7 135.24 41.85 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 179.491 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -90.31 -30.84 17.22 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.63 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.5 m -62.95 117.97 37.84 Favored Pre-proline 0 C--O 1.236 0.35 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.655 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.6 Cg_exo -64.37 116.48 3.78 Favored 'Trans proline' 0 N--CA 1.457 -0.658 0 C-N-CA 122.386 2.058 . . . . 0.0 112.662 -179.414 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.3 2.31 47.8 Favored Glycine 0 N--CA 1.445 -0.75 0 CA-C-N 115.373 -0.831 . . . . 0.0 112.107 179.635 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.63 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 88.9 m -97.78 123.13 41.6 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.334 0.588 . . . . 0.0 111.497 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.8 p -90.07 141.58 28.53 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.293 179.467 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.8 t -73.06 134.28 44.52 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.663 0.744 . . . . 0.0 110.95 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.2 m -147.19 68.61 1.15 Allowed 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.056 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.426 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.7 t90 -28.14 129.6 0.21 Allowed Pre-proline 0 N--CA 1.463 0.187 0 CA-C-N 113.962 -1.472 . . . . 0.0 113.421 -176.252 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.426 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 68.8 Cg_endo -98.03 23.31 23.11 Favored 'Cis proline' 0 N--CA 1.461 -0.439 0 C-N-CA 123.62 -1.408 . . . . 0.0 113.275 0.307 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.61 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -129.99 147.02 33.24 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -177.4 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 77.3 m -82.05 125.34 30.71 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.494 179.464 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.523 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 32.4 p -101.06 146.47 27.41 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.156 0.503 . . . . 0.0 111.195 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.435 ' HG2' ' SG ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -101.79 107.86 19.19 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 177.879 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 17.7 p30 49.36 28.83 2.49 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 124.319 1.012 . . . . 0.0 112.776 -178.421 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 124.33 -29.62 4.99 Favored Glycine 0 CA--C 1.521 0.451 0 C-N-CA 120.035 -1.079 . . . . 0.0 114.518 178.141 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.427 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.7 pt? -125.81 135.46 27.05 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 117.776 0.788 . . . . 0.0 111.109 -179.007 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 35.0 Cg_exo -60.85 104.75 0.28 Allowed 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.861 2.374 . . . . 0.0 113.404 -178.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 27' ' ' LEU . 6.1 t . . . . . 0 C--N 1.325 -0.475 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 178.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.671 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 8.9 m . . . . . 0 CA--C 1.518 -0.268 0 CA-C-O 120.763 0.316 . . . . 0.0 110.25 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.27 31.72 81.47 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -177.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -133.51 148.31 51.67 Favored 'General case' 0 N--CA 1.444 -0.766 0 CA-C-N 113.928 -1.136 . . . . 0.0 110.509 -177.72 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.6 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 26.4 p -110.45 142.86 41.6 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.808 179.325 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.582 ' HB3' ' SG ' ' A' ' 10' ' ' CYS . 26.6 p -115.36 46.95 1.38 Allowed 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.739 0.78 . . . . 0.0 109.278 178.071 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.408 HG23 ' HB ' ' A' ' 4' ' ' THR . 12.8 t -56.55 -32.42 36.8 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 114.624 -1.171 . . . . 0.0 109.658 179.474 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.23 21.88 43.73 Favored Glycine 0 N--CA 1.448 -0.535 0 CA-C-N 115.617 -0.72 . . . . 0.0 111.811 178.384 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.36 39.52 97.37 Favored Glycine 0 C--N 1.335 0.524 0 C-N-CA 121.527 -0.368 . . . . 0.0 112.668 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.03 143.86 25.43 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 120.684 0.278 . . . . 0.0 111.597 -179.294 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.582 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 70.4 m -134.78 135.01 41.51 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.421 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -88.58 -31.1 18.79 Favored 'General case' 0 C--N 1.321 -0.662 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.615 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.7 m -63.59 117.72 37.49 Favored Pre-proline 0 C--O 1.236 0.381 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.752 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_exo -65.05 115.66 3.41 Favored 'Trans proline' 0 N--CA 1.459 -0.536 0 C-N-CA 122.316 2.011 . . . . 0.0 112.438 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 108.87 -8.73 34.01 Favored Glycine 0 N--CA 1.446 -0.681 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.738 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.615 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 88.2 m -89.98 122.69 33.23 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.42 0.629 . . . . 0.0 111.762 -179.677 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.0 p -90.67 144.35 25.83 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.078 -0.964 . . . . 0.0 110.113 179.212 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.4 t -74.06 134.27 42.96 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.592 0.71 . . . . 0.0 111.092 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 m -147.45 68.27 1.13 Allowed 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 106.517 -1.661 . . . . 0.0 106.517 179.053 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.451 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.8 t90 -28.16 129.44 0.21 Allowed Pre-proline 0 N--CA 1.463 0.191 0 CA-C-N 114.007 -1.451 . . . . 0.0 113.437 -176.256 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.451 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.9 Cg_endo -98.36 23.18 22.77 Favored 'Cis proline' 0 C--N 1.345 0.388 0 C-N-CA 123.617 -1.41 . . . . 0.0 113.257 0.334 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.6 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -129.48 148.64 33.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -177.447 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.572 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 73.5 m -83.55 126.19 32.55 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.723 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.513 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 20.1 p -99.68 148.2 24.6 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.771 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.671 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 57.9 ttp180 -130.4 131.94 45.52 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.024 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 6.6 p-10 44.59 36.4 1.72 Allowed 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 113.324 0.861 . . . . 0.0 113.324 -179.413 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 100.17 0.84 55.89 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 115.621 1.008 . . . . 0.0 115.621 177.272 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -161.61 144.97 9.41 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 118.473 1.137 . . . . 0.0 111.046 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.513 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 20.8 Cg_exo -65.14 104.32 0.59 Allowed 'Trans proline' 0 N--CA 1.464 -0.255 0 C-N-CA 122.444 2.096 . . . . 0.0 112.904 -179.109 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.9 t . . . . . 0 C--N 1.325 -0.498 0 CA-C-O 122.063 0.935 . . . . 0.0 108.551 179.112 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.693 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 16.6 m . . . . . 0 CA--C 1.516 -0.33 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 66.5 30.28 76.24 Favored Glycine 0 N--CA 1.45 -0.422 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 -177.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -130.24 152.69 49.38 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 114.126 -1.037 . . . . 0.0 110.544 -178.199 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.63 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.3 p -115.24 143.34 45.4 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.241 178.44 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.639 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.8 p -115.73 47.46 1.35 Allowed 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.915 0.865 . . . . 0.0 109.362 178.666 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -57.52 -32.23 41.24 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 114.552 -1.204 . . . . 0.0 109.481 179.387 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -96.51 19.9 52.69 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.828 178.281 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.9 39.73 97.91 Favored Glycine 0 C--N 1.335 0.48 0 C-N-CA 121.524 -0.37 . . . . 0.0 112.746 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.04 144.96 26.12 Favored 'General case' 0 C--N 1.324 -0.528 0 O-C-N 122.734 -0.274 . . . . 0.0 111.472 -179.275 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.529 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 85.6 m -134.62 133.57 40.29 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.088 -0.505 . . . . 0.0 109.81 179.539 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -90.14 -34.04 16.02 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.676 -179.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.673 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.1 m -61.98 121.19 63.82 Favored Pre-proline 0 C--O 1.236 0.366 0 CA-C-O 120.943 0.401 . . . . 0.0 110.654 -179.673 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -64.58 114.79 2.87 Favored 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 122.44 2.093 . . . . 0.0 112.691 -179.535 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 106.08 0.94 38.74 Favored Glycine 0 N--CA 1.445 -0.705 0 CA-C-N 115.465 -0.789 . . . . 0.0 111.68 179.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.673 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 84.2 m -98.91 119.74 38.19 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 121.46 0.648 . . . . 0.0 111.658 -179.8 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.8 p -90.59 144.82 25.39 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.023 179.095 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 52.7 t -72.84 134.4 44.85 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.697 0.761 . . . . 0.0 111.109 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 20.1 m -147.13 66.96 1.14 Allowed 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 106.217 -1.771 . . . . 0.0 106.217 178.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.9 t90 -28.24 129.53 0.21 Allowed Pre-proline 0 C--O 1.233 0.195 0 CA-C-N 113.89 -1.504 . . . . 0.0 113.436 -176.142 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.461 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 64.6 Cg_endo -98.32 24.19 21.41 Favored 'Cis proline' 0 N--CA 1.461 -0.384 0 C-N-CA 123.645 -1.398 . . . . 0.0 113.284 0.43 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.63 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.2 m -129.15 147.76 33.34 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 113.562 0.949 . . . . 0.0 113.562 -177.409 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.639 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 91.8 m -84.37 123.76 30.55 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.737 179.663 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.54 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 34.6 p -100.08 146.46 26.75 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.338 179.531 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.693 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 25.5 ttp85 -117.4 122.05 42.75 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 21.6 p30 46.82 32.3 1.74 Allowed 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.342 1.057 . . . . 0.0 113.595 -179.031 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 116.48 -17.44 14.02 Favored Glycine 0 CA--C 1.522 0.489 0 C-N-CA 119.92 -1.133 . . . . 0.0 115.325 177.133 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -144.13 144.36 25.83 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-N 118.367 1.083 . . . . 0.0 111.669 -178.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.54 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 16.9 Cg_exo -65.93 103.61 0.62 Allowed 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 122.623 2.215 . . . . 0.0 112.479 -179.738 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.49 HG23 ' HB3' ' A' ' 24' ' ' ARG . 3.6 m . . . . . 0 C--N 1.321 -0.651 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.231 179.22 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.549 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 11.6 m . . . . . 0 CA--C 1.517 -0.323 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.71 31.17 80.02 Favored Glycine 0 C--N 1.335 0.503 0 N-CA-C 109.241 -1.543 . . . . 0.0 109.241 -178.099 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.407 ' CD ' ' H ' ' A' ' 11' ' ' ASN . 38.4 tt0 -132.76 149.08 52.32 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 114.0 -1.1 . . . . 0.0 110.147 -177.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.604 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 19.1 p -110.9 144.41 39.99 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.629 179.308 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.583 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 26.7 p -116.64 46.86 1.54 Allowed 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 121.789 0.804 . . . . 0.0 109.282 178.56 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -56.85 -32.59 39.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 CA-C-N 114.587 -1.188 . . . . 0.0 109.531 179.45 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -98.39 21.78 44.24 Favored Glycine 0 N--CA 1.446 -0.64 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.906 178.368 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.41 40.08 98.17 Favored Glycine 0 C--N 1.335 0.504 0 C-N-CA 121.431 -0.414 . . . . 0.0 112.832 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -148.73 144.7 27.24 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 120.69 0.281 . . . . 0.0 111.514 -179.23 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.544 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 86.4 m -136.41 133.42 36.67 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.3 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . 0.407 ' H ' ' CD ' ' A' ' 3' ' ' GLU . 64.7 m-80 -88.34 -32.21 18.52 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.189 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.659 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.6 m -63.25 118.85 47.37 Favored Pre-proline 0 C--O 1.236 0.382 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.816 -179.618 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -64.76 115.8 3.44 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.438 2.092 . . . . 0.0 112.553 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 106.4 -3.62 37.33 Favored Glycine 0 N--CA 1.445 -0.707 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.89 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.659 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 93.1 m -93.91 121.14 35.07 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.377 0.608 . . . . 0.0 111.822 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.4 p -89.88 143.87 26.43 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.053 178.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.6 t -73.26 134.36 44.23 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.7 0.762 . . . . 0.0 111.009 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.5 m -147.01 68.08 1.16 Allowed 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 106.378 -1.712 . . . . 0.0 106.378 178.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.462 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 8.3 t90 -28.3 129.52 0.21 Allowed Pre-proline 0 C--O 1.232 0.147 0 CA-C-N 113.874 -1.512 . . . . 0.0 113.413 -176.205 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.462 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.0 Cg_endo -98.37 24.34 21.14 Favored 'Cis proline' 0 N--CA 1.46 -0.466 0 C-N-CA 123.696 -1.377 . . . . 0.0 113.324 0.34 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.604 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.3 m -130.32 148.27 33.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -177.325 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 71.5 m -83.59 127.23 33.58 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.602 179.635 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.437 HG22 ' HG3' ' A' ' 28' ' ' PRO . 32.1 p -105.46 149.04 26.52 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.762 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.549 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 41.3 ttp85 -130.86 123.94 30.14 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.253 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 79.4 m-20 62.11 29.31 17.55 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.779 -178.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.42 5.18 75.95 Favored Glycine 0 CA--C 1.523 0.549 0 CA-C-N 115.704 -0.68 . . . . 0.0 114.055 179.112 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.417 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.7 pt? -147.23 139.13 13.73 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-N 117.845 0.822 . . . . 0.0 110.765 179.415 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.437 ' HG3' HG22 ' A' ' 23' ' ' THR . 23.4 Cg_exo -64.3 104.81 0.54 Allowed 'Trans proline' 0 N--CA 1.466 -0.142 0 C-N-CA 122.63 2.22 . . . . 0.0 112.878 -178.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.2 t . . . . . 0 C--N 1.326 -0.435 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.062 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.544 ' SG ' ' HB2' ' A' ' 24' ' ' ARG . 4.0 m . . . . . 0 CA--C 1.518 -0.276 0 CA-C-O 120.793 0.33 . . . . 0.0 110.501 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 64.3 31.09 79.71 Favored Glycine 0 C--N 1.334 0.435 0 N-CA-C 109.439 -1.465 . . . . 0.0 109.439 -178.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -128.79 149.33 50.77 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-N 113.883 -1.159 . . . . 0.0 109.793 -177.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.587 ' HA ' ' HA ' ' A' ' 21' ' ' VAL . 27.2 p -109.74 142.6 40.73 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.136 179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.583 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 29.8 p -116.54 45.31 1.83 Allowed 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.64 0.734 . . . . 0.0 109.296 177.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.44 HG23 ' HB ' ' A' ' 4' ' ' THR . 11.4 t -55.75 -33.33 33.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 114.735 -1.121 . . . . 0.0 109.906 179.477 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -99.74 22.59 39.71 Favored Glycine 0 N--CA 1.447 -0.609 0 CA-C-N 115.708 -0.678 . . . . 0.0 112.011 178.57 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.99 40.24 99.06 Favored Glycine 0 C--N 1.334 0.461 0 C-N-CA 121.3 -0.476 . . . . 0.0 112.63 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -146.2 146.17 30.7 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 120.822 0.344 . . . . 0.0 111.565 -179.357 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 80.1 m -141.33 130.53 23.48 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 178.763 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 6.0 m120 -89.31 -27.19 20.69 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.48 -179.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.594 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 1.8 m -65.56 117.48 41.43 Favored Pre-proline 0 C--O 1.237 0.423 0 CA-C-O 120.949 0.404 . . . . 0.0 110.259 179.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -64.14 114.04 2.48 Favored 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 122.315 2.01 . . . . 0.0 113.149 -179.064 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 107.28 -5.41 35.8 Favored Glycine 0 N--CA 1.442 -0.936 0 CA-C-N 115.282 -0.872 . . . . 0.0 112.014 179.609 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.594 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 99.5 m -89.9 123.11 33.55 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.403 0.62 . . . . 0.0 111.49 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.6 p -90.01 141.54 28.57 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.305 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 50.7 t -71.94 134.52 46.03 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 121.706 0.765 . . . . 0.0 110.911 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.3 m -147.08 68.1 1.15 Allowed 'General case' 0 C--N 1.312 -1.043 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 179.192 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.422 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 7.7 t90 -27.73 129.26 0.2 Allowed Pre-proline 0 C--O 1.232 0.154 0 CA-C-N 113.976 -1.465 . . . . 0.0 113.516 -176.121 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.422 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 62.6 Cg_endo -97.91 23.14 23.54 Favored 'Cis proline' 0 N--CA 1.462 -0.376 0 C-N-CA 123.675 -1.386 . . . . 0.0 113.282 0.368 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.587 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 1.4 m -130.05 146.44 34.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 113.803 1.038 . . . . 0.0 113.803 -177.316 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.583 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 82.2 m -81.6 126.9 32.3 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.355 179.417 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.446 ' HA ' ' HA ' ' A' ' 28' ' ' PRO . 24.7 p -101.68 145.76 28.65 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.294 0.569 . . . . 0.0 111.426 -179.688 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.544 ' HB2' ' SG ' ' A' ' 1' ' ' CYS . 27.1 tpt180 -117.48 117.28 29.03 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.212 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 63.5 m-20 60.48 32.23 20.47 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.465 -178.583 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.45 -12.73 69.08 Favored Glycine 0 CA--C 1.524 0.618 0 C-N-CA 120.808 -0.711 . . . . 0.0 114.214 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.415 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 1.5 pt? -129.21 137.14 30.34 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 118.113 0.956 . . . . 0.0 110.95 -179.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.446 ' HA ' ' HA ' ' A' ' 23' ' ' THR . 24.7 Cg_exo -63.03 103.8 0.37 Allowed 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.679 2.252 . . . . 0.0 113.252 -178.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 13.5 t . . . . . 0 C--N 1.325 -0.458 0 CA-C-O 121.958 0.885 . . . . 0.0 108.931 179.424 . . . . . . . . 0 0 . 1 stop_ save_